<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/">

	<channel><title><![CDATA[Latest Publisher Reports]]></title><atom:link href="http://www.researchmoz.com/publisher" rel="self" type="application/rss+xml" />
	<link>http://www.researchmoz.com</link>
	<description><![CDATA[Latest Publisher Reports]]></description>
	<lastBuildDate>Wed, 18 Jul 2012 12:20:54 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.1</generator><item><title>Oil &amp; Gas Monthly Deals Analysis -  April 2013: M&amp;A and Investment Trends</title><link>http://www.researchmoz.com/oil-and-gas-monthly-deals-analysis-april-2013-manda-and-investment-trends-report.html</link><comments>http://www.researchmoz.com/oil-and-gas-monthly-deals-analysis-april-2013-manda-and-investment-trends-report.html#comments</comments><pubDate>Wed, 15 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/oil-and-gas-monthly-deals-analysis-april-2013-manda-and-investment-trends-report.html</guid><description><![CDATA[

Oil &amp; Gas Monthly Deals Analysis April 2013: M&amp;A and Investment Trends

Summary

GlobalData's Oil &amp; Gas Monthly Deals Analysis April 2013: M&amp;A and Investment Trends report is an essential source of data and trend analysis on the mergers and acquisitions (M&amp;As) and financings in the oil and gas industry. The report provides detailed information on M&amp;As, equity/debt offerings, private equity, venture financing and partnership transactions registered in the oil and gas industry in April 2013. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, segments and geographies. Additionally, the report provides information on the top financial advisory firms in the oil and gas industry.

Data presented in this report is derived from GlobalDatas proprietary in-house deals database and primary and secondary research.

Scope




Analyze market trends for the oil and gas industry <br><br>Original Post <a href=http://www.researchmoz.com/oil-and-gas-monthly-deals-analysis-april-2013-manda-and-investment-trends-report.html>Oil &amp; Gas Monthly Deals Analysis -  April 2013: M&amp;A and Investment Trends</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Oil &amp; Gas Monthly Deals Analysis April 2013: M&amp;A and Investment Trends

Summary

GlobalData's Oil &amp; Gas Monthly Deals Analysis April 2013: M&amp;A and Investment Trends report is an essential source of data and trend analysis on the mergers and acquisitions (M&amp;As) and financings in the oil and gas industry. The report provides detailed information on M&amp;As, equity/debt offerings, private equity, venture financing and partnership transactions registered in the oil and gas industry in April 2013. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, segments and geographies. Additionally, the report provides information on the top financial advisory firms in the oil and gas industry.

Data presented in this report is derived from GlobalDatas proprietary in-house deals database and primary and secondary research.

Scope




Analyze market trends for the oil and gas industry <br><br>Original Post <a href=http://www.researchmoz.com/oil-and-gas-monthly-deals-analysis-april-2013-manda-and-investment-trends-report.html>Oil &amp; Gas Monthly Deals Analysis -  April 2013: M&amp;A and Investment Trends</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/oil-and-gas-monthly-deals-analysis-april-2013-manda-and-investment-trends-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Comstock Resources Inc., Company Intelligence Report</title><link>http://www.researchmoz.com/comstock-resources-inc-company-intelligence-report-report.html</link><comments>http://www.researchmoz.com/comstock-resources-inc-company-intelligence-report-report.html#comments</comments><pubDate>Wed, 15 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/comstock-resources-inc-company-intelligence-report-report.html</guid><description><![CDATA[

Comstock Resources Inc., Company Intelligence Report

Summary

Comstock Resources Inc. (Comstock) is an independent energy company, headquartered in Frisco, the US. The company acquires, develops, explores and produces oil and natural gas properties. The companys strategy is to increase its production and recoverable reserves through development drilling and workovers, and to maximize the value of its oil and gas properties through recompletion and exploitation activities. The company uses advanced industry technology, including 3D seismic data, horizontal drilling, improved logging tools, and formation stimulation techniques. Its Exploration and Production (E&amp;P) activities are mainly located in East Texas/North Louisiana and South Texas. Comstock also has properties in Arkansas, Kentucky, Kansas, New Mexico and Oklahoma. Its principal operating fields in East Texas/North Louisiana are Beckville, Waskom, Blocker, Hico-Knowles, Logansport, and Toledo Bend. Its major operatin <br><br>Original Post <a href=http://www.researchmoz.com/comstock-resources-inc-company-intelligence-report-report.html>Comstock Resources Inc., Company Intelligence Report</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Comstock Resources Inc., Company Intelligence Report

Summary

Comstock Resources Inc. (Comstock) is an independent energy company, headquartered in Frisco, the US. The company acquires, develops, explores and produces oil and natural gas properties. The companys strategy is to increase its production and recoverable reserves through development drilling and workovers, and to maximize the value of its oil and gas properties through recompletion and exploitation activities. The company uses advanced industry technology, including 3D seismic data, horizontal drilling, improved logging tools, and formation stimulation techniques. Its Exploration and Production (E&amp;P) activities are mainly located in East Texas/North Louisiana and South Texas. Comstock also has properties in Arkansas, Kentucky, Kansas, New Mexico and Oklahoma. Its principal operating fields in East Texas/North Louisiana are Beckville, Waskom, Blocker, Hico-Knowles, Logansport, and Toledo Bend. Its major operatin <br><br>Original Post <a href=http://www.researchmoz.com/comstock-resources-inc-company-intelligence-report-report.html>Comstock Resources Inc., Company Intelligence Report</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/comstock-resources-inc-company-intelligence-report-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Statoil ASA Company Intelligence Report</title><link>http://www.researchmoz.com/statoil-asa-company-intelligence-report-report.html</link><comments>http://www.researchmoz.com/statoil-asa-company-intelligence-report-report.html#comments</comments><pubDate>Wed, 15 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/statoil-asa-company-intelligence-report-report.html</guid><description><![CDATA[

Statoil ASA Company Intelligence Report

Summary

Statoil ASA (Statoil) is an integrated oil and gas energy company with a presence across the entire oil and gas value chain. The companys headquarters are located in Norway and it has business operations in 41 countries worldwide. Apart from Norway, the company has business operations in the US, Canada, Cuba, the Bahamas, Mexico, Brazil, Venezuela, Suriname, Algeria, Angola, Libya, Egypt, Nigeria, Tanzania, Mozambique, Azerbaijan, Iran, Iraq, Turkey, the United Arab Emirates, Russia, the UK, Germany, Ireland, Poland, Sweden and China. The companys major business activities can be categorized as follows: exploration; development and production of crude oil and natural gas; transportation and processing of gas and Liquefied Natural Gas (LNG); and marketing and sale of crude oil and refined products. Statoils operations are managed through various operating segments which include Development and Production Norway (DPN), Development <br><br>Original Post <a href=http://www.researchmoz.com/statoil-asa-company-intelligence-report-report.html>Statoil ASA Company Intelligence Report</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Statoil ASA Company Intelligence Report

Summary

Statoil ASA (Statoil) is an integrated oil and gas energy company with a presence across the entire oil and gas value chain. The companys headquarters are located in Norway and it has business operations in 41 countries worldwide. Apart from Norway, the company has business operations in the US, Canada, Cuba, the Bahamas, Mexico, Brazil, Venezuela, Suriname, Algeria, Angola, Libya, Egypt, Nigeria, Tanzania, Mozambique, Azerbaijan, Iran, Iraq, Turkey, the United Arab Emirates, Russia, the UK, Germany, Ireland, Poland, Sweden and China. The companys major business activities can be categorized as follows: exploration; development and production of crude oil and natural gas; transportation and processing of gas and Liquefied Natural Gas (LNG); and marketing and sale of crude oil and refined products. Statoils operations are managed through various operating segments which include Development and Production Norway (DPN), Development <br><br>Original Post <a href=http://www.researchmoz.com/statoil-asa-company-intelligence-report-report.html>Statoil ASA Company Intelligence Report</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/statoil-asa-company-intelligence-report-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Global Oil and Gas Pipelines Industry Outlook, 2013 - Details of All Active and Planned Crude Oil, Petroleum Products and Natural Gas Pipelines</title><link>http://www.researchmoz.com/global-oil-and-gas-pipelines-industry-outlook-2013-details-of-all-active-and-planned-crude-oil-petroleum-products-and-natural-gas-pipelines-report.html</link><comments>http://www.researchmoz.com/global-oil-and-gas-pipelines-industry-outlook-2013-details-of-all-active-and-planned-crude-oil-petroleum-products-and-natural-gas-pipelines-report.html#comments</comments><pubDate>Wed, 15 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/global-oil-and-gas-pipelines-industry-outlook-2013-details-of-all-active-and-planned-crude-oil-petroleum-products-and-natural-gas-pipelines-report.html</guid><description><![CDATA[

Global Oil and Gas Pipelines Industry Outlook, 2013 Details of All Active and Planned Crude Oil, Petroleum Products and Natural Gas Pipelines

Summary

GlobalDatas energy offering, Global Oil and Gas Pipelines Industry Outlook, 2013 Details of All Active and Planned Crude Oil, Petroleum Products and Natural Gas Pipelines is the essential source for industry data and information related to the pipeline industry across the globe. It provides asset level information related to all active and planned crude oil, petroleum products and natural gas transmission pipelines across the globe. The profiles of major companies operating in the pipeline industry across globe are included in the report. The latest news and deals related to the sector are also provided and analyzed.

Scope



This report provides updated information relating to all active and planned crude oil, petroleum products and natural gas pipelines
Provides operator information, start year, start point, end point, <br><br>Original Post <a href=http://www.researchmoz.com/global-oil-and-gas-pipelines-industry-outlook-2013-details-of-all-active-and-planned-crude-oil-petroleum-products-and-natural-gas-pipelines-report.html>Global Oil and Gas Pipelines Industry Outlook, 2013 - Details of All Active and Planned Crude Oil, Petroleum Products and Natural Gas Pipelines</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Global Oil and Gas Pipelines Industry Outlook, 2013 Details of All Active and Planned Crude Oil, Petroleum Products and Natural Gas Pipelines

Summary

GlobalDatas energy offering, Global Oil and Gas Pipelines Industry Outlook, 2013 Details of All Active and Planned Crude Oil, Petroleum Products and Natural Gas Pipelines is the essential source for industry data and information related to the pipeline industry across the globe. It provides asset level information related to all active and planned crude oil, petroleum products and natural gas transmission pipelines across the globe. The profiles of major companies operating in the pipeline industry across globe are included in the report. The latest news and deals related to the sector are also provided and analyzed.

Scope



This report provides updated information relating to all active and planned crude oil, petroleum products and natural gas pipelines
Provides operator information, start year, start point, end point, <br><br>Original Post <a href=http://www.researchmoz.com/global-oil-and-gas-pipelines-industry-outlook-2013-details-of-all-active-and-planned-crude-oil-petroleum-products-and-natural-gas-pipelines-report.html>Global Oil and Gas Pipelines Industry Outlook, 2013 - Details of All Active and Planned Crude Oil, Petroleum Products and Natural Gas Pipelines</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/global-oil-and-gas-pipelines-industry-outlook-2013-details-of-all-active-and-planned-crude-oil-petroleum-products-and-natural-gas-pipelines-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - France</title><link>http://www.researchmoz.com/countryfocus-healthcare-regulatory-and-reimbursement-landscape-france-report.html</link><comments>http://www.researchmoz.com/countryfocus-healthcare-regulatory-and-reimbursement-landscape-france-report.html#comments</comments><pubDate>Wed, 15 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/countryfocus-healthcare-regulatory-and-reimbursement-landscape-france-report.html</guid><description><![CDATA[

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape France

Summary

GlobalData, the industry analysis specialist, has released its new report, CountryFocus: Healthcare, Regulatory and Reimbursement Landscape France. The report is an essential source of information and an analysis on the healthcare, regulatory and reimbursement landscape of France. The report identifies the key trends in the healthcare market and provides insights on the demographic, regulatory, reimbursement landscape and healthcare infrastructure of France. Most importantly, the report provides valuable insights on the trends and segmentation of the pharmaceutical and medical devices market. This report is built using data and information sourced from proprietary databases, secondary research and in-house analysis by GlobalDatas team of industry experts.

In 2012, france's population was approximately 65.3 million. The growth rate of the French population is decreasing steadily and this may be  <br><br>Original Post <a href=http://www.researchmoz.com/countryfocus-healthcare-regulatory-and-reimbursement-landscape-france-report.html>CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - France</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape France

Summary

GlobalData, the industry analysis specialist, has released its new report, CountryFocus: Healthcare, Regulatory and Reimbursement Landscape France. The report is an essential source of information and an analysis on the healthcare, regulatory and reimbursement landscape of France. The report identifies the key trends in the healthcare market and provides insights on the demographic, regulatory, reimbursement landscape and healthcare infrastructure of France. Most importantly, the report provides valuable insights on the trends and segmentation of the pharmaceutical and medical devices market. This report is built using data and information sourced from proprietary databases, secondary research and in-house analysis by GlobalDatas team of industry experts.

In 2012, france's population was approximately 65.3 million. The growth rate of the French population is decreasing steadily and this may be  <br><br>Original Post <a href=http://www.researchmoz.com/countryfocus-healthcare-regulatory-and-reimbursement-landscape-france-report.html>CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - France</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/countryfocus-healthcare-regulatory-and-reimbursement-landscape-france-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Italy</title><link>http://www.researchmoz.com/countryfocus-healthcare-regulatory-and-reimbursement-landscape-italy-report.html</link><comments>http://www.researchmoz.com/countryfocus-healthcare-regulatory-and-reimbursement-landscape-italy-report.html#comments</comments><pubDate>Wed, 15 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/countryfocus-healthcare-regulatory-and-reimbursement-landscape-italy-report.html</guid><description><![CDATA[

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape Italy

Summary

GlobalData, the industry analysis specialist, has released its new report, CountryFocus: Healthcare, Regulatory and Reimbursement Landscape Italy. The report is an essential source of information and analysis on Italys healthcare, regulatory and reimbursement landscape. It identifies the key trends in the healthcare market and provides insights into the demographic, regulatory and reimbursement landscape and the countrys healthcare infrastructure. Most importantly, it provides valuable insights into the trends and segmentation of the Italian pharmaceutical and medical device markets. The report is built using data and information sourced from proprietary databases, secondary research and in-house analysis by GlobalDatas team of industry experts.

Italys population was 61.3 million in 2012, and is increasing due to a positive balance between the birth and death rates, as well as through immigratio <br><br>Original Post <a href=http://www.researchmoz.com/countryfocus-healthcare-regulatory-and-reimbursement-landscape-italy-report.html>CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Italy</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape Italy

Summary

GlobalData, the industry analysis specialist, has released its new report, CountryFocus: Healthcare, Regulatory and Reimbursement Landscape Italy. The report is an essential source of information and analysis on Italys healthcare, regulatory and reimbursement landscape. It identifies the key trends in the healthcare market and provides insights into the demographic, regulatory and reimbursement landscape and the countrys healthcare infrastructure. Most importantly, it provides valuable insights into the trends and segmentation of the Italian pharmaceutical and medical device markets. The report is built using data and information sourced from proprietary databases, secondary research and in-house analysis by GlobalDatas team of industry experts.

Italys population was 61.3 million in 2012, and is increasing due to a positive balance between the birth and death rates, as well as through immigratio <br><br>Original Post <a href=http://www.researchmoz.com/countryfocus-healthcare-regulatory-and-reimbursement-landscape-italy-report.html>CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Italy</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/countryfocus-healthcare-regulatory-and-reimbursement-landscape-italy-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>PharmaPoint: Chronic Myeloid Leukemia (CML) - Current and Future Players</title><link>http://www.researchmoz.com/pharmapoint-chronic-myeloid-leukemia-cml-current-and-future-players-report.html</link><comments>http://www.researchmoz.com/pharmapoint-chronic-myeloid-leukemia-cml-current-and-future-players-report.html#comments</comments><pubDate>Wed, 15 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/pharmapoint-chronic-myeloid-leukemia-cml-current-and-future-players-report.html</guid><description><![CDATA[

PharmaPoint: Chronic Myeloid Leukemia (CML) Current and Future Players

Summary

GlobalData has released its pharma report, PharmaPoint: Chronic Myeloid Leukemia (CML) Current and Future Players. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing CML Market. The report identifies and analyses the key companies shaping and driving the global CML market. The report provides insight into the competitive CML landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalDatas team of industry experts.

Scope



Investigation of current and future market competition for CML
Competitor assessment
Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.
Strategic assessment of the CML sector through market impact analy <br><br>Original Post <a href=http://www.researchmoz.com/pharmapoint-chronic-myeloid-leukemia-cml-current-and-future-players-report.html>PharmaPoint: Chronic Myeloid Leukemia (CML) - Current and Future Players</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

PharmaPoint: Chronic Myeloid Leukemia (CML) Current and Future Players

Summary

GlobalData has released its pharma report, PharmaPoint: Chronic Myeloid Leukemia (CML) Current and Future Players. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing CML Market. The report identifies and analyses the key companies shaping and driving the global CML market. The report provides insight into the competitive CML landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalDatas team of industry experts.

Scope



Investigation of current and future market competition for CML
Competitor assessment
Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.
Strategic assessment of the CML sector through market impact analy <br><br>Original Post <a href=http://www.researchmoz.com/pharmapoint-chronic-myeloid-leukemia-cml-current-and-future-players-report.html>PharmaPoint: Chronic Myeloid Leukemia (CML) - Current and Future Players</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/pharmapoint-chronic-myeloid-leukemia-cml-current-and-future-players-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Gleevec (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022</title><link>http://www.researchmoz.com/gleevec-chronic-myeloid-leukemia-forecast-and-market-analysis-to-2022-report.html</link><comments>http://www.researchmoz.com/gleevec-chronic-myeloid-leukemia-forecast-and-market-analysis-to-2022-report.html#comments</comments><pubDate>Wed, 15 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/gleevec-chronic-myeloid-leukemia-forecast-and-market-analysis-to-2022-report.html</guid><description><![CDATA[

Gleevec (Chronic Myeloid Leukemia) Forecast and Market Analysis to 2022

Summary

GlobalData has released its new PharmaPoint Drug Evaluation report, Gleevec (Chronic Myeloid Leukemia) Forecast and Market Analysis to 2022. Chronic myeloid leukemia (CML) is a rare myeloproliferative blood cancer that is characterized by the presence of the BCR-ABL fusion protein. The stage of CML is classified as chronic, accelerated or blast phase, ranging from least to most severe. Multiple BCR-ABL tyrosine kinase inhibitors (TKIs) are approved, and are the standard of care for CML. TKIs have transformed most cases of the disease into a manageable, chronic condition. As a result, patients survival rates and the prevalence of CML are increasing, placing a growing burden on global healthcare systems.&nbsp;

Novartis Gleevec (imatinib mesylate) was the first BCR-ABL TKI approved for CML. Gleevec was first approved in the US and the 5EU in 2001 for Ph+ CML patients in blast phase, accelerated ph <br><br>Original Post <a href=http://www.researchmoz.com/gleevec-chronic-myeloid-leukemia-forecast-and-market-analysis-to-2022-report.html>Gleevec (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Gleevec (Chronic Myeloid Leukemia) Forecast and Market Analysis to 2022

Summary

GlobalData has released its new PharmaPoint Drug Evaluation report, Gleevec (Chronic Myeloid Leukemia) Forecast and Market Analysis to 2022. Chronic myeloid leukemia (CML) is a rare myeloproliferative blood cancer that is characterized by the presence of the BCR-ABL fusion protein. The stage of CML is classified as chronic, accelerated or blast phase, ranging from least to most severe. Multiple BCR-ABL tyrosine kinase inhibitors (TKIs) are approved, and are the standard of care for CML. TKIs have transformed most cases of the disease into a manageable, chronic condition. As a result, patients survival rates and the prevalence of CML are increasing, placing a growing burden on global healthcare systems.&nbsp;

Novartis Gleevec (imatinib mesylate) was the first BCR-ABL TKI approved for CML. Gleevec was first approved in the US and the 5EU in 2001 for Ph+ CML patients in blast phase, accelerated ph <br><br>Original Post <a href=http://www.researchmoz.com/gleevec-chronic-myeloid-leukemia-forecast-and-market-analysis-to-2022-report.html>Gleevec (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/gleevec-chronic-myeloid-leukemia-forecast-and-market-analysis-to-2022-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Sprycel (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022</title><link>http://www.researchmoz.com/sprycel-chronic-myeloid-leukemia-forecast-and-market-analysis-to-2022-report.html</link><comments>http://www.researchmoz.com/sprycel-chronic-myeloid-leukemia-forecast-and-market-analysis-to-2022-report.html#comments</comments><pubDate>Wed, 15 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/sprycel-chronic-myeloid-leukemia-forecast-and-market-analysis-to-2022-report.html</guid><description><![CDATA[

Sprycel (Chronic Myeloid Leukemia) Forecast and Market Analysis to 2022

Summary

GlobalData has released its new PharmaPoint Drug Evaluation report, &ldquo;Sprycel (Chronic Myeloid Leukemia) Forecast and Market Analysis to 2022&rdquo;. Chronic myeloid leukemia (CML) is a rare myeloproliferative blood cancer that is characterized by the presence of the BCR-ABL fusion protein. The stage of CML is classified as chronic, accelerated or blast phase, ranging from least to most severe. Multiple BCR-ABL tyrosine kinase inhibitors (TKIs) are approved, and are the standard of care for CML. TKIs have transformed most cases of the disease into a manageable, chronic condition. As a result, patients&rsquo; survival rates and the prevalence of CML are increasing, placing a growing burden on global healthcare systems.&nbsp;

BMS&rsquo; Sprycel (dasatinib) is a second-generation BCR-ABL TKI. Sprycel has a slightly different mechanism of action (MOA) than other TKIs used to treat CML, as it a <br><br>Original Post <a href=http://www.researchmoz.com/sprycel-chronic-myeloid-leukemia-forecast-and-market-analysis-to-2022-report.html>Sprycel (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Sprycel (Chronic Myeloid Leukemia) Forecast and Market Analysis to 2022

Summary

GlobalData has released its new PharmaPoint Drug Evaluation report, &ldquo;Sprycel (Chronic Myeloid Leukemia) Forecast and Market Analysis to 2022&rdquo;. Chronic myeloid leukemia (CML) is a rare myeloproliferative blood cancer that is characterized by the presence of the BCR-ABL fusion protein. The stage of CML is classified as chronic, accelerated or blast phase, ranging from least to most severe. Multiple BCR-ABL tyrosine kinase inhibitors (TKIs) are approved, and are the standard of care for CML. TKIs have transformed most cases of the disease into a manageable, chronic condition. As a result, patients&rsquo; survival rates and the prevalence of CML are increasing, placing a growing burden on global healthcare systems.&nbsp;

BMS&rsquo; Sprycel (dasatinib) is a second-generation BCR-ABL TKI. Sprycel has a slightly different mechanism of action (MOA) than other TKIs used to treat CML, as it a <br><br>Original Post <a href=http://www.researchmoz.com/sprycel-chronic-myeloid-leukemia-forecast-and-market-analysis-to-2022-report.html>Sprycel (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/sprycel-chronic-myeloid-leukemia-forecast-and-market-analysis-to-2022-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Tasigna (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022</title><link>http://www.researchmoz.com/tasigna-chronic-myeloid-leukemia-forecast-and-market-analysis-to-2022-report.html</link><comments>http://www.researchmoz.com/tasigna-chronic-myeloid-leukemia-forecast-and-market-analysis-to-2022-report.html#comments</comments><pubDate>Wed, 15 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/tasigna-chronic-myeloid-leukemia-forecast-and-market-analysis-to-2022-report.html</guid><description><![CDATA[

Tasigna (Chronic Myeloid Leukemia) Forecast and Market Analysis to 2022

Summary

GlobalData has released its new PharmaPoint Drug Evaluation report, Tasigna (Chronic Myeloid Leukemia) Forecast and Market Analysis to 2022. Chronic myeloid leukemia (CML) is a rare myeloproliferative blood cancer that is characterized by the presence of the BCR-ABL fusion protein. The stage of CML is classified as chronic, accelerated or blast phase, ranging from least to most severe. Multiple BCR-ABL tyrosine kinase inhibitors (TKIs) are approved, and are the standard of care for CML. TKIs have transformed most cases of the disease into a manageable, chronic condition. As a result, patients survival rates and the prevalence of CML are increasing, placing a growing burden on global healthcare systems.

Novartis Tasigna (nilotinib) is a second-generation BCR-ABL TKI. It was first approved in the US and 5EU in 2007 and in Japan in 2009 as a second-line therapy for patients with CP or AP CML that  <br><br>Original Post <a href=http://www.researchmoz.com/tasigna-chronic-myeloid-leukemia-forecast-and-market-analysis-to-2022-report.html>Tasigna (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Tasigna (Chronic Myeloid Leukemia) Forecast and Market Analysis to 2022

Summary

GlobalData has released its new PharmaPoint Drug Evaluation report, Tasigna (Chronic Myeloid Leukemia) Forecast and Market Analysis to 2022. Chronic myeloid leukemia (CML) is a rare myeloproliferative blood cancer that is characterized by the presence of the BCR-ABL fusion protein. The stage of CML is classified as chronic, accelerated or blast phase, ranging from least to most severe. Multiple BCR-ABL tyrosine kinase inhibitors (TKIs) are approved, and are the standard of care for CML. TKIs have transformed most cases of the disease into a manageable, chronic condition. As a result, patients survival rates and the prevalence of CML are increasing, placing a growing burden on global healthcare systems.

Novartis Tasigna (nilotinib) is a second-generation BCR-ABL TKI. It was first approved in the US and 5EU in 2007 and in Japan in 2009 as a second-line therapy for patients with CP or AP CML that  <br><br>Original Post <a href=http://www.researchmoz.com/tasigna-chronic-myeloid-leukemia-forecast-and-market-analysis-to-2022-report.html>Tasigna (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/tasigna-chronic-myeloid-leukemia-forecast-and-market-analysis-to-2022-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Bosulif (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022</title><link>http://www.researchmoz.com/bosulif-chronic-myeloid-leukemia-forecast-and-market-analysis-to-2022-report.html</link><comments>http://www.researchmoz.com/bosulif-chronic-myeloid-leukemia-forecast-and-market-analysis-to-2022-report.html#comments</comments><pubDate>Wed, 15 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/bosulif-chronic-myeloid-leukemia-forecast-and-market-analysis-to-2022-report.html</guid><description><![CDATA[

Bosulif (Chronic Myeloid Leukemia) Forecast and Market Analysis to 2022

Summary

GlobalData has released its new PharmaPoint Drug Evaluation report, Bosulif (Chronic Myeloid Leukemia) Forecast and Market Analysis to 2022. Chronic myeloid leukemia (CML) is a rare myeloproliferative blood cancer that is characterized by the presence of the BCR-ABL fusion protein. The stage of CML is classified as chronic, accelerated or blast phase, ranging from least to most severe. Multiple BCR-ABL tyrosine kinase inhibitors (TKIs) are approved, and are the standard of care for CML. TKIs have transformed most cases of the disease into a manageable, chronic condition. As a result, patients survival rates and the prevalence of CML are increasing, placing a growing burden on global healthcare systems.&nbsp;

Pfizers Bosulif (bosutinib) is a second-generation TKI that inhibits BCR-ABL, as well as SRC-family kinases (Bosulif Prescribing Information, 2012). Bosulif received FDA approval in Septemb <br><br>Original Post <a href=http://www.researchmoz.com/bosulif-chronic-myeloid-leukemia-forecast-and-market-analysis-to-2022-report.html>Bosulif (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Bosulif (Chronic Myeloid Leukemia) Forecast and Market Analysis to 2022

Summary

GlobalData has released its new PharmaPoint Drug Evaluation report, Bosulif (Chronic Myeloid Leukemia) Forecast and Market Analysis to 2022. Chronic myeloid leukemia (CML) is a rare myeloproliferative blood cancer that is characterized by the presence of the BCR-ABL fusion protein. The stage of CML is classified as chronic, accelerated or blast phase, ranging from least to most severe. Multiple BCR-ABL tyrosine kinase inhibitors (TKIs) are approved, and are the standard of care for CML. TKIs have transformed most cases of the disease into a manageable, chronic condition. As a result, patients survival rates and the prevalence of CML are increasing, placing a growing burden on global healthcare systems.&nbsp;

Pfizers Bosulif (bosutinib) is a second-generation TKI that inhibits BCR-ABL, as well as SRC-family kinases (Bosulif Prescribing Information, 2012). Bosulif received FDA approval in Septemb <br><br>Original Post <a href=http://www.researchmoz.com/bosulif-chronic-myeloid-leukemia-forecast-and-market-analysis-to-2022-report.html>Bosulif (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/bosulif-chronic-myeloid-leukemia-forecast-and-market-analysis-to-2022-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Iclusig (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022</title><link>http://www.researchmoz.com/iclusig-chronic-myeloid-leukemia-forecast-and-market-analysis-to-2022-report.html</link><comments>http://www.researchmoz.com/iclusig-chronic-myeloid-leukemia-forecast-and-market-analysis-to-2022-report.html#comments</comments><pubDate>Wed, 15 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/iclusig-chronic-myeloid-leukemia-forecast-and-market-analysis-to-2022-report.html</guid><description><![CDATA[

Iclusig (Chronic Myeloid Leukemia) Forecast and Market Analysis to 2022

Summary

GlobalData has released its new PharmaPoint Drug Evaluation report, Iclusig (Chronic Myeloid Leukemia) Forecast and Market Analysis to 2022. Chronic myeloid leukemia (CML) is a rare myeloproliferative blood cancer that is characterized by the presence of the BCR-ABL fusion protein. The stage of CML is classified as chronic, accelerated or blast phase, ranging from least to most severe. Multiple BCR-ABL tyrosine kinase inhibitors (TKIs) are approved, and are the standard of care for CML. TKIs have transformed most cases of the disease into a manageable, chronic condition. As a result, patients survival rates and the prevalence of CML are increasing, placing a growing burden on global healthcare systems.&nbsp;

Ariads Iclusig (ponatinib) is an orally administered, third-generation TKI that inhibits the activity of wild-type ABL and T315I mutant ABL in vitro. Iclusig has received orphan drug design <br><br>Original Post <a href=http://www.researchmoz.com/iclusig-chronic-myeloid-leukemia-forecast-and-market-analysis-to-2022-report.html>Iclusig (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Iclusig (Chronic Myeloid Leukemia) Forecast and Market Analysis to 2022

Summary

GlobalData has released its new PharmaPoint Drug Evaluation report, Iclusig (Chronic Myeloid Leukemia) Forecast and Market Analysis to 2022. Chronic myeloid leukemia (CML) is a rare myeloproliferative blood cancer that is characterized by the presence of the BCR-ABL fusion protein. The stage of CML is classified as chronic, accelerated or blast phase, ranging from least to most severe. Multiple BCR-ABL tyrosine kinase inhibitors (TKIs) are approved, and are the standard of care for CML. TKIs have transformed most cases of the disease into a manageable, chronic condition. As a result, patients survival rates and the prevalence of CML are increasing, placing a growing burden on global healthcare systems.&nbsp;

Ariads Iclusig (ponatinib) is an orally administered, third-generation TKI that inhibits the activity of wild-type ABL and T315I mutant ABL in vitro. Iclusig has received orphan drug design <br><br>Original Post <a href=http://www.researchmoz.com/iclusig-chronic-myeloid-leukemia-forecast-and-market-analysis-to-2022-report.html>Iclusig (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/iclusig-chronic-myeloid-leukemia-forecast-and-market-analysis-to-2022-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Synribo (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022</title><link>http://www.researchmoz.com/synribo-chronic-myeloid-leukemia-forecast-and-market-analysis-to-2022-report.html</link><comments>http://www.researchmoz.com/synribo-chronic-myeloid-leukemia-forecast-and-market-analysis-to-2022-report.html#comments</comments><pubDate>Wed, 15 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/synribo-chronic-myeloid-leukemia-forecast-and-market-analysis-to-2022-report.html</guid><description><![CDATA[

Synribo (Chronic Myeloid Leukemia) Forecast and Market Analysis to 2022

Summary

GlobalData has released its new PharmaPoint Drug Evaluation report, Synribo (Chronic Myeloid Leukemia) Forecast and Market Analysis to 2022. Chronic myeloid leukemia (CML) is a rare myeloproliferative blood cancer that is characterized by the presence of the BCR-ABL fusion protein. The stage of CML is classified as chronic, accelerated or blast phase, ranging from least to most severe. Multiple BCR-ABL tyrosine kinase inhibitors (TKIs) are approved, and are the standard of care for CML. TKIs have transformed most cases of the disease into a manageable, chronic condition. As a result, patients survival rates and the prevalence of CML are increasing, placing a growing burden on global healthcare systems.

Tevas Synribo (omacetaxine mepesuccinate) is a chemotherapy for the treatment of CP or AP CML that is resistant to prior therapy with multiple TKIs. Synribo was originally developed by ChemGenex, <br><br>Original Post <a href=http://www.researchmoz.com/synribo-chronic-myeloid-leukemia-forecast-and-market-analysis-to-2022-report.html>Synribo (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Synribo (Chronic Myeloid Leukemia) Forecast and Market Analysis to 2022

Summary

GlobalData has released its new PharmaPoint Drug Evaluation report, Synribo (Chronic Myeloid Leukemia) Forecast and Market Analysis to 2022. Chronic myeloid leukemia (CML) is a rare myeloproliferative blood cancer that is characterized by the presence of the BCR-ABL fusion protein. The stage of CML is classified as chronic, accelerated or blast phase, ranging from least to most severe. Multiple BCR-ABL tyrosine kinase inhibitors (TKIs) are approved, and are the standard of care for CML. TKIs have transformed most cases of the disease into a manageable, chronic condition. As a result, patients survival rates and the prevalence of CML are increasing, placing a growing burden on global healthcare systems.

Tevas Synribo (omacetaxine mepesuccinate) is a chemotherapy for the treatment of CP or AP CML that is resistant to prior therapy with multiple TKIs. Synribo was originally developed by ChemGenex, <br><br>Original Post <a href=http://www.researchmoz.com/synribo-chronic-myeloid-leukemia-forecast-and-market-analysis-to-2022-report.html>Synribo (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/synribo-chronic-myeloid-leukemia-forecast-and-market-analysis-to-2022-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>EpiCast Report: Meningococcal Disease - Epidemiology Forecast to 2022</title><link>http://www.researchmoz.com/epicast-report-meningococcal-disease-epidemiology-forecast-to-2022-report.html</link><comments>http://www.researchmoz.com/epicast-report-meningococcal-disease-epidemiology-forecast-to-2022-report.html#comments</comments><pubDate>Wed, 15 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/epicast-report-meningococcal-disease-epidemiology-forecast-to-2022-report.html</guid><description><![CDATA[

EpiCast Report: Meningococcal Disease Epidemiology Forecast to 2022

Summary

Meningococcal disease is caused by Neisseria meningitidis, which is an encapsulated, Gram-negative bacterium that has an incidence of one to three cases per 100,000 population worldwide (Giuliani et al., 2006). Strains of Neisseria meningitidis are classified based on the chemical composition of unique polysaccharide capsules. Although there are 13 different serogroups, nearly all disease in humans is caused by strains representative of six serogroups: A, B, C, W-135, X and Y (CDC, 2012d; Halperin et al., 2012; Rosenstein et al., 2001). Humans are the only natural reservoir of Neisseria meningitidis, and the bacterium causes three common clinical forms of meningococcal disease: meningitis, blood infection, and pneumonia (CDC, 2012d; Wilder-Smith and Memish, 2003). Up to 10% of adolescents and adults are asymptomatic, transient carriers of the bacterium, which can be transmitted via respiratory droplet <br><br>Original Post <a href=http://www.researchmoz.com/epicast-report-meningococcal-disease-epidemiology-forecast-to-2022-report.html>EpiCast Report: Meningococcal Disease - Epidemiology Forecast to 2022</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

EpiCast Report: Meningococcal Disease Epidemiology Forecast to 2022

Summary

Meningococcal disease is caused by Neisseria meningitidis, which is an encapsulated, Gram-negative bacterium that has an incidence of one to three cases per 100,000 population worldwide (Giuliani et al., 2006). Strains of Neisseria meningitidis are classified based on the chemical composition of unique polysaccharide capsules. Although there are 13 different serogroups, nearly all disease in humans is caused by strains representative of six serogroups: A, B, C, W-135, X and Y (CDC, 2012d; Halperin et al., 2012; Rosenstein et al., 2001). Humans are the only natural reservoir of Neisseria meningitidis, and the bacterium causes three common clinical forms of meningococcal disease: meningitis, blood infection, and pneumonia (CDC, 2012d; Wilder-Smith and Memish, 2003). Up to 10% of adolescents and adults are asymptomatic, transient carriers of the bacterium, which can be transmitted via respiratory droplet <br><br>Original Post <a href=http://www.researchmoz.com/epicast-report-meningococcal-disease-epidemiology-forecast-to-2022-report.html>EpiCast Report: Meningococcal Disease - Epidemiology Forecast to 2022</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/epicast-report-meningococcal-disease-epidemiology-forecast-to-2022-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>MediFocus: Medical Devices for the Treatment of Obesity</title><link>http://www.researchmoz.com/medifocus-medical-devices-for-the-treatment-of-obesity-report.html</link><comments>http://www.researchmoz.com/medifocus-medical-devices-for-the-treatment-of-obesity-report.html#comments</comments><pubDate>Wed, 15 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/medifocus-medical-devices-for-the-treatment-of-obesity-report.html</guid><description><![CDATA[

MediFocus: Medical Devices for the Treatment of Obesity

Summary

The obesity treatment market is drastically underserved and considerably underdeveloped. While bariatric surgery has significant improvement in recent decades, evolving to become the gold standard for proven treatment in the absence of effective pharmacotherapy, only 1% of obese patients opt for surgical intervention. Less-invasive that surgery, obesity treatment medical devices have seen notable advancement in recent years, and several technologies have gained international adoption; however, long-term efficacy is still lacking, prompting continued development and ever-changing market competition.&nbsp;

GlobalData has released its medical device report, "MediFocus: Medical Devices for the Treatment of Obesity". The report offers a comprehensive analysis of the global obesity medical device market, including development and approval of artificial fullness devices, deep brain stimulation devices, endoscopic sur <br><br>Original Post <a href=http://www.researchmoz.com/medifocus-medical-devices-for-the-treatment-of-obesity-report.html>MediFocus: Medical Devices for the Treatment of Obesity</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

MediFocus: Medical Devices for the Treatment of Obesity

Summary

The obesity treatment market is drastically underserved and considerably underdeveloped. While bariatric surgery has significant improvement in recent decades, evolving to become the gold standard for proven treatment in the absence of effective pharmacotherapy, only 1% of obese patients opt for surgical intervention. Less-invasive that surgery, obesity treatment medical devices have seen notable advancement in recent years, and several technologies have gained international adoption; however, long-term efficacy is still lacking, prompting continued development and ever-changing market competition.&nbsp;

GlobalData has released its medical device report, "MediFocus: Medical Devices for the Treatment of Obesity". The report offers a comprehensive analysis of the global obesity medical device market, including development and approval of artificial fullness devices, deep brain stimulation devices, endoscopic sur <br><br>Original Post <a href=http://www.researchmoz.com/medifocus-medical-devices-for-the-treatment-of-obesity-report.html>MediFocus: Medical Devices for the Treatment of Obesity</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/medifocus-medical-devices-for-the-treatment-of-obesity-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Medical Equipment Monthly Deals Analysis: April 2013 - M&amp;A and Investment Trends</title><link>http://www.researchmoz.com/medical-equipment-monthly-deals-analysis-april-2013-manda-and-investment-trends-report.html</link><comments>http://www.researchmoz.com/medical-equipment-monthly-deals-analysis-april-2013-manda-and-investment-trends-report.html#comments</comments><pubDate>Wed, 15 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/medical-equipment-monthly-deals-analysis-april-2013-manda-and-investment-trends-report.html</guid><description><![CDATA[

Medical Equipment Monthly Deals Analysis: April 2013 M&amp;A and Investment Trends

Summary

GlobalData's Medical Equipment Monthly Deals Analysis: April 2013 M&amp;A and Investment Trends report is an essential source of data and trend analysis on the mergers and acquisitions (M&amp;As) and financings in the medical equipment industry. The report provides detailed information on M&amp;As, equity/debt offerings, private equity, venture financing and partnership transactions registered in the medical equipment industry in April 2013. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, segments and geographies. Additionally, the report provides information on the top financial advisory firms in the medical equipment industry.

Data presented in this report is derived from GlobalDatas proprietary in-house deals database and primary and secondary research.

Scope




Analyze market trends fo <br><br>Original Post <a href=http://www.researchmoz.com/medical-equipment-monthly-deals-analysis-april-2013-manda-and-investment-trends-report.html>Medical Equipment Monthly Deals Analysis: April 2013 - M&amp;A and Investment Trends</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Medical Equipment Monthly Deals Analysis: April 2013 M&amp;A and Investment Trends

Summary

GlobalData's Medical Equipment Monthly Deals Analysis: April 2013 M&amp;A and Investment Trends report is an essential source of data and trend analysis on the mergers and acquisitions (M&amp;As) and financings in the medical equipment industry. The report provides detailed information on M&amp;As, equity/debt offerings, private equity, venture financing and partnership transactions registered in the medical equipment industry in April 2013. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, segments and geographies. Additionally, the report provides information on the top financial advisory firms in the medical equipment industry.

Data presented in this report is derived from GlobalDatas proprietary in-house deals database and primary and secondary research.

Scope




Analyze market trends fo <br><br>Original Post <a href=http://www.researchmoz.com/medical-equipment-monthly-deals-analysis-april-2013-manda-and-investment-trends-report.html>Medical Equipment Monthly Deals Analysis: April 2013 - M&amp;A and Investment Trends</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/medical-equipment-monthly-deals-analysis-april-2013-manda-and-investment-trends-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Partnerships, Licensing, Investments and M&amp;A Deals and Trends for April 2013 in Pharmaceuticals</title><link>http://www.researchmoz.com/partnerships-licensing-investments-and-manda-deals-and-trends-for-april-2013-in-pharmaceuticals-report.html</link><comments>http://www.researchmoz.com/partnerships-licensing-investments-and-manda-deals-and-trends-for-april-2013-in-pharmaceuticals-report.html#comments</comments><pubDate>Wed, 15 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/partnerships-licensing-investments-and-manda-deals-and-trends-for-april-2013-in-pharmaceuticals-report.html</guid><description><![CDATA[

Partnerships, Licensing, Investments and M&amp;A Deals and Trends for April 2013 in Pharmaceuticals

Summary

GlobalData's Partnerships, Licensing, Investments and M&amp;A Deals and Trends for April 2013 in Pharmaceuticals report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&amp;As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&amp;As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in April 2013. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalDatas proprietary in-house deals database  <br><br>Original Post <a href=http://www.researchmoz.com/partnerships-licensing-investments-and-manda-deals-and-trends-for-april-2013-in-pharmaceuticals-report.html>Partnerships, Licensing, Investments and M&amp;A Deals and Trends for April 2013 in Pharmaceuticals</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Partnerships, Licensing, Investments and M&amp;A Deals and Trends for April 2013 in Pharmaceuticals

Summary

GlobalData's Partnerships, Licensing, Investments and M&amp;A Deals and Trends for April 2013 in Pharmaceuticals report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&amp;As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&amp;As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in April 2013. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalDatas proprietary in-house deals database  <br><br>Original Post <a href=http://www.researchmoz.com/partnerships-licensing-investments-and-manda-deals-and-trends-for-april-2013-in-pharmaceuticals-report.html>Partnerships, Licensing, Investments and M&amp;A Deals and Trends for April 2013 in Pharmaceuticals</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/partnerships-licensing-investments-and-manda-deals-and-trends-for-april-2013-in-pharmaceuticals-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Solar Trackers - Global Market Size, Average Price, Competitive Landscape and Key Country Analysis to 2020</title><link>http://www.researchmoz.com/solar-trackers-global-market-size-average-price-competitive-landscape-and-key-country-analysis-to-2020-report.html</link><comments>http://www.researchmoz.com/solar-trackers-global-market-size-average-price-competitive-landscape-and-key-country-analysis-to-2020-report.html#comments</comments><pubDate>Fri, 10 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/solar-trackers-global-market-size-average-price-competitive-landscape-and-key-country-analysis-to-2020-report.html</guid><description><![CDATA[Solar Trackers - Global Market Size, Average Price, Competitive Landscape and Key Country Analysis to 2020


Summary


Solar Trackers - Global Market Size, Average Price, Competitive Landscape and Key Country Analysis to 2020 is the latest report from industry analysis specialists GlobalData, offering comprehensive information and understanding of the solar trackers market. The research provides an understanding of the technology, key drivers and challenges in global solar trackers market.&nbsp;


It also provides historical and forecast data to 2020 for solar PV installed capacity and trackers installed. The report covers detailed sections on segmental analysis, price analysis and competitive landscape of major manufacturers. The report analyses solar PV power initiatives with policy framework in key countries such as Germany, Italy, Spain, Greece, the US, Canada, China and India.

The report is built using data and information sourced from proprietary databases, primary an <br><br>Original Post <a href=http://www.researchmoz.com/solar-trackers-global-market-size-average-price-competitive-landscape-and-key-country-analysis-to-2020-report.html>Solar Trackers - Global Market Size, Average Price, Competitive Landscape and Key Country Analysis to 2020</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[Solar Trackers - Global Market Size, Average Price, Competitive Landscape and Key Country Analysis to 2020


Summary


Solar Trackers - Global Market Size, Average Price, Competitive Landscape and Key Country Analysis to 2020 is the latest report from industry analysis specialists GlobalData, offering comprehensive information and understanding of the solar trackers market. The research provides an understanding of the technology, key drivers and challenges in global solar trackers market.&nbsp;


It also provides historical and forecast data to 2020 for solar PV installed capacity and trackers installed. The report covers detailed sections on segmental analysis, price analysis and competitive landscape of major manufacturers. The report analyses solar PV power initiatives with policy framework in key countries such as Germany, Italy, Spain, Greece, the US, Canada, China and India.

The report is built using data and information sourced from proprietary databases, primary an <br><br>Original Post <a href=http://www.researchmoz.com/solar-trackers-global-market-size-average-price-competitive-landscape-and-key-country-analysis-to-2020-report.html>Solar Trackers - Global Market Size, Average Price, Competitive Landscape and Key Country Analysis to 2020</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/solar-trackers-global-market-size-average-price-competitive-landscape-and-key-country-analysis-to-2020-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>MC3, Inc. - Product Pipeline Analysis, 2013 Update</title><link>http://www.researchmoz.com/mc3-inc-product-pipeline-analysis-2013-update-report.html</link><comments>http://www.researchmoz.com/mc3-inc-product-pipeline-analysis-2013-update-report.html#comments</comments><pubDate>Thu, 09 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/mc3-inc-product-pipeline-analysis-2013-update-report.html</guid><description><![CDATA[

Summary

MC3, Inc. (MC3) is a medical device company. The company provides medical devices for the cardiovascular markets. Its product portfolio includes BioLung-artificial lung, Mpump-blood pump and biocompatible coatings. MC3 has tools to transfer medical device technologies from concept stage to commercial product. The company does GLP testing which includes bench top fluid dynamic testing, invitro blood testing, mechanical properties of polymer, heart valve hemodynamic performance, design and oversight of animal studies. MC3 markets its products through brand Biolung. It is ISO 13485:2003 certified. MC3 is headquartered in Ann Arbor, Michigan, the US.

This report is a source for data, analysis and actionable intelligence on the MC3, Inc. portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the development stage, trial phase, product milestones, pipeline territory, estimated approval date, and est <br><br>Original Post <a href=http://www.researchmoz.com/mc3-inc-product-pipeline-analysis-2013-update-report.html>MC3, Inc. - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Summary

MC3, Inc. (MC3) is a medical device company. The company provides medical devices for the cardiovascular markets. Its product portfolio includes BioLung-artificial lung, Mpump-blood pump and biocompatible coatings. MC3 has tools to transfer medical device technologies from concept stage to commercial product. The company does GLP testing which includes bench top fluid dynamic testing, invitro blood testing, mechanical properties of polymer, heart valve hemodynamic performance, design and oversight of animal studies. MC3 markets its products through brand Biolung. It is ISO 13485:2003 certified. MC3 is headquartered in Ann Arbor, Michigan, the US.

This report is a source for data, analysis and actionable intelligence on the MC3, Inc. portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the development stage, trial phase, product milestones, pipeline territory, estimated approval date, and est <br><br>Original Post <a href=http://www.researchmoz.com/mc3-inc-product-pipeline-analysis-2013-update-report.html>MC3, Inc. - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/mc3-inc-product-pipeline-analysis-2013-update-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>InSightec Ltd. - Product Pipeline Analysis, 2013 Update</title><link>http://www.researchmoz.com/insightec-ltd-product-pipeline-analysis-2013-update-report.html</link><comments>http://www.researchmoz.com/insightec-ltd-product-pipeline-analysis-2013-update-report.html#comments</comments><pubDate>Thu, 09 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/insightec-ltd-product-pipeline-analysis-2013-update-report.html</guid><description><![CDATA[

Summary

InSightec Ltd. (InSightec) is a medical device company. The company develops and markets medical devices for the diagnostic markets. Its products include ExAblate O.R., ExAblate neuro and system components. The companys ExAblate neuro integrates ultrasound surgery with continuous magnetic resonance imaging (MRI) to provide a non invasive, acoustic surgery for treating neurological disorders. InSightecs system components include patient table, ergonomic cradle, cradle storage and replacement rack, operator console, equipment cabinet, and water system. Its ExAblate O.R. is used for the treatment of uterine fibroids and for adenomyosis. The company also offers a non-ionizing radiation treatment alternative for pain palliation of bone metastases. Its product was approved by the US Food and Drug Administration (FDA) for the treatment of symptomatic uterine fibroids. InSightec is headquartered in Tirat Carmel, Israel.

This report is a source for data, analysis and actionabl <br><br>Original Post <a href=http://www.researchmoz.com/insightec-ltd-product-pipeline-analysis-2013-update-report.html>InSightec Ltd. - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Summary

InSightec Ltd. (InSightec) is a medical device company. The company develops and markets medical devices for the diagnostic markets. Its products include ExAblate O.R., ExAblate neuro and system components. The companys ExAblate neuro integrates ultrasound surgery with continuous magnetic resonance imaging (MRI) to provide a non invasive, acoustic surgery for treating neurological disorders. InSightecs system components include patient table, ergonomic cradle, cradle storage and replacement rack, operator console, equipment cabinet, and water system. Its ExAblate O.R. is used for the treatment of uterine fibroids and for adenomyosis. The company also offers a non-ionizing radiation treatment alternative for pain palliation of bone metastases. Its product was approved by the US Food and Drug Administration (FDA) for the treatment of symptomatic uterine fibroids. InSightec is headquartered in Tirat Carmel, Israel.

This report is a source for data, analysis and actionabl <br><br>Original Post <a href=http://www.researchmoz.com/insightec-ltd-product-pipeline-analysis-2013-update-report.html>InSightec Ltd. - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/insightec-ltd-product-pipeline-analysis-2013-update-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Oxford Gene Technology - Product Pipeline Analysis, 2013 Update</title><link>http://www.researchmoz.com/oxford-gene-technology-product-pipeline-analysis-2013-update-report.html</link><comments>http://www.researchmoz.com/oxford-gene-technology-product-pipeline-analysis-2013-update-report.html#comments</comments><pubDate>Thu, 09 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/oxford-gene-technology-product-pipeline-analysis-2013-update-report.html</guid><description><![CDATA[

Summary

Oxford Gene Technology (OGT) is a biotechnology company. The company develops biomarkers. Its products include hematological cancer +SNP array, ISCA arrays, ISCA + SNP array, ISCA UPD array, ISCA sample tracking spike-ins, syndrome plus v2 array, molecular testing arrays and panels, DMD array, aneuploidy array, chromosome X arrays, custom designed aCGH arrays, genomic DNA labeling kits, interpret software, automation instruments and microbial array products. OGT offers services such as clinical genetic research, targeted sequencing, microarray services, diagnostic development, and immune-monitoring and in-house biomarker discovery. The companys customers include Agilent Technologies, University of Cambridge, Cancer Research UK, Alberta Childrens Hospital, Bioarray and many more. OGT is headquartered in Begbroke, Oxfordshire, the UK.

This report is a source for data, analysis and actionable intelligence on the Oxford Gene Technology portfolio of pipeline products. The  <br><br>Original Post <a href=http://www.researchmoz.com/oxford-gene-technology-product-pipeline-analysis-2013-update-report.html>Oxford Gene Technology - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Summary

Oxford Gene Technology (OGT) is a biotechnology company. The company develops biomarkers. Its products include hematological cancer +SNP array, ISCA arrays, ISCA + SNP array, ISCA UPD array, ISCA sample tracking spike-ins, syndrome plus v2 array, molecular testing arrays and panels, DMD array, aneuploidy array, chromosome X arrays, custom designed aCGH arrays, genomic DNA labeling kits, interpret software, automation instruments and microbial array products. OGT offers services such as clinical genetic research, targeted sequencing, microarray services, diagnostic development, and immune-monitoring and in-house biomarker discovery. The companys customers include Agilent Technologies, University of Cambridge, Cancer Research UK, Alberta Childrens Hospital, Bioarray and many more. OGT is headquartered in Begbroke, Oxfordshire, the UK.

This report is a source for data, analysis and actionable intelligence on the Oxford Gene Technology portfolio of pipeline products. The  <br><br>Original Post <a href=http://www.researchmoz.com/oxford-gene-technology-product-pipeline-analysis-2013-update-report.html>Oxford Gene Technology - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/oxford-gene-technology-product-pipeline-analysis-2013-update-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Digna Biotech, S.L. - Product Pipeline Analysis, 2013 Update</title><link>http://www.researchmoz.com/digna-biotech-sl-product-pipeline-analysis-2013-update-report.html</link><comments>http://www.researchmoz.com/digna-biotech-sl-product-pipeline-analysis-2013-update-report.html#comments</comments><pubDate>Thu, 09 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/digna-biotech-sl-product-pipeline-analysis-2013-update-report.html</guid><description><![CDATA[

Summary

Digna Biotech, S.L. (Digna) is a biotechnology company. The company generates robust clinical therapeutic and diagnostic candidates. It has eighteen products including 12 therapeutic candidates, four clinical-Stage Products, panning 23 indications across six key franchises, four diagnostic tests, and two research products. Dignas therapeutic areas include P144, P17, IFN alfa 5, cardiotrophin -1 (CT-1), AAV-phorphyria, IFN +CT1 + oncostatin and MTA. The company focuses research and development in oncology, cardiovascular physio pathology, neuroscience, and, finally, gene therapy and hepatology. It partners with DIGNA Biotech, CIMA, the University Clinic of Navarra, and the University of Navarra. Digna is headquartered in Pamplona, Spain.

This report is a source for data, analysis and actionable intelligence on the Digna Biotech, S.L. portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the de <br><br>Original Post <a href=http://www.researchmoz.com/digna-biotech-sl-product-pipeline-analysis-2013-update-report.html>Digna Biotech, S.L. - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Summary

Digna Biotech, S.L. (Digna) is a biotechnology company. The company generates robust clinical therapeutic and diagnostic candidates. It has eighteen products including 12 therapeutic candidates, four clinical-Stage Products, panning 23 indications across six key franchises, four diagnostic tests, and two research products. Dignas therapeutic areas include P144, P17, IFN alfa 5, cardiotrophin -1 (CT-1), AAV-phorphyria, IFN +CT1 + oncostatin and MTA. The company focuses research and development in oncology, cardiovascular physio pathology, neuroscience, and, finally, gene therapy and hepatology. It partners with DIGNA Biotech, CIMA, the University Clinic of Navarra, and the University of Navarra. Digna is headquartered in Pamplona, Spain.

This report is a source for data, analysis and actionable intelligence on the Digna Biotech, S.L. portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the de <br><br>Original Post <a href=http://www.researchmoz.com/digna-biotech-sl-product-pipeline-analysis-2013-update-report.html>Digna Biotech, S.L. - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/digna-biotech-sl-product-pipeline-analysis-2013-update-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Pronota NV - Product Pipeline Analysis, 2013 Update</title><link>http://www.researchmoz.com/pronota-nv-product-pipeline-analysis-2013-update-report.html</link><comments>http://www.researchmoz.com/pronota-nv-product-pipeline-analysis-2013-update-report.html#comments</comments><pubDate>Thu, 09 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/pronota-nv-product-pipeline-analysis-2013-update-report.html</guid><description><![CDATA[

Summary

Pronota NV (PNV) is a diagnostic service provider company. The company research and develops solutions for early life-threatening conditions. It provides products such as pre-eclampsia, cardio-renel syndrome, ovarian cancer and sepsis. PNV provide services such as non-invasive, validated and diagnostics, patent protected protein chemistry techniques, advanced separation sciences, high-end mass spectrometry and in house developed proprietary bioinformatics tools. Its technologies include MASStermind, a protein biomarker discovery platform that enables identification and relative quantitation of proteins; and MASSterclass, a mass spectrometry based antibody-free assay platform that provides contract assay development and biomarker screening services. The company also provides contract proteomic research and development services to the pharmaceutical and diagnostic industry. PNV is headquartered in Ghent, Flandre Orientale, Belgium.

This report is a source for data, anal <br><br>Original Post <a href=http://www.researchmoz.com/pronota-nv-product-pipeline-analysis-2013-update-report.html>Pronota NV - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Summary

Pronota NV (PNV) is a diagnostic service provider company. The company research and develops solutions for early life-threatening conditions. It provides products such as pre-eclampsia, cardio-renel syndrome, ovarian cancer and sepsis. PNV provide services such as non-invasive, validated and diagnostics, patent protected protein chemistry techniques, advanced separation sciences, high-end mass spectrometry and in house developed proprietary bioinformatics tools. Its technologies include MASStermind, a protein biomarker discovery platform that enables identification and relative quantitation of proteins; and MASSterclass, a mass spectrometry based antibody-free assay platform that provides contract assay development and biomarker screening services. The company also provides contract proteomic research and development services to the pharmaceutical and diagnostic industry. PNV is headquartered in Ghent, Flandre Orientale, Belgium.

This report is a source for data, anal <br><br>Original Post <a href=http://www.researchmoz.com/pronota-nv-product-pipeline-analysis-2013-update-report.html>Pronota NV - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/pronota-nv-product-pipeline-analysis-2013-update-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Adept Medical Limited - Product Pipeline Analysis, 2013 Update</title><link>http://www.researchmoz.com/adept-medical-limited-product-pipeline-analysis-2013-update-report.html</link><comments>http://www.researchmoz.com/adept-medical-limited-product-pipeline-analysis-2013-update-report.html#comments</comments><pubDate>Thu, 09 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/adept-medical-limited-product-pipeline-analysis-2013-update-report.html</guid><description><![CDATA[

Summary

Adept Medical Limited (Adept Medical) is a medical device company. The company manufactures and markets surgical and ENT products. Its product portfolio includes otological ventilation tubes, sterile otology kits and instruments, disposable ear care products, splints, and corner protector. The company offers STARBoard which is a forearm and hand support for trans-radial procedures. Its Corner Protector provides a barrier between the Sterile Wrap and the potentially sharp corners of an Instrument Tray. The company offers products for Otology, Rhinology and Interventional Cardiology. It develops products for central sterilisation service departments. The company markets its products under the trademark NeoZoline. Adept Medical is headquartered in Auckland, New Zealand.

This report is a source for data, analysis and actionable intelligence on the Adept Medical Limited portfolio of pipeline products. The report provides detailed analysis on each pipeline product with info <br><br>Original Post <a href=http://www.researchmoz.com/adept-medical-limited-product-pipeline-analysis-2013-update-report.html>Adept Medical Limited - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Summary

Adept Medical Limited (Adept Medical) is a medical device company. The company manufactures and markets surgical and ENT products. Its product portfolio includes otological ventilation tubes, sterile otology kits and instruments, disposable ear care products, splints, and corner protector. The company offers STARBoard which is a forearm and hand support for trans-radial procedures. Its Corner Protector provides a barrier between the Sterile Wrap and the potentially sharp corners of an Instrument Tray. The company offers products for Otology, Rhinology and Interventional Cardiology. It develops products for central sterilisation service departments. The company markets its products under the trademark NeoZoline. Adept Medical is headquartered in Auckland, New Zealand.

This report is a source for data, analysis and actionable intelligence on the Adept Medical Limited portfolio of pipeline products. The report provides detailed analysis on each pipeline product with info <br><br>Original Post <a href=http://www.researchmoz.com/adept-medical-limited-product-pipeline-analysis-2013-update-report.html>Adept Medical Limited - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/adept-medical-limited-product-pipeline-analysis-2013-update-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Spectros Corporation - Product Pipeline Analysis, 2013 Update</title><link>http://www.researchmoz.com/spectros-corporation-product-pipeline-analysis-2013-update-report.html</link><comments>http://www.researchmoz.com/spectros-corporation-product-pipeline-analysis-2013-update-report.html#comments</comments><pubDate>Thu, 09 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/spectros-corporation-product-pipeline-analysis-2013-update-report.html</guid><description><![CDATA[

Summary

Spectros Corporation (Spectros) is a medical device company. The company develops molecular sensing and imaging devices. Its T-Stat is the medical device to be labeled by the FDA as sensitive to ischemia. The companys T-Stat VLS Tissue Oximeter provides a continuous, non-invasive and localized measurement, sensitive to regional and global ischemia. Spectros consists of single-use tissue probes designed for specific application. Its sensor contains a visible white light source for illuminating the tissue and a fiber optic bundle that transmits directly back to the monitor. The company develops a series of optical agents for human clinical use. Spectros is headquartered in Portola Valley, California, the US.

This report is a source for data, analysis and actionable intelligence on the Spectros Corporation portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the development stage, trial phase,  <br><br>Original Post <a href=http://www.researchmoz.com/spectros-corporation-product-pipeline-analysis-2013-update-report.html>Spectros Corporation - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Summary

Spectros Corporation (Spectros) is a medical device company. The company develops molecular sensing and imaging devices. Its T-Stat is the medical device to be labeled by the FDA as sensitive to ischemia. The companys T-Stat VLS Tissue Oximeter provides a continuous, non-invasive and localized measurement, sensitive to regional and global ischemia. Spectros consists of single-use tissue probes designed for specific application. Its sensor contains a visible white light source for illuminating the tissue and a fiber optic bundle that transmits directly back to the monitor. The company develops a series of optical agents for human clinical use. Spectros is headquartered in Portola Valley, California, the US.

This report is a source for data, analysis and actionable intelligence on the Spectros Corporation portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the development stage, trial phase,  <br><br>Original Post <a href=http://www.researchmoz.com/spectros-corporation-product-pipeline-analysis-2013-update-report.html>Spectros Corporation - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/spectros-corporation-product-pipeline-analysis-2013-update-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>OraSure Technologies, Inc. (OSUR) - Product Pipeline Analysis, 2013 Update</title><link>http://www.researchmoz.com/orasure-technologies-inc-osur-product-pipeline-analysis-2013-update-report.html</link><comments>http://www.researchmoz.com/orasure-technologies-inc-osur-product-pipeline-analysis-2013-update-report.html#comments</comments><pubDate>Thu, 09 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/orasure-technologies-inc-osur-product-pipeline-analysis-2013-update-report.html</guid><description><![CDATA[

Summary

OraSure Technologies, Inc. (OraSure) caters to the in vitro diagnostics segment. The company undertakes the development, manufacture and sale of oral fluid specimen collection devices, diagnostic products, and other medical devices. The company also sells immunoassay tests and reagents for insurance risk assessment, substance-abuse testing and forensic toxicology applications. The company's products are distributed to various hospitals, clinics, community-based organizations and other public health organizations, distributors, government clinical laboratories, government agencies, physicians offices, and commercial and industrial entities. The company sells its product in North America, Europe, Central and South America, and Australia. OraSure is headquartered in Pennsylvania, the US.

This report is a source for data, analysis and actionable intelligence on the OraSure Technologies, Inc. portfolio of pipeline products. The report provides detailed analysis on each pip <br><br>Original Post <a href=http://www.researchmoz.com/orasure-technologies-inc-osur-product-pipeline-analysis-2013-update-report.html>OraSure Technologies, Inc. (OSUR) - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Summary

OraSure Technologies, Inc. (OraSure) caters to the in vitro diagnostics segment. The company undertakes the development, manufacture and sale of oral fluid specimen collection devices, diagnostic products, and other medical devices. The company also sells immunoassay tests and reagents for insurance risk assessment, substance-abuse testing and forensic toxicology applications. The company's products are distributed to various hospitals, clinics, community-based organizations and other public health organizations, distributors, government clinical laboratories, government agencies, physicians offices, and commercial and industrial entities. The company sells its product in North America, Europe, Central and South America, and Australia. OraSure is headquartered in Pennsylvania, the US.

This report is a source for data, analysis and actionable intelligence on the OraSure Technologies, Inc. portfolio of pipeline products. The report provides detailed analysis on each pip <br><br>Original Post <a href=http://www.researchmoz.com/orasure-technologies-inc-osur-product-pipeline-analysis-2013-update-report.html>OraSure Technologies, Inc. (OSUR) - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/orasure-technologies-inc-osur-product-pipeline-analysis-2013-update-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Tepha, Inc. - Product Pipeline Analysis, 2013 Update</title><link>http://www.researchmoz.com/tepha-inc-product-pipeline-analysis-2013-update-report.html</link><comments>http://www.researchmoz.com/tepha-inc-product-pipeline-analysis-2013-update-report.html#comments</comments><pubDate>Thu, 09 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/tepha-inc-product-pipeline-analysis-2013-update-report.html</guid><description><![CDATA[

Summary

Tepha, Inc. (Tepha) is a medical device company. The company develops and commercializes products based on its proprietary biomaterial technology. Its products include monofilament suture, monofilament mesh, surgical film and composite mesh. Tepha offers various platforms such as monofilament fiber, multifilament braid, multifilament mesh, nonwoven textiles, cardiovascular stents, microspheres and drug delivery. The companys products are made from two materials such as TephaFLEX material and TephELAST polymer. It also offers technologies such as polymer processing/material attributes, and polymer manufacturing. The company partners with B Braun and Tornier. It is FDA and ISO certified company. Tepha is headquartered in Lexington, Massachusetts, the US.

This report is a source for data, analysis and actionable intelligence on the Tepha, Inc. portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication <br><br>Original Post <a href=http://www.researchmoz.com/tepha-inc-product-pipeline-analysis-2013-update-report.html>Tepha, Inc. - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Summary

Tepha, Inc. (Tepha) is a medical device company. The company develops and commercializes products based on its proprietary biomaterial technology. Its products include monofilament suture, monofilament mesh, surgical film and composite mesh. Tepha offers various platforms such as monofilament fiber, multifilament braid, multifilament mesh, nonwoven textiles, cardiovascular stents, microspheres and drug delivery. The companys products are made from two materials such as TephaFLEX material and TephELAST polymer. It also offers technologies such as polymer processing/material attributes, and polymer manufacturing. The company partners with B Braun and Tornier. It is FDA and ISO certified company. Tepha is headquartered in Lexington, Massachusetts, the US.

This report is a source for data, analysis and actionable intelligence on the Tepha, Inc. portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication <br><br>Original Post <a href=http://www.researchmoz.com/tepha-inc-product-pipeline-analysis-2013-update-report.html>Tepha, Inc. - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/tepha-inc-product-pipeline-analysis-2013-update-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>InsightMRI - Product Pipeline Analysis, 2013 Update</title><link>http://www.researchmoz.com/insightmri-product-pipeline-analysis-2013-update-report.html</link><comments>http://www.researchmoz.com/insightmri-product-pipeline-analysis-2013-update-report.html#comments</comments><pubDate>Thu, 09 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/insightmri-product-pipeline-analysis-2013-update-report.html</guid><description><![CDATA[

Summary

InsightMRI is a medical device company. The company provides medical devices for the diagnostic imaging markets. Its human imaging products consist of breast coil, insight head coil, insight wrist coil, insight ankle coil and the insight knee coil. InsightMRIs customers include hospitals, clinics, surgery centers, physician offices, nursing homes, long-term care facilities, home healthcare, and retail healthcare. The company develops MRI electronics and apparatus for both clinical and research use. It has strong focus on its research and development activities and has a dedicated department, which develops new technologies and products. It is ISO 13485:2003 certified company. InsightMRI is headquartered in Worcester, Massachusetts, the US.

This report is a source for data, analysis and actionable intelligence on the InsightMRI portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the developm <br><br>Original Post <a href=http://www.researchmoz.com/insightmri-product-pipeline-analysis-2013-update-report.html>InsightMRI - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Summary

InsightMRI is a medical device company. The company provides medical devices for the diagnostic imaging markets. Its human imaging products consist of breast coil, insight head coil, insight wrist coil, insight ankle coil and the insight knee coil. InsightMRIs customers include hospitals, clinics, surgery centers, physician offices, nursing homes, long-term care facilities, home healthcare, and retail healthcare. The company develops MRI electronics and apparatus for both clinical and research use. It has strong focus on its research and development activities and has a dedicated department, which develops new technologies and products. It is ISO 13485:2003 certified company. InsightMRI is headquartered in Worcester, Massachusetts, the US.

This report is a source for data, analysis and actionable intelligence on the InsightMRI portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the developm <br><br>Original Post <a href=http://www.researchmoz.com/insightmri-product-pipeline-analysis-2013-update-report.html>InsightMRI - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/insightmri-product-pipeline-analysis-2013-update-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>BioResonator - Product Pipeline Analysis, 2013 Update</title><link>http://www.researchmoz.com/bioresonator-product-pipeline-analysis-2013-update-report.html</link><comments>http://www.researchmoz.com/bioresonator-product-pipeline-analysis-2013-update-report.html#comments</comments><pubDate>Thu, 09 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/bioresonator-product-pipeline-analysis-2013-update-report.html</guid><description><![CDATA[

Summary

BioResonator is a medical device company. It develops and markets biomedical sensors and diagnostic systems for the healthcare market. The companys products include ART manual and ART Servo. Its products are used for the diagnosis of various diseases. BioResonator provides services for glaucoma disease where medical examination is carried out based on intraocular pressure. It has entered into collaborative agreements with various universities and commercial organizations. The company conducts research and development activities for resonance technology, scientific verification of the technology and product development in the field of IOP-measurement. It is ISO 8612:2001 quality management systems certified. The company has distributed products in 16 European countries. BioResonator is headquartered in Umea, Sweden.

This report is a source for data, analysis and actionable intelligence on the BioResonator portfolio of pipeline products. The report provides detailed ana <br><br>Original Post <a href=http://www.researchmoz.com/bioresonator-product-pipeline-analysis-2013-update-report.html>BioResonator - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Summary

BioResonator is a medical device company. It develops and markets biomedical sensors and diagnostic systems for the healthcare market. The companys products include ART manual and ART Servo. Its products are used for the diagnosis of various diseases. BioResonator provides services for glaucoma disease where medical examination is carried out based on intraocular pressure. It has entered into collaborative agreements with various universities and commercial organizations. The company conducts research and development activities for resonance technology, scientific verification of the technology and product development in the field of IOP-measurement. It is ISO 8612:2001 quality management systems certified. The company has distributed products in 16 European countries. BioResonator is headquartered in Umea, Sweden.

This report is a source for data, analysis and actionable intelligence on the BioResonator portfolio of pipeline products. The report provides detailed ana <br><br>Original Post <a href=http://www.researchmoz.com/bioresonator-product-pipeline-analysis-2013-update-report.html>BioResonator - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/bioresonator-product-pipeline-analysis-2013-update-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>HyperBranch Medical Technology, Inc. - Product Pipeline Analysis, 2013 Update</title><link>http://www.researchmoz.com/hyperbranch-medical-technology-inc-product-pipeline-analysis-2013-update-report.html</link><comments>http://www.researchmoz.com/hyperbranch-medical-technology-inc-product-pipeline-analysis-2013-update-report.html#comments</comments><pubDate>Thu, 09 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/hyperbranch-medical-technology-inc-product-pipeline-analysis-2013-update-report.html</guid><description><![CDATA[

Summary

Hyper branch Medical Technology, Inc. (Hyper branch Medical) is a medical device company. The company develops and markets products for the surgically induced wound market. Its product portfolio includes ouzel liquid ocular bandage, durra sealant, hernia mesh fixation, spine sealant and cardiovascular sealant. The products are used in abdominoplasty surgical procedures, for stabilizing ocular wounds and also as an aid in intracranial aneurysms, tumors and spinal disc diseases. Its OcuSeal, a liquid ocular bandage is used for direct application on the surface of the eye to form an ocular bandage, covering an opening in the eye and providing an immediate protective barrier. The company also provides Adherus spinal sealant, which is used in spinal surgeries where a water tight seal is required to prevent cerebrospinal fluid leakage from the dural repair. It offers its products through distributors. Hyperbranch Medical is headquartered in Durham North Carolina, the US.

Th <br><br>Original Post <a href=http://www.researchmoz.com/hyperbranch-medical-technology-inc-product-pipeline-analysis-2013-update-report.html>HyperBranch Medical Technology, Inc. - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Summary

Hyper branch Medical Technology, Inc. (Hyper branch Medical) is a medical device company. The company develops and markets products for the surgically induced wound market. Its product portfolio includes ouzel liquid ocular bandage, durra sealant, hernia mesh fixation, spine sealant and cardiovascular sealant. The products are used in abdominoplasty surgical procedures, for stabilizing ocular wounds and also as an aid in intracranial aneurysms, tumors and spinal disc diseases. Its OcuSeal, a liquid ocular bandage is used for direct application on the surface of the eye to form an ocular bandage, covering an opening in the eye and providing an immediate protective barrier. The company also provides Adherus spinal sealant, which is used in spinal surgeries where a water tight seal is required to prevent cerebrospinal fluid leakage from the dural repair. It offers its products through distributors. Hyperbranch Medical is headquartered in Durham North Carolina, the US.

Th <br><br>Original Post <a href=http://www.researchmoz.com/hyperbranch-medical-technology-inc-product-pipeline-analysis-2013-update-report.html>HyperBranch Medical Technology, Inc. - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/hyperbranch-medical-technology-inc-product-pipeline-analysis-2013-update-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Caprion Inc. - Product Pipeline Analysis, 2013 Update</title><link>http://www.researchmoz.com/caprion-inc-product-pipeline-analysis-2013-update-report.html</link><comments>http://www.researchmoz.com/caprion-inc-product-pipeline-analysis-2013-update-report.html#comments</comments><pubDate>Thu, 09 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/caprion-inc-product-pipeline-analysis-2013-update-report.html</guid><description><![CDATA[


Summary


Caprion Inc. (Caprion) is a biotechnology company. The company provides proteomics biomarker and target identification services. It offers services such as biomarker services, in-vitro diagnostics and drug targets. Caprion provides services for target discovery and clinical validation of biomarkers using its proteomics discovery platform CellCarta. Caprions CellCarta is used in profiling proteins in solid tissues and plasma. It develops in-vitro diagnostic product candidates in the areas of infectious diseases, oncology and diabetes. It also provides bio analytical services, cell fractionation and sample procurement services. It has manufacturing facilities in Montreal, Quebec and Menlo Park, California, The company serves various pharmaceutical industry and clients from North America, Europe, and Asia. Caprion is headquartered in Montreal, Quebec, Canada.

This report is a source for data, analysis and actionable intelligence on the Caprion Inc. portfolio of pipel <br><br>Original Post <a href=http://www.researchmoz.com/caprion-inc-product-pipeline-analysis-2013-update-report.html>Caprion Inc. - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[


Summary


Caprion Inc. (Caprion) is a biotechnology company. The company provides proteomics biomarker and target identification services. It offers services such as biomarker services, in-vitro diagnostics and drug targets. Caprion provides services for target discovery and clinical validation of biomarkers using its proteomics discovery platform CellCarta. Caprions CellCarta is used in profiling proteins in solid tissues and plasma. It develops in-vitro diagnostic product candidates in the areas of infectious diseases, oncology and diabetes. It also provides bio analytical services, cell fractionation and sample procurement services. It has manufacturing facilities in Montreal, Quebec and Menlo Park, California, The company serves various pharmaceutical industry and clients from North America, Europe, and Asia. Caprion is headquartered in Montreal, Quebec, Canada.

This report is a source for data, analysis and actionable intelligence on the Caprion Inc. portfolio of pipel <br><br>Original Post <a href=http://www.researchmoz.com/caprion-inc-product-pipeline-analysis-2013-update-report.html>Caprion Inc. - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/caprion-inc-product-pipeline-analysis-2013-update-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Tissue Regenix Ltd - Product Pipeline Analysis, 2013 Update</title><link>http://www.researchmoz.com/tissue-regenix-ltd-product-pipeline-analysis-2013-update-report.html</link><comments>http://www.researchmoz.com/tissue-regenix-ltd-product-pipeline-analysis-2013-update-report.html#comments</comments><pubDate>Thu, 09 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/tissue-regenix-ltd-product-pipeline-analysis-2013-update-report.html</guid><description><![CDATA[


Summary


Tissue Regenix Ltd (TRL) is a medical technology company. The company develops solutions in the areas of Vascular, Cardiac and Orthopaedics. Its product includes dcell vascular patch. TRL offers two products into the clinic, which comprises a vascular patch and an A-V graft among several other products in cardiac and orthopaedic areas. The company develops and commercializes cellular tissue repair products. It provides biocompatible patch for peripheral vascular reconstruction and infiltration of the patients own cells allowing host tissue regeneration. The company applications are applied for critical clinical needs such as vascular disease, heart valve replacement and knee repair. TRL is headquartered in Heslington, York, the UK.

This report is a source for data, analysis and actionable intelligence on the Tissue Regenix Ltd portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the deve <br><br>Original Post <a href=http://www.researchmoz.com/tissue-regenix-ltd-product-pipeline-analysis-2013-update-report.html>Tissue Regenix Ltd - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[


Summary


Tissue Regenix Ltd (TRL) is a medical technology company. The company develops solutions in the areas of Vascular, Cardiac and Orthopaedics. Its product includes dcell vascular patch. TRL offers two products into the clinic, which comprises a vascular patch and an A-V graft among several other products in cardiac and orthopaedic areas. The company develops and commercializes cellular tissue repair products. It provides biocompatible patch for peripheral vascular reconstruction and infiltration of the patients own cells allowing host tissue regeneration. The company applications are applied for critical clinical needs such as vascular disease, heart valve replacement and knee repair. TRL is headquartered in Heslington, York, the UK.

This report is a source for data, analysis and actionable intelligence on the Tissue Regenix Ltd portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the deve <br><br>Original Post <a href=http://www.researchmoz.com/tissue-regenix-ltd-product-pipeline-analysis-2013-update-report.html>Tissue Regenix Ltd - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/tissue-regenix-ltd-product-pipeline-analysis-2013-update-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>JetGuide Ltd. - Product Pipeline Analysis, 2013 Update</title><link>http://www.researchmoz.com/jetguide-ltd-product-pipeline-analysis-2013-update-report.html</link><comments>http://www.researchmoz.com/jetguide-ltd-product-pipeline-analysis-2013-update-report.html#comments</comments><pubDate>Thu, 09 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/jetguide-ltd-product-pipeline-analysis-2013-update-report.html</guid><description><![CDATA[

Summary

JetGuide Ltd. (JetGuide) is a medical device company. The company develops systems for real-time intraoperative monitoring with feedback throughout processes of surgical procedures of bone drilling and dissecting tumor from soft healthy tissue. It provides a solution to one of the major problems of dental implantology-optimal drilling. JetGuide's technology is based on ultrasonic wave transmission and reception through a jet stream of liquid, as physiological solution, to measure the distance between the bottom of the drilled bore in the bone and the upper layer of sensitive tissue throughout the drilling procedure. The company also offers applications such as trauma, plastic surgeries and ENT. JetGuide is headquartered in Haifa, Israel.

This report is a source for data, analysis and actionable intelligence on the JetGuide Ltd. portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the develop <br><br>Original Post <a href=http://www.researchmoz.com/jetguide-ltd-product-pipeline-analysis-2013-update-report.html>JetGuide Ltd. - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Summary

JetGuide Ltd. (JetGuide) is a medical device company. The company develops systems for real-time intraoperative monitoring with feedback throughout processes of surgical procedures of bone drilling and dissecting tumor from soft healthy tissue. It provides a solution to one of the major problems of dental implantology-optimal drilling. JetGuide's technology is based on ultrasonic wave transmission and reception through a jet stream of liquid, as physiological solution, to measure the distance between the bottom of the drilled bore in the bone and the upper layer of sensitive tissue throughout the drilling procedure. The company also offers applications such as trauma, plastic surgeries and ENT. JetGuide is headquartered in Haifa, Israel.

This report is a source for data, analysis and actionable intelligence on the JetGuide Ltd. portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the develop <br><br>Original Post <a href=http://www.researchmoz.com/jetguide-ltd-product-pipeline-analysis-2013-update-report.html>JetGuide Ltd. - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/jetguide-ltd-product-pipeline-analysis-2013-update-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Innocoll Technologies Ltd - Product Pipeline Analysis, 2013 Update</title><link>http://www.researchmoz.com/innocoll-technologies-ltd-product-pipeline-analysis-2013-update-report.html</link><comments>http://www.researchmoz.com/innocoll-technologies-ltd-product-pipeline-analysis-2013-update-report.html#comments</comments><pubDate>Thu, 09 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/innocoll-technologies-ltd-product-pipeline-analysis-2013-update-report.html</guid><description><![CDATA[

Summary

Innocoll Technologies Ltd (Innocoll Technologies) is a biopharmaceutical company. The company develops and markets drug delivery devices for the pharmaceutical and medical markets. Its products include cogenzia, xaracoll, gentamicin surgical implant, procoll and durieva. The companys approved products include zorprevasurgical haemostat, collacare family, gentamicin surgical implant, collexa, lidocoll, collaguard adhesion barrier and innocoll dental. Its products are developed using its technologies namely CollaRx and Liquicoll. Innocoll Technologies products are used in a variety of medical applications such as preventing surgical adhesions in the treatment of post-operative or post-traumatic pain or inflammation and treating deep wounds such as ulcers, burns and acute trauma injuries. It partners with Baxter, EUSA pharma, Merus labs, curesys, KMA and Pioneer Pharma. Innocoll Technologies is headquartered in Westmeath, Ireland.

This report is a source for data, analys <br><br>Original Post <a href=http://www.researchmoz.com/innocoll-technologies-ltd-product-pipeline-analysis-2013-update-report.html>Innocoll Technologies Ltd - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Summary

Innocoll Technologies Ltd (Innocoll Technologies) is a biopharmaceutical company. The company develops and markets drug delivery devices for the pharmaceutical and medical markets. Its products include cogenzia, xaracoll, gentamicin surgical implant, procoll and durieva. The companys approved products include zorprevasurgical haemostat, collacare family, gentamicin surgical implant, collexa, lidocoll, collaguard adhesion barrier and innocoll dental. Its products are developed using its technologies namely CollaRx and Liquicoll. Innocoll Technologies products are used in a variety of medical applications such as preventing surgical adhesions in the treatment of post-operative or post-traumatic pain or inflammation and treating deep wounds such as ulcers, burns and acute trauma injuries. It partners with Baxter, EUSA pharma, Merus labs, curesys, KMA and Pioneer Pharma. Innocoll Technologies is headquartered in Westmeath, Ireland.

This report is a source for data, analys <br><br>Original Post <a href=http://www.researchmoz.com/innocoll-technologies-ltd-product-pipeline-analysis-2013-update-report.html>Innocoll Technologies Ltd - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/innocoll-technologies-ltd-product-pipeline-analysis-2013-update-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Luminex Corporation (LMNX) - Product Pipeline Analysis, 2013 Update</title><link>http://www.researchmoz.com/luminex-corporation-lmnx-product-pipeline-analysis-2013-update-report.html</link><comments>http://www.researchmoz.com/luminex-corporation-lmnx-product-pipeline-analysis-2013-update-report.html#comments</comments><pubDate>Thu, 09 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/luminex-corporation-lmnx-product-pipeline-analysis-2013-update-report.html</guid><description><![CDATA[

Summary

Luminex Corporation (Luminex) is a medical devices company, which develops, manufactures and markets its proprietary biological testing technologies. Its proprietary technologies consist of xMAP technology, xTAG and MultiCode technology. It operates its business through two reportable business segments, namely, the Technology and Strategic Partnerships (TSP) segment and the Assays and Related Products (ARP) segment. Its TRP segment's product portfolio consists of Luminex LX 100/200, FLEXMAP 3D and MAGPIX; xPONENT, MicroPlex Microspheres, MagPlex Microspheres, xTAG Microspheres, SeroMAP Microspheres, and calibration and control microspheres. The ARP segment comprises assay products including respiratory viral family, gastrointestinal pathogen detection family, MultiCode assays and products family, among others. Luminex offers its product and services in the North America, Europe and Asia-Pacific. Luminex is headquartered in Texas, the US.&nbsp;

The company focuses on s <br><br>Original Post <a href=http://www.researchmoz.com/luminex-corporation-lmnx-product-pipeline-analysis-2013-update-report.html>Luminex Corporation (LMNX) - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Summary

Luminex Corporation (Luminex) is a medical devices company, which develops, manufactures and markets its proprietary biological testing technologies. Its proprietary technologies consist of xMAP technology, xTAG and MultiCode technology. It operates its business through two reportable business segments, namely, the Technology and Strategic Partnerships (TSP) segment and the Assays and Related Products (ARP) segment. Its TRP segment's product portfolio consists of Luminex LX 100/200, FLEXMAP 3D and MAGPIX; xPONENT, MicroPlex Microspheres, MagPlex Microspheres, xTAG Microspheres, SeroMAP Microspheres, and calibration and control microspheres. The ARP segment comprises assay products including respiratory viral family, gastrointestinal pathogen detection family, MultiCode assays and products family, among others. Luminex offers its product and services in the North America, Europe and Asia-Pacific. Luminex is headquartered in Texas, the US.&nbsp;

The company focuses on s <br><br>Original Post <a href=http://www.researchmoz.com/luminex-corporation-lmnx-product-pipeline-analysis-2013-update-report.html>Luminex Corporation (LMNX) - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/luminex-corporation-lmnx-product-pipeline-analysis-2013-update-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Merit Medical Systems, Inc. (MMSI) - Product Pipeline Analysis, 2013 Update</title><link>http://www.researchmoz.com/merit-medical-systems-inc-mmsi-product-pipeline-analysis-2013-update-report.html</link><comments>http://www.researchmoz.com/merit-medical-systems-inc-mmsi-product-pipeline-analysis-2013-update-report.html#comments</comments><pubDate>Thu, 09 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/merit-medical-systems-inc-mmsi-product-pipeline-analysis-2013-update-report.html</guid><description><![CDATA[

Summary

Merit Medical Systems, Inc. (Merit Medical) is a medical device company. It undertakes the manufacturing and marketing of single-use medical devices for use in interventional and diagnostic procedures. Its product lines include inflation devices and accessories, diagnostic and therapeutic catheters and guide wires, pressure sensors, medication syringes, safety products, and needles. The company has expertise in four primary areas, namely, radiology, cardiology, pulmonology, and gastroenterology. The company markets and sells its products through direct sales force in the US and Europe and through a network of OEM partners and distributors in the Europe, Africa, Middle East, Asia, South and Central America, and Canada. Merit Medical is headquartered in Utah, the US.&nbsp;

The company focuses on expanding its product portfolio as recently, it launched various products including Embosphere Microspheres and others.

This report is a source for data, analysis and actiona <br><br>Original Post <a href=http://www.researchmoz.com/merit-medical-systems-inc-mmsi-product-pipeline-analysis-2013-update-report.html>Merit Medical Systems, Inc. (MMSI) - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Summary

Merit Medical Systems, Inc. (Merit Medical) is a medical device company. It undertakes the manufacturing and marketing of single-use medical devices for use in interventional and diagnostic procedures. Its product lines include inflation devices and accessories, diagnostic and therapeutic catheters and guide wires, pressure sensors, medication syringes, safety products, and needles. The company has expertise in four primary areas, namely, radiology, cardiology, pulmonology, and gastroenterology. The company markets and sells its products through direct sales force in the US and Europe and through a network of OEM partners and distributors in the Europe, Africa, Middle East, Asia, South and Central America, and Canada. Merit Medical is headquartered in Utah, the US.&nbsp;

The company focuses on expanding its product portfolio as recently, it launched various products including Embosphere Microspheres and others.

This report is a source for data, analysis and actiona <br><br>Original Post <a href=http://www.researchmoz.com/merit-medical-systems-inc-mmsi-product-pipeline-analysis-2013-update-report.html>Merit Medical Systems, Inc. (MMSI) - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/merit-medical-systems-inc-mmsi-product-pipeline-analysis-2013-update-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Stratatech Corporation - Product Pipeline Analysis, 2013 Update</title><link>http://www.researchmoz.com/stratatech-corporation-product-pipeline-analysis-2013-update-report.html</link><comments>http://www.researchmoz.com/stratatech-corporation-product-pipeline-analysis-2013-update-report.html#comments</comments><pubDate>Thu, 09 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/stratatech-corporation-product-pipeline-analysis-2013-update-report.html</guid><description><![CDATA[

Summary

Stratatech Corporation (Stratatech) is a regenerative medicine company. The company provides proprietary skin substitute products for therapeutic and research uses. It offers human tissue substitutes generated with NIKS keratinocytes and cells derived from them for biological therapies. Stratatech's products include stratagraft, a temporary wound cover that promotes wound healing by the patient's own cells and improve the wound bed to receive autografts; expressgraft, a genetically enhanced tissue that produces various levels of natural wound healing and antimicrobial factors and stratatest. Stratatech is headquartered in Madison, Wisconsin, the US.

This report is a source for data, analysis and actionable intelligence on the Stratatech Corporation portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the development stage, trial phase, product milestones, pipeline territory, estimated approv <br><br>Original Post <a href=http://www.researchmoz.com/stratatech-corporation-product-pipeline-analysis-2013-update-report.html>Stratatech Corporation - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Summary

Stratatech Corporation (Stratatech) is a regenerative medicine company. The company provides proprietary skin substitute products for therapeutic and research uses. It offers human tissue substitutes generated with NIKS keratinocytes and cells derived from them for biological therapies. Stratatech's products include stratagraft, a temporary wound cover that promotes wound healing by the patient's own cells and improve the wound bed to receive autografts; expressgraft, a genetically enhanced tissue that produces various levels of natural wound healing and antimicrobial factors and stratatest. Stratatech is headquartered in Madison, Wisconsin, the US.

This report is a source for data, analysis and actionable intelligence on the Stratatech Corporation portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the development stage, trial phase, product milestones, pipeline territory, estimated approv <br><br>Original Post <a href=http://www.researchmoz.com/stratatech-corporation-product-pipeline-analysis-2013-update-report.html>Stratatech Corporation - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/stratatech-corporation-product-pipeline-analysis-2013-update-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Delcath Systems, Inc. (DCTH) - Product Pipeline Analysis, 2013 Update</title><link>http://www.researchmoz.com/delcath-systems-inc-dcth-product-pipeline-analysis-2013-update-report.html</link><comments>http://www.researchmoz.com/delcath-systems-inc-dcth-product-pipeline-analysis-2013-update-report.html#comments</comments><pubDate>Thu, 09 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/delcath-systems-inc-dcth-product-pipeline-analysis-2013-update-report.html</guid><description><![CDATA[

Summary

Delcath Systems, Inc. (Delcath) is a US-based development stage, specialty pharmaceutical and medical device company. It specializes in developing percutaneous perfusion technologies for the targeted administration of high-dose chemotherapeutic agents to treat primary and metastatic liver cancers. Delcath's patented drug delivery platform delivers ultra-high doses of anti-cancer drugs to the liver, while preventing them from entering the patient's bloodstream. Its clinical trial product, the Delcath Percutaneous Hepatic Perfusion System (the Delcath PHP System), also known as Hepatic Chemosaturation therapy allows physicians to deliver ultra-high doses of anti-cancer agents to the liver while controlling their systemic exposure. Delcath is headquartered in New York City, New York, the US.

This report is a source for data, analysis and actionable intelligence on the Delcath Systems, Inc. portfolio of pipeline products. The report provides detailed analysis on each pipe <br><br>Original Post <a href=http://www.researchmoz.com/delcath-systems-inc-dcth-product-pipeline-analysis-2013-update-report.html>Delcath Systems, Inc. (DCTH) - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Summary

Delcath Systems, Inc. (Delcath) is a US-based development stage, specialty pharmaceutical and medical device company. It specializes in developing percutaneous perfusion technologies for the targeted administration of high-dose chemotherapeutic agents to treat primary and metastatic liver cancers. Delcath's patented drug delivery platform delivers ultra-high doses of anti-cancer drugs to the liver, while preventing them from entering the patient's bloodstream. Its clinical trial product, the Delcath Percutaneous Hepatic Perfusion System (the Delcath PHP System), also known as Hepatic Chemosaturation therapy allows physicians to deliver ultra-high doses of anti-cancer agents to the liver while controlling their systemic exposure. Delcath is headquartered in New York City, New York, the US.

This report is a source for data, analysis and actionable intelligence on the Delcath Systems, Inc. portfolio of pipeline products. The report provides detailed analysis on each pipe <br><br>Original Post <a href=http://www.researchmoz.com/delcath-systems-inc-dcth-product-pipeline-analysis-2013-update-report.html>Delcath Systems, Inc. (DCTH) - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/delcath-systems-inc-dcth-product-pipeline-analysis-2013-update-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Rayner Intraocular Lenses Limited - Product Pipeline Analysis, 2013 Update</title><link>http://www.researchmoz.com/rayner-intraocular-lenses-limited-product-pipeline-analysis-2013-update-report.html</link><comments>http://www.researchmoz.com/rayner-intraocular-lenses-limited-product-pipeline-analysis-2013-update-report.html#comments</comments><pubDate>Thu, 09 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/rayner-intraocular-lenses-limited-product-pipeline-analysis-2013-update-report.html</guid><description><![CDATA[

Summary

Rayner Intraocular Lenses Limited (Rayner) is a medical device company. The company manufactures intra ocular lens (IOL). Its products include sulcoflex which includes sulcoflex aspheric, sulcoflex toric and sulcoflex multifocal; multifocal which includes M-flex, M-flex T and sulcoflex multifocul; toric which includes T-flex, M-flex T and sulcoflex toric; spherical which includes C-flex and superflex; aspheric which includes C-flex, superflex and sulcoflex; surgical equipment, lense injection system, PMMA intraocular lenses. Rayner also provides web based toric calculator and ordering system namely Raytrace. The company operates as a subsidiary of Rayner &amp; Keeler Ltd. Rayner is headquartered in Hove, East Sussex, the UK.

This report is a source for data, analysis and actionable intelligence on the Rayner Intraocular Lenses Limited portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the  <br><br>Original Post <a href=http://www.researchmoz.com/rayner-intraocular-lenses-limited-product-pipeline-analysis-2013-update-report.html>Rayner Intraocular Lenses Limited - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Summary

Rayner Intraocular Lenses Limited (Rayner) is a medical device company. The company manufactures intra ocular lens (IOL). Its products include sulcoflex which includes sulcoflex aspheric, sulcoflex toric and sulcoflex multifocal; multifocal which includes M-flex, M-flex T and sulcoflex multifocul; toric which includes T-flex, M-flex T and sulcoflex toric; spherical which includes C-flex and superflex; aspheric which includes C-flex, superflex and sulcoflex; surgical equipment, lense injection system, PMMA intraocular lenses. Rayner also provides web based toric calculator and ordering system namely Raytrace. The company operates as a subsidiary of Rayner &amp; Keeler Ltd. Rayner is headquartered in Hove, East Sussex, the UK.

This report is a source for data, analysis and actionable intelligence on the Rayner Intraocular Lenses Limited portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the  <br><br>Original Post <a href=http://www.researchmoz.com/rayner-intraocular-lenses-limited-product-pipeline-analysis-2013-update-report.html>Rayner Intraocular Lenses Limited - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/rayner-intraocular-lenses-limited-product-pipeline-analysis-2013-update-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Perfint Healthcare Pvt. Ltd. - Product Pipeline Analysis, 2013 Update</title><link>http://www.researchmoz.com/perfint-healthcare-pvt-ltd-product-pipeline-analysis-2013-update-report.html</link><comments>http://www.researchmoz.com/perfint-healthcare-pvt-ltd-product-pipeline-analysis-2013-update-report.html#comments</comments><pubDate>Thu, 09 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/perfint-healthcare-pvt-ltd-product-pipeline-analysis-2013-update-report.html</guid><description><![CDATA[
Summary

Perfint Healthcare Pvt. Ltd. (Perfint) is a medical device company. The company develops medical devices for the healthcare market. Its products include Maxio, Robio EX, Robio EZ and Robio. Robio are used by radiologists for biopsy, drug delivery, ablation, drainage and fine needle aspiration. Perfints Maxio product allows clinicians to visually plan, execute, and validate ablation procedures on a single system, and all in 3D. The company installs products in Hospital. It is CE certified company. The company has its presence in the US and China. Perfint is headquartered in Chennai, Tamil Nadu, India.

This report is a source for data, analysis and actionable intelligence on the Perfint Healthcare Pvt. Ltd. portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the development stage, trial phase, product milestones, pipeline territory, estimated approval date, and estimated launch date.

Each pi <br><br>Original Post <a href=http://www.researchmoz.com/perfint-healthcare-pvt-ltd-product-pipeline-analysis-2013-update-report.html>Perfint Healthcare Pvt. Ltd. - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[
Summary

Perfint Healthcare Pvt. Ltd. (Perfint) is a medical device company. The company develops medical devices for the healthcare market. Its products include Maxio, Robio EX, Robio EZ and Robio. Robio are used by radiologists for biopsy, drug delivery, ablation, drainage and fine needle aspiration. Perfints Maxio product allows clinicians to visually plan, execute, and validate ablation procedures on a single system, and all in 3D. The company installs products in Hospital. It is CE certified company. The company has its presence in the US and China. Perfint is headquartered in Chennai, Tamil Nadu, India.

This report is a source for data, analysis and actionable intelligence on the Perfint Healthcare Pvt. Ltd. portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the development stage, trial phase, product milestones, pipeline territory, estimated approval date, and estimated launch date.

Each pi <br><br>Original Post <a href=http://www.researchmoz.com/perfint-healthcare-pvt-ltd-product-pipeline-analysis-2013-update-report.html>Perfint Healthcare Pvt. Ltd. - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/perfint-healthcare-pvt-ltd-product-pipeline-analysis-2013-update-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Advanced Medical Diagnostics, LLC. - Product Pipeline Analysis, 2013 Update</title><link>http://www.researchmoz.com/advanced-medical-diagnostics-llc-product-pipeline-analysis-2013-update-report.html</link><comments>http://www.researchmoz.com/advanced-medical-diagnostics-llc-product-pipeline-analysis-2013-update-report.html#comments</comments><pubDate>Thu, 09 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/advanced-medical-diagnostics-llc-product-pipeline-analysis-2013-update-report.html</guid><description><![CDATA[

Summary

Advanced Medical Diagnostics, LLC. (AMD) is a medical device company. The company develops plans to elevate the quality of medical care and to improve the financial performance of small and mid-size hospitals. Its services include imaging utilization and market assessment, equipment upgrade or installation, unparalleled flexibility, technologist training, physician education, medical marketing, and legal consultation. The company offers services which provides clinical and financial consulting, technologist training, and risk-free utilization of next generation imaging equipment. It operates through hospitals, physician offices, and imaging centers. The company assists hospital administrators and physicians from dozens of hospitals across the country. AMD is headquartered in Mission Viejo, California, the US.

This report is a source for data, analysis and actionable intelligence on the Advanced Medical Diagnostics, LLC. portfolio of pipeline products. The report provi <br><br>Original Post <a href=http://www.researchmoz.com/advanced-medical-diagnostics-llc-product-pipeline-analysis-2013-update-report.html>Advanced Medical Diagnostics, LLC. - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Summary

Advanced Medical Diagnostics, LLC. (AMD) is a medical device company. The company develops plans to elevate the quality of medical care and to improve the financial performance of small and mid-size hospitals. Its services include imaging utilization and market assessment, equipment upgrade or installation, unparalleled flexibility, technologist training, physician education, medical marketing, and legal consultation. The company offers services which provides clinical and financial consulting, technologist training, and risk-free utilization of next generation imaging equipment. It operates through hospitals, physician offices, and imaging centers. The company assists hospital administrators and physicians from dozens of hospitals across the country. AMD is headquartered in Mission Viejo, California, the US.

This report is a source for data, analysis and actionable intelligence on the Advanced Medical Diagnostics, LLC. portfolio of pipeline products. The report provi <br><br>Original Post <a href=http://www.researchmoz.com/advanced-medical-diagnostics-llc-product-pipeline-analysis-2013-update-report.html>Advanced Medical Diagnostics, LLC. - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/advanced-medical-diagnostics-llc-product-pipeline-analysis-2013-update-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>VentriPoint, Inc. - Product Pipeline Analysis, 2013 Update</title><link>http://www.researchmoz.com/ventripoint-inc-product-pipeline-analysis-2013-update-report.html</link><comments>http://www.researchmoz.com/ventripoint-inc-product-pipeline-analysis-2013-update-report.html#comments</comments><pubDate>Thu, 09 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/ventripoint-inc-product-pipeline-analysis-2013-update-report.html</guid><description><![CDATA[

Summary

VentriPoint, Inc. (VentriPoint) is a medical device company. The company develops and markets medical devices for the cardiovascular market. Its product includes ventripoint diagnostic system, which is used for the measurement of right ventricular volume. VentriPoints medical systems are utilized by pediatric cardiologists in the treatment of children and adults suffering from congenital heart defects. The company provides right and left ventricular volume and function accurately. It sells its products through the brand name, VMS. The company also offers a virtual 3D surface to complement the 2D views. It is a subsidiary of VentriPoint Diagnostics Ltd. VentriPoint is headquartered in Seattle, Washington, the US.

This report is a source for data, analysis and actionable intelligence on the VentriPoint, Inc. portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the development stage, trial phas <br><br>Original Post <a href=http://www.researchmoz.com/ventripoint-inc-product-pipeline-analysis-2013-update-report.html>VentriPoint, Inc. - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Summary

VentriPoint, Inc. (VentriPoint) is a medical device company. The company develops and markets medical devices for the cardiovascular market. Its product includes ventripoint diagnostic system, which is used for the measurement of right ventricular volume. VentriPoints medical systems are utilized by pediatric cardiologists in the treatment of children and adults suffering from congenital heart defects. The company provides right and left ventricular volume and function accurately. It sells its products through the brand name, VMS. The company also offers a virtual 3D surface to complement the 2D views. It is a subsidiary of VentriPoint Diagnostics Ltd. VentriPoint is headquartered in Seattle, Washington, the US.

This report is a source for data, analysis and actionable intelligence on the VentriPoint, Inc. portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the development stage, trial phas <br><br>Original Post <a href=http://www.researchmoz.com/ventripoint-inc-product-pipeline-analysis-2013-update-report.html>VentriPoint, Inc. - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/ventripoint-inc-product-pipeline-analysis-2013-update-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>CollPlant Ltd. - Product Pipeline Analysis, 2013 Update</title><link>http://www.researchmoz.com/collplant-ltd-product-pipeline-analysis-2013-update-report.html</link><comments>http://www.researchmoz.com/collplant-ltd-product-pipeline-analysis-2013-update-report.html#comments</comments><pubDate>Thu, 09 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/collplant-ltd-product-pipeline-analysis-2013-update-report.html</guid><description><![CDATA[

Summary

CollPlant Ltd. (CollPlant) is a medical device company. The company develops regenerative medicine by utilizing proprietary processing technologies for human collagen and other recombinant proteins. Its products include collage, wound management, vergenix WD wound dressing matrix, vergenix FG flowable wound gel, orthopaedics, verginixBVF bone void filler and vergenixTRA tendon repair augmentation. CollPlant develops and manufactures medical devices for tissue repair in the areas of orthopaedic soft and hard tissue applications and for the advanced wound healing field. The companys protein polymers and composites are used in orthopedics, aesthetic medicine, urinary incontinence, and wound healing applications. CollPlant is headquartered in Ness-Ziona, Tel Aviv, Israel.

This report is a source for data, analysis and actionable intelligence on the CollPlant Ltd. portfolio of pipeline products. The report provides detailed analysis on each pipeline product with informatio <br><br>Original Post <a href=http://www.researchmoz.com/collplant-ltd-product-pipeline-analysis-2013-update-report.html>CollPlant Ltd. - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Summary

CollPlant Ltd. (CollPlant) is a medical device company. The company develops regenerative medicine by utilizing proprietary processing technologies for human collagen and other recombinant proteins. Its products include collage, wound management, vergenix WD wound dressing matrix, vergenix FG flowable wound gel, orthopaedics, verginixBVF bone void filler and vergenixTRA tendon repair augmentation. CollPlant develops and manufactures medical devices for tissue repair in the areas of orthopaedic soft and hard tissue applications and for the advanced wound healing field. The companys protein polymers and composites are used in orthopedics, aesthetic medicine, urinary incontinence, and wound healing applications. CollPlant is headquartered in Ness-Ziona, Tel Aviv, Israel.

This report is a source for data, analysis and actionable intelligence on the CollPlant Ltd. portfolio of pipeline products. The report provides detailed analysis on each pipeline product with informatio <br><br>Original Post <a href=http://www.researchmoz.com/collplant-ltd-product-pipeline-analysis-2013-update-report.html>CollPlant Ltd. - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/collplant-ltd-product-pipeline-analysis-2013-update-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Focus Diagnostics, Inc. - Product Pipeline Analysis, 2013 Update</title><link>http://www.researchmoz.com/focus-diagnostics-inc-product-pipeline-analysis-2013-update-report.html</link><comments>http://www.researchmoz.com/focus-diagnostics-inc-product-pipeline-analysis-2013-update-report.html#comments</comments><pubDate>Thu, 09 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/focus-diagnostics-inc-product-pipeline-analysis-2013-update-report.html</guid><description><![CDATA[


Summary


Focus Diagnostics, Inc. (Focus Diagnostics) is a medical device company. The company manufactures and distributes molecular and immunology products. Its products include 3M integrated cycler, simplexa molecular products, herpeselect type, dxselect serology products, serology reagents and molecular reagents. Focus Diagnostics offers clinical diagnostic testing services and Flu A/B &amp; RSV Direct test. Its clinical diagnostic testing offers services for clinical trials to vaccine and pharmaceutical development companies. The companys Flu A/B &amp; RSV Direct test is a molecular test product that eliminates nucleic-acid sample extraction. It also provides diagnostic test kits and reagents. The company markets products through brand such as Simplexa, HerpeSelect and DxSelect. Focus Diagnostics is headquartered in Cypress, California, the US.

This report is a source for data, analysis and actionable intelligence on the Focus Diagnostics, Inc. portfolio of pipeline pr <br><br>Original Post <a href=http://www.researchmoz.com/focus-diagnostics-inc-product-pipeline-analysis-2013-update-report.html>Focus Diagnostics, Inc. - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[


Summary


Focus Diagnostics, Inc. (Focus Diagnostics) is a medical device company. The company manufactures and distributes molecular and immunology products. Its products include 3M integrated cycler, simplexa molecular products, herpeselect type, dxselect serology products, serology reagents and molecular reagents. Focus Diagnostics offers clinical diagnostic testing services and Flu A/B &amp; RSV Direct test. Its clinical diagnostic testing offers services for clinical trials to vaccine and pharmaceutical development companies. The companys Flu A/B &amp; RSV Direct test is a molecular test product that eliminates nucleic-acid sample extraction. It also provides diagnostic test kits and reagents. The company markets products through brand such as Simplexa, HerpeSelect and DxSelect. Focus Diagnostics is headquartered in Cypress, California, the US.

This report is a source for data, analysis and actionable intelligence on the Focus Diagnostics, Inc. portfolio of pipeline pr <br><br>Original Post <a href=http://www.researchmoz.com/focus-diagnostics-inc-product-pipeline-analysis-2013-update-report.html>Focus Diagnostics, Inc. - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/focus-diagnostics-inc-product-pipeline-analysis-2013-update-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Cohera Medical, Inc. - Product Pipeline Analysis, 2013 Update</title><link>http://www.researchmoz.com/cohera-medical-inc-product-pipeline-analysis-2013-update-report.html</link><comments>http://www.researchmoz.com/cohera-medical-inc-product-pipeline-analysis-2013-update-report.html#comments</comments><pubDate>Thu, 09 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/cohera-medical-inc-product-pipeline-analysis-2013-update-report.html</guid><description><![CDATA[

Summary

Cohera Medical, Inc. (Cohera) is a medical device company. The company develops tissue adhesive by a revolutionary line of surgical adhesives and wound management products. Its products include adhesive technology, tissuglu surgical adhesive, bowel sealant, and mesh fixation. Coheras TissuGlu is a wound adhesive for securing planar flaps of tissue to reduce fluid accumulation in the wound. The company offers sylys surgical sealant for sealing bowel anastomoses. Its products are based on a unique chemical design. The company has received CE Mark approval for adhesive TissuGlu Surgical. It operates an office in the Netherlands. Cohera is headquartered in Pittsburgh, Pennsylvania, the US.

This report is a source for data, analysis and actionable intelligence on the Cohera Medical, Inc. portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the development stage, trial phase, product milestones, p <br><br>Original Post <a href=http://www.researchmoz.com/cohera-medical-inc-product-pipeline-analysis-2013-update-report.html>Cohera Medical, Inc. - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Summary

Cohera Medical, Inc. (Cohera) is a medical device company. The company develops tissue adhesive by a revolutionary line of surgical adhesives and wound management products. Its products include adhesive technology, tissuglu surgical adhesive, bowel sealant, and mesh fixation. Coheras TissuGlu is a wound adhesive for securing planar flaps of tissue to reduce fluid accumulation in the wound. The company offers sylys surgical sealant for sealing bowel anastomoses. Its products are based on a unique chemical design. The company has received CE Mark approval for adhesive TissuGlu Surgical. It operates an office in the Netherlands. Cohera is headquartered in Pittsburgh, Pennsylvania, the US.

This report is a source for data, analysis and actionable intelligence on the Cohera Medical, Inc. portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the development stage, trial phase, product milestones, p <br><br>Original Post <a href=http://www.researchmoz.com/cohera-medical-inc-product-pipeline-analysis-2013-update-report.html>Cohera Medical, Inc. - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/cohera-medical-inc-product-pipeline-analysis-2013-update-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Veridex, LLC - Product Pipeline Analysis, 2013 Update</title><link>http://www.researchmoz.com/veridex-llc-product-pipeline-analysis-2013-update-report.html</link><comments>http://www.researchmoz.com/veridex-llc-product-pipeline-analysis-2013-update-report.html#comments</comments><pubDate>Thu, 09 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/veridex-llc-product-pipeline-analysis-2013-update-report.html</guid><description><![CDATA[

Summary

Veridex, LLC (Veridex) is a medical device company. The company provides disease specific test reagents for the in-vitro diagnostic markets. It offers rare cell technology and custom services. Veridexs products include Circulating Tumor Cell Kit, CTC Control Kit, CellSave Preservative Tube, AutoPrep System and CellTracks Analyzer II. The CellSearch Circulating Tumor Cell Test, is a simple blood test that traces and assesses tumor cells to determine the prognosis of patients with metastatic breast cancer. Its CTC tests are used by oncologists for reading of tumor information. Veridex distributes, sells and markets its products through the trademark CellSearch, CellTracks, CellTracks Analyzer II, Magnest and AutoPrep. The companys products are approved by FDA. Veridex is headquartered in Raritan, New Jersey, the US.

This report is a source for data, analysis and actionable intelligence on the Veridex, LLC portfolio of pipeline products. The report provides detailed anal <br><br>Original Post <a href=http://www.researchmoz.com/veridex-llc-product-pipeline-analysis-2013-update-report.html>Veridex, LLC - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Summary

Veridex, LLC (Veridex) is a medical device company. The company provides disease specific test reagents for the in-vitro diagnostic markets. It offers rare cell technology and custom services. Veridexs products include Circulating Tumor Cell Kit, CTC Control Kit, CellSave Preservative Tube, AutoPrep System and CellTracks Analyzer II. The CellSearch Circulating Tumor Cell Test, is a simple blood test that traces and assesses tumor cells to determine the prognosis of patients with metastatic breast cancer. Its CTC tests are used by oncologists for reading of tumor information. Veridex distributes, sells and markets its products through the trademark CellSearch, CellTracks, CellTracks Analyzer II, Magnest and AutoPrep. The companys products are approved by FDA. Veridex is headquartered in Raritan, New Jersey, the US.

This report is a source for data, analysis and actionable intelligence on the Veridex, LLC portfolio of pipeline products. The report provides detailed anal <br><br>Original Post <a href=http://www.researchmoz.com/veridex-llc-product-pipeline-analysis-2013-update-report.html>Veridex, LLC - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/veridex-llc-product-pipeline-analysis-2013-update-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Banyan Biomarkers - Product Pipeline Analysis, 2013 Update</title><link>http://www.researchmoz.com/banyan-biomarkers-product-pipeline-analysis-2013-update-report.html</link><comments>http://www.researchmoz.com/banyan-biomarkers-product-pipeline-analysis-2013-update-report.html#comments</comments><pubDate>Thu, 09 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/banyan-biomarkers-product-pipeline-analysis-2013-update-report.html</guid><description><![CDATA[

Summary

Banyan Biomarkers (Banyan) is a research and development company. It develops and markets biomarker diagnostic tests for the healthcare markets. Banyan creates point of care blood test to diagnose traumatic brain injury. The company offers biomarkers for traumatic brain injuries and strokes, psychiatric disorders, neuroinflammation, apoptosis, necrosis, and liver injuries. It provides biomarkers for stroke, Alzheimers disease, Parkinsons and Huntingtons disease, and depression; and therapeutic candidates for neuro-protection. The company serves pharmaceutical companies, biotechnology companies, and investigators at academic research institutes. The company provides primary neuronal culture models of neuroinjury and neurotoxicity, including cerebrocortical cultures, cerebellum granule neurons, and hippocampal neurons; protease enzyme assays; cell-based protease assays; and others. Banyan is headquartered in Alachua, Florida, the US.

This report is a source for data, an <br><br>Original Post <a href=http://www.researchmoz.com/banyan-biomarkers-product-pipeline-analysis-2013-update-report.html>Banyan Biomarkers - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Summary

Banyan Biomarkers (Banyan) is a research and development company. It develops and markets biomarker diagnostic tests for the healthcare markets. Banyan creates point of care blood test to diagnose traumatic brain injury. The company offers biomarkers for traumatic brain injuries and strokes, psychiatric disorders, neuroinflammation, apoptosis, necrosis, and liver injuries. It provides biomarkers for stroke, Alzheimers disease, Parkinsons and Huntingtons disease, and depression; and therapeutic candidates for neuro-protection. The company serves pharmaceutical companies, biotechnology companies, and investigators at academic research institutes. The company provides primary neuronal culture models of neuroinjury and neurotoxicity, including cerebrocortical cultures, cerebellum granule neurons, and hippocampal neurons; protease enzyme assays; cell-based protease assays; and others. Banyan is headquartered in Alachua, Florida, the US.

This report is a source for data, an <br><br>Original Post <a href=http://www.researchmoz.com/banyan-biomarkers-product-pipeline-analysis-2013-update-report.html>Banyan Biomarkers - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/banyan-biomarkers-product-pipeline-analysis-2013-update-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Medispec LTD - Product Pipeline Analysis, 2013 Update</title><link>http://www.researchmoz.com/medispec-ltd-product-pipeline-analysis-2013-update-report.html</link><comments>http://www.researchmoz.com/medispec-ltd-product-pipeline-analysis-2013-update-report.html#comments</comments><pubDate>Thu, 09 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/medispec-ltd-product-pipeline-analysis-2013-update-report.html</guid><description><![CDATA[

Summary

Medispec LTD, (Medispec) is a medical device manufacturing company. The company develops, manufactures and markets non invasive medical devices for the cardiovascular, urology, orthopedic, physiotherapy, thermotherapy and veterinary markets. Its product portfolio includes lithotripters, uroflowmeters and radial and microwave thermotherapy instruments. Medispec also offers solutions which include cardiospec, erectile dysfunction, lithotripsy, thermaspec, uroflowmetry, orthopedics and physiotherapy and aesthetics. The companys products are used in treating kidney stones, BPH, prostatitis, bone calcification, heel spurs and tendonitis. It serves its products and related services to governments, universities and private medical institutions worldwide. Medispec is headquartered in Germantown, Maryland, the US.

This report is a source for data, analysis and actionable intelligence on the Medispec LTD portfolio of pipeline products. The report provides detailed analysis on e <br><br>Original Post <a href=http://www.researchmoz.com/medispec-ltd-product-pipeline-analysis-2013-update-report.html>Medispec LTD - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Summary

Medispec LTD, (Medispec) is a medical device manufacturing company. The company develops, manufactures and markets non invasive medical devices for the cardiovascular, urology, orthopedic, physiotherapy, thermotherapy and veterinary markets. Its product portfolio includes lithotripters, uroflowmeters and radial and microwave thermotherapy instruments. Medispec also offers solutions which include cardiospec, erectile dysfunction, lithotripsy, thermaspec, uroflowmetry, orthopedics and physiotherapy and aesthetics. The companys products are used in treating kidney stones, BPH, prostatitis, bone calcification, heel spurs and tendonitis. It serves its products and related services to governments, universities and private medical institutions worldwide. Medispec is headquartered in Germantown, Maryland, the US.

This report is a source for data, analysis and actionable intelligence on the Medispec LTD portfolio of pipeline products. The report provides detailed analysis on e <br><br>Original Post <a href=http://www.researchmoz.com/medispec-ltd-product-pipeline-analysis-2013-update-report.html>Medispec LTD - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/medispec-ltd-product-pipeline-analysis-2013-update-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Micronics, Inc. (of Sony Group) - Product Pipeline Analysis, 2013 Update</title><link>http://www.researchmoz.com/micronics-inc-of-sony-group-product-pipeline-analysis-2013-update-report.html</link><comments>http://www.researchmoz.com/micronics-inc-of-sony-group-product-pipeline-analysis-2013-update-report.html#comments</comments><pubDate>Thu, 09 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/micronics-inc-of-sony-group-product-pipeline-analysis-2013-update-report.html</guid><description><![CDATA[

Summary

Micronics, Inc. (Micronics) is a medical device company. The company develops and markets in vitro diagnostic products for disease diagnosis, prognosis and treatment monitoring. It offers diagnostics products and research and development products. The companys research and development products include single-use, stand alone, disposable microfluidics-enabled cartridges and the microFlow integrated workstation with cartridges that permits assay development and optimization in the micro-nano domain. Micronics provides services such as rapid prototyping, reagent printing, integrate MEMs, microplumbing and lab card design and development services. The company holds 73 issued patents and has more than 40 pending applications on its microfluidics technologies. Micronics is headquartered in Redmond, Washington, the US.

This report is a source for data, analysis and actionable intelligence on the Micronics, Inc. (of Sony Group) portfolio of pipeline products. The report provi <br><br>Original Post <a href=http://www.researchmoz.com/micronics-inc-of-sony-group-product-pipeline-analysis-2013-update-report.html>Micronics, Inc. (of Sony Group) - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Summary

Micronics, Inc. (Micronics) is a medical device company. The company develops and markets in vitro diagnostic products for disease diagnosis, prognosis and treatment monitoring. It offers diagnostics products and research and development products. The companys research and development products include single-use, stand alone, disposable microfluidics-enabled cartridges and the microFlow integrated workstation with cartridges that permits assay development and optimization in the micro-nano domain. Micronics provides services such as rapid prototyping, reagent printing, integrate MEMs, microplumbing and lab card design and development services. The company holds 73 issued patents and has more than 40 pending applications on its microfluidics technologies. Micronics is headquartered in Redmond, Washington, the US.

This report is a source for data, analysis and actionable intelligence on the Micronics, Inc. (of Sony Group) portfolio of pipeline products. The report provi <br><br>Original Post <a href=http://www.researchmoz.com/micronics-inc-of-sony-group-product-pipeline-analysis-2013-update-report.html>Micronics, Inc. (of Sony Group) - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/micronics-inc-of-sony-group-product-pipeline-analysis-2013-update-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>T2 Biosystems, Inc. - Product Pipeline Analysis, 2013 Update</title><link>http://www.researchmoz.com/t2-biosystems-inc-product-pipeline-analysis-2013-update-report.html</link><comments>http://www.researchmoz.com/t2-biosystems-inc-product-pipeline-analysis-2013-update-report.html#comments</comments><pubDate>Thu, 09 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/t2-biosystems-inc-product-pipeline-analysis-2013-update-report.html</guid><description><![CDATA[

Summary

T2 Biosystems, Inc. (T2 Biosystems) is a medical device company. The company provides disrupting the landscape of clinical diagnostics through direct detection with T2MR. Its T2 Magnetic Resonance (T2MR) technology allows direct detection in complex samples such as whole blood, plasma, serum, sputum and urine. T2 Biosystems offer T2MR instruments that include T2Dx, a system that allows medical decisions; and T2Hemostatis. The companys T2MR detection technology is a biosensor technology, which provides rapid diagnostic results with minimal or no sample preparation. It also offers hemostasis measurements from unpurified clinical samples in hospitals, labs and physicians offices. T2 Biosystems is headquartered in Lexington, Massachusetts, the US.

This report is a source for data, analysis and actionable intelligence on the T2 Biosystems, Inc. portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, <br><br>Original Post <a href=http://www.researchmoz.com/t2-biosystems-inc-product-pipeline-analysis-2013-update-report.html>T2 Biosystems, Inc. - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Summary

T2 Biosystems, Inc. (T2 Biosystems) is a medical device company. The company provides disrupting the landscape of clinical diagnostics through direct detection with T2MR. Its T2 Magnetic Resonance (T2MR) technology allows direct detection in complex samples such as whole blood, plasma, serum, sputum and urine. T2 Biosystems offer T2MR instruments that include T2Dx, a system that allows medical decisions; and T2Hemostatis. The companys T2MR detection technology is a biosensor technology, which provides rapid diagnostic results with minimal or no sample preparation. It also offers hemostasis measurements from unpurified clinical samples in hospitals, labs and physicians offices. T2 Biosystems is headquartered in Lexington, Massachusetts, the US.

This report is a source for data, analysis and actionable intelligence on the T2 Biosystems, Inc. portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, <br><br>Original Post <a href=http://www.researchmoz.com/t2-biosystems-inc-product-pipeline-analysis-2013-update-report.html>T2 Biosystems, Inc. - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/t2-biosystems-inc-product-pipeline-analysis-2013-update-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Randox Laboratories Ltd. - Product Pipeline Analysis, 2013 Update</title><link>http://www.researchmoz.com/randox-laboratories-ltd-product-pipeline-analysis-2013-update-report.html</link><comments>http://www.researchmoz.com/randox-laboratories-ltd-product-pipeline-analysis-2013-update-report.html#comments</comments><pubDate>Thu, 09 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/randox-laboratories-ltd-product-pipeline-analysis-2013-update-report.html</guid><description><![CDATA[

Summary

Randox Laboratories Ltd. (Randox) is a pharmaceutical and healthcare company. It develops and manufactures diagnostic kits for biochemistry laboratories. Its major product categories include biochip analyzers, biochip immunoassays, biochip molecular diagnostics, cardiovascular biomarkers and regents, clinical chemistry analyzers and diagnostic reagents. The company operates along with its major subsidiaries including Randox Food Diagnostics, Randox Toxicology, Randox Life Sciences, Randox Health, Randox Testing Services and Randox Pharma Services. It also operates an online store. The companys products are used in more than 145 countries worldwide by hospital laboratories, forensic laboratories, A and E units, food and wine testing laboratories, sports testing organizations, horse racing authorities, veterinary clinics, contract research organizations and pharmaceutical companies. Randox is headquartered in Crumlin, Antrim, the UK.

This report is a source for data, an <br><br>Original Post <a href=http://www.researchmoz.com/randox-laboratories-ltd-product-pipeline-analysis-2013-update-report.html>Randox Laboratories Ltd. - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Summary

Randox Laboratories Ltd. (Randox) is a pharmaceutical and healthcare company. It develops and manufactures diagnostic kits for biochemistry laboratories. Its major product categories include biochip analyzers, biochip immunoassays, biochip molecular diagnostics, cardiovascular biomarkers and regents, clinical chemistry analyzers and diagnostic reagents. The company operates along with its major subsidiaries including Randox Food Diagnostics, Randox Toxicology, Randox Life Sciences, Randox Health, Randox Testing Services and Randox Pharma Services. It also operates an online store. The companys products are used in more than 145 countries worldwide by hospital laboratories, forensic laboratories, A and E units, food and wine testing laboratories, sports testing organizations, horse racing authorities, veterinary clinics, contract research organizations and pharmaceutical companies. Randox is headquartered in Crumlin, Antrim, the UK.

This report is a source for data, an <br><br>Original Post <a href=http://www.researchmoz.com/randox-laboratories-ltd-product-pipeline-analysis-2013-update-report.html>Randox Laboratories Ltd. - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/randox-laboratories-ltd-product-pipeline-analysis-2013-update-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Mystic Pharmaceuticals, Inc. - Product Pipeline Analysis, 2013 Update</title><link>http://www.researchmoz.com/mystic-pharmaceuticals-inc-product-pipeline-analysis-2013-update-report.html</link><comments>http://www.researchmoz.com/mystic-pharmaceuticals-inc-product-pipeline-analysis-2013-update-report.html#comments</comments><pubDate>Thu, 09 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/mystic-pharmaceuticals-inc-product-pipeline-analysis-2013-update-report.html</guid><description><![CDATA[

Summary

Mystic Pharmaceuticals, Inc. (Mystic) is a pharmaceutical service company. The company develops and commercializes drug delivery systems. It offers services such as device manufacturing, drug compounding, sterilization filtration, aseptic form fill seal blister production, packaging and labeling, delivery system customization and optimization, drug formulation, analytical method development, filtration process development, bulk drug formula analysis, finished product analysis and sterilizing filter medium pre-selection among others. Mystic offers drug delivery platforms such as VRx2 and VersiDoser. The company develops projects in the areas of absorption enhancers, lyophilized drug delivery and intranasal vaccines and anti-virals. Mystic is headquartered in Austin, Texas, the US.

This report is a source for data, analysis and actionable intelligence on the Mystic Pharmaceuticals, Inc. portfolio of pipeline products. The report provides detailed analysis on each pipeli <br><br>Original Post <a href=http://www.researchmoz.com/mystic-pharmaceuticals-inc-product-pipeline-analysis-2013-update-report.html>Mystic Pharmaceuticals, Inc. - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Summary

Mystic Pharmaceuticals, Inc. (Mystic) is a pharmaceutical service company. The company develops and commercializes drug delivery systems. It offers services such as device manufacturing, drug compounding, sterilization filtration, aseptic form fill seal blister production, packaging and labeling, delivery system customization and optimization, drug formulation, analytical method development, filtration process development, bulk drug formula analysis, finished product analysis and sterilizing filter medium pre-selection among others. Mystic offers drug delivery platforms such as VRx2 and VersiDoser. The company develops projects in the areas of absorption enhancers, lyophilized drug delivery and intranasal vaccines and anti-virals. Mystic is headquartered in Austin, Texas, the US.

This report is a source for data, analysis and actionable intelligence on the Mystic Pharmaceuticals, Inc. portfolio of pipeline products. The report provides detailed analysis on each pipeli <br><br>Original Post <a href=http://www.researchmoz.com/mystic-pharmaceuticals-inc-product-pipeline-analysis-2013-update-report.html>Mystic Pharmaceuticals, Inc. - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/mystic-pharmaceuticals-inc-product-pipeline-analysis-2013-update-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>BioBehavioral Diagnostics Company - Product Pipeline Analysis, 2013 Update</title><link>http://www.researchmoz.com/biobehavioral-diagnostics-company-product-pipeline-analysis-2013-update-report.html</link><comments>http://www.researchmoz.com/biobehavioral-diagnostics-company-product-pipeline-analysis-2013-update-report.html#comments</comments><pubDate>Thu, 09 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/biobehavioral-diagnostics-company-product-pipeline-analysis-2013-update-report.html</guid><description><![CDATA[

Summary

BioBehavioral Diagnostics Company (BioBDx) is a medical device company. It manufactures and markets technologies for the diagnosis and management of neurological and psychiatric conditions. BioBDX provides proprietary platform technology to measure specific behaviors that correlate with brain function and deficits in inhibitory control. The company offers Quotient ADHD system which collects and reports objective, accurate data on hyperactivity, impulsivity and inattention. BioBDXs products find application in the treatment of attention-deficit and hyperactivity disorder in children, adolescents and adults. It serves for neurologists, pediatricians, and psychiatrists in the US. BioBDX is headquartered in Westford, Massachusetts, the US.

This report is a source for data, analysis and actionable intelligence on the BioBehavioral Diagnostics Company portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indic <br><br>Original Post <a href=http://www.researchmoz.com/biobehavioral-diagnostics-company-product-pipeline-analysis-2013-update-report.html>BioBehavioral Diagnostics Company - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Summary

BioBehavioral Diagnostics Company (BioBDx) is a medical device company. It manufactures and markets technologies for the diagnosis and management of neurological and psychiatric conditions. BioBDX provides proprietary platform technology to measure specific behaviors that correlate with brain function and deficits in inhibitory control. The company offers Quotient ADHD system which collects and reports objective, accurate data on hyperactivity, impulsivity and inattention. BioBDXs products find application in the treatment of attention-deficit and hyperactivity disorder in children, adolescents and adults. It serves for neurologists, pediatricians, and psychiatrists in the US. BioBDX is headquartered in Westford, Massachusetts, the US.

This report is a source for data, analysis and actionable intelligence on the BioBehavioral Diagnostics Company portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indic <br><br>Original Post <a href=http://www.researchmoz.com/biobehavioral-diagnostics-company-product-pipeline-analysis-2013-update-report.html>BioBehavioral Diagnostics Company - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/biobehavioral-diagnostics-company-product-pipeline-analysis-2013-update-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Metabolon, Inc. - Product Pipeline Analysis, 2013 Update</title><link>http://www.researchmoz.com/metabolon-inc-product-pipeline-analysis-2013-update-report.html</link><comments>http://www.researchmoz.com/metabolon-inc-product-pipeline-analysis-2013-update-report.html#comments</comments><pubDate>Thu, 09 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/metabolon-inc-product-pipeline-analysis-2013-update-report.html</guid><description><![CDATA[

Summary

Metabolon, Inc. (Metabolon) is a biotechnology company. The company provides analysis of complex biological samples for the discovery of markers and pathways that are associated with drug action and disease. It offers services such as separation and detection, informatics to identify biochemicals, statistics to identify changes, client samples, biochemical profile plots, global analysis, identification and biochemical interpretation. Metabolons biomarker discovery platform is used to identify biomarkers for various diseases such as prostate cancer, kidney cancer, bladder cancer, nephrotoxicity of chemotherapy drugs and diabetes/insulin resistance. The company offers services for scientists in academic and government institutions. Metabolon is headquartered in Durham, North Carolina, the US.

In August 2012, the company acquired Lipomics Technologies, Inc.

This report is a source for data, analysis and actionable intelligence on the Metabolon, Inc. portfolio of pipel <br><br>Original Post <a href=http://www.researchmoz.com/metabolon-inc-product-pipeline-analysis-2013-update-report.html>Metabolon, Inc. - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Summary

Metabolon, Inc. (Metabolon) is a biotechnology company. The company provides analysis of complex biological samples for the discovery of markers and pathways that are associated with drug action and disease. It offers services such as separation and detection, informatics to identify biochemicals, statistics to identify changes, client samples, biochemical profile plots, global analysis, identification and biochemical interpretation. Metabolons biomarker discovery platform is used to identify biomarkers for various diseases such as prostate cancer, kidney cancer, bladder cancer, nephrotoxicity of chemotherapy drugs and diabetes/insulin resistance. The company offers services for scientists in academic and government institutions. Metabolon is headquartered in Durham, North Carolina, the US.

In August 2012, the company acquired Lipomics Technologies, Inc.

This report is a source for data, analysis and actionable intelligence on the Metabolon, Inc. portfolio of pipel <br><br>Original Post <a href=http://www.researchmoz.com/metabolon-inc-product-pipeline-analysis-2013-update-report.html>Metabolon, Inc. - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/metabolon-inc-product-pipeline-analysis-2013-update-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>PRO-IV Medical Ltd. - Product Pipeline Analysis, 2013 Update</title><link>http://www.researchmoz.com/pro-iv-medical-ltd-product-pipeline-analysis-2013-update-report.html</link><comments>http://www.researchmoz.com/pro-iv-medical-ltd-product-pipeline-analysis-2013-update-report.html#comments</comments><pubDate>Thu, 09 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/pro-iv-medical-ltd-product-pipeline-analysis-2013-update-report.html</guid><description><![CDATA[

Summary

Pro-IV Medical Ltd. (Pro-IV) is a medical device company. The company develops a series of medical devices that provides safety of injectable drug administration and blood transfusion. Its products include IMMAGES (Intravenous Monitoring, Management and Safety) is an intravenous drug and blood transfusion system that enhances three critical infusion functions, and PRIDE (Preventing Intravenous Drug Errors) is used in delivering a high-degree of errorprevention. Pro-IV conducts clinical trials, which consist of protocol compliance, point of care electronic recording bedside events, and monitoring and controlling of infusion flow rate. The company also provides home care services. Pro-IV Medical is headquartered in Kfar Vitkin, Israel.

This report is a source for data, analysis and actionable intelligence on the PRO-IV Medical Ltd. portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the devel <br><br>Original Post <a href=http://www.researchmoz.com/pro-iv-medical-ltd-product-pipeline-analysis-2013-update-report.html>PRO-IV Medical Ltd. - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Summary

Pro-IV Medical Ltd. (Pro-IV) is a medical device company. The company develops a series of medical devices that provides safety of injectable drug administration and blood transfusion. Its products include IMMAGES (Intravenous Monitoring, Management and Safety) is an intravenous drug and blood transfusion system that enhances three critical infusion functions, and PRIDE (Preventing Intravenous Drug Errors) is used in delivering a high-degree of errorprevention. Pro-IV conducts clinical trials, which consist of protocol compliance, point of care electronic recording bedside events, and monitoring and controlling of infusion flow rate. The company also provides home care services. Pro-IV Medical is headquartered in Kfar Vitkin, Israel.

This report is a source for data, analysis and actionable intelligence on the PRO-IV Medical Ltd. portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the devel <br><br>Original Post <a href=http://www.researchmoz.com/pro-iv-medical-ltd-product-pipeline-analysis-2013-update-report.html>PRO-IV Medical Ltd. - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/pro-iv-medical-ltd-product-pipeline-analysis-2013-update-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>CW Optics, Inc. - Product Pipeline Analysis, 2013 Update</title><link>http://www.researchmoz.com/cw-optics-inc-product-pipeline-analysis-2013-update-report.html</link><comments>http://www.researchmoz.com/cw-optics-inc-product-pipeline-analysis-2013-update-report.html#comments</comments><pubDate>Thu, 09 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/cw-optics-inc-product-pipeline-analysis-2013-update-report.html</guid><description><![CDATA[

Summary

CW Optics, Inc. (CW Optics) is a healthcare technology company. The company develops hardware and software solutions for optical and laser devices. CW Optics products include woundimager, sepscope and retinalimager. The company operates through system design and development, simulation, modeling, and data management. It offers device development, software solutions and electronics design. The company provides services in optics based system design and development for medical and military industries. It has developed noninvasive optical solution for monitoring wound site perfusion It markets its products under the brands, WoundImager, SepScope and RetinalImager. CW Optics is headquartered in Seaford, Virginia, the US.

This report is a source for data, analysis and actionable intelligence on the CW Optics, Inc. portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the development stage, trial p <br><br>Original Post <a href=http://www.researchmoz.com/cw-optics-inc-product-pipeline-analysis-2013-update-report.html>CW Optics, Inc. - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Summary

CW Optics, Inc. (CW Optics) is a healthcare technology company. The company develops hardware and software solutions for optical and laser devices. CW Optics products include woundimager, sepscope and retinalimager. The company operates through system design and development, simulation, modeling, and data management. It offers device development, software solutions and electronics design. The company provides services in optics based system design and development for medical and military industries. It has developed noninvasive optical solution for monitoring wound site perfusion It markets its products under the brands, WoundImager, SepScope and RetinalImager. CW Optics is headquartered in Seaford, Virginia, the US.

This report is a source for data, analysis and actionable intelligence on the CW Optics, Inc. portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the development stage, trial p <br><br>Original Post <a href=http://www.researchmoz.com/cw-optics-inc-product-pipeline-analysis-2013-update-report.html>CW Optics, Inc. - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/cw-optics-inc-product-pipeline-analysis-2013-update-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Spine Wave, Inc. - Product Pipeline Analysis, 2013 Update</title><link>http://www.researchmoz.com/spine-wave-inc-product-pipeline-analysis-2013-update-report.html</link><comments>http://www.researchmoz.com/spine-wave-inc-product-pipeline-analysis-2013-update-report.html#comments</comments><pubDate>Thu, 09 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/spine-wave-inc-product-pipeline-analysis-2013-update-report.html</guid><description><![CDATA[

Summary

Spine Wave, Inc. (Spine Wave) is a medical device company. The company develops, manufactures and distributes medical devices for the treatment of spinal disorders. Its products include various brands such as StaXx, CapSure and StaXxFX. Spine Waves products such as nucoresurgical implants staxx xd expandable device, capsure ps3 spine system, staxx fx structural kyphoplasty system, nucore injectable nucleus and staxx fx percutaneous vertebral augmentation. The company surgical solutions are utilized in spinal fusion, vertebral compression fracture repair, and nucleus replacement and augmentation. It operates through its business sectors worldwide. Spine Wave is headquartered in Shelton, Connecticut, the US.

This report is a source for data, analysis and actionable intelligence on the Spine Wave, Inc. portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the development stage, trial phase, prod <br><br>Original Post <a href=http://www.researchmoz.com/spine-wave-inc-product-pipeline-analysis-2013-update-report.html>Spine Wave, Inc. - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Summary

Spine Wave, Inc. (Spine Wave) is a medical device company. The company develops, manufactures and distributes medical devices for the treatment of spinal disorders. Its products include various brands such as StaXx, CapSure and StaXxFX. Spine Waves products such as nucoresurgical implants staxx xd expandable device, capsure ps3 spine system, staxx fx structural kyphoplasty system, nucore injectable nucleus and staxx fx percutaneous vertebral augmentation. The company surgical solutions are utilized in spinal fusion, vertebral compression fracture repair, and nucleus replacement and augmentation. It operates through its business sectors worldwide. Spine Wave is headquartered in Shelton, Connecticut, the US.

This report is a source for data, analysis and actionable intelligence on the Spine Wave, Inc. portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the development stage, trial phase, prod <br><br>Original Post <a href=http://www.researchmoz.com/spine-wave-inc-product-pipeline-analysis-2013-update-report.html>Spine Wave, Inc. - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/spine-wave-inc-product-pipeline-analysis-2013-update-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Biocrates Life Sciences AG - Product Pipeline Analysis, 2013 Update</title><link>http://www.researchmoz.com/biocrates-life-sciences-ag-product-pipeline-analysis-2013-update-report.html</link><comments>http://www.researchmoz.com/biocrates-life-sciences-ag-product-pipeline-analysis-2013-update-report.html#comments</comments><pubDate>Thu, 09 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/biocrates-life-sciences-ag-product-pipeline-analysis-2013-update-report.html</guid><description><![CDATA[

Summary

Biocrates Life Sciences AG, (Biocrates) is a biotechnology company. It develops metabolomic products and and vitro diagnostics (IVDs) for early disease detection. The company's metabolomic kits are used in areas of nephrology, central nervous system disorders, gynecology, sports, nutrition, diabetics, pharmaceutical research and endocrinology. Its product portfolio includes Research Products comprising AbsoluteIDQ Kits and Diagnostic Products including MetaDisIDQKit and SteroIDQ Kit. The company offers partners with pharmaceutical, biotechnology and nutrition companies, namely, Chenomox, Hamilton, Pfize, Gene Go and V&amp;F among others. The company markets its products through distributors in Denmark, Spain, Sweden, Finland, Norway and Iceland. Biocrates is headquartered Innsbruck, Austria.

This report is a source for data, analysis and actionable intelligence on the Biocrates Life Sciences AG portfolio of pipeline products. The report provides detailed analysis on e <br><br>Original Post <a href=http://www.researchmoz.com/biocrates-life-sciences-ag-product-pipeline-analysis-2013-update-report.html>Biocrates Life Sciences AG - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Summary

Biocrates Life Sciences AG, (Biocrates) is a biotechnology company. It develops metabolomic products and and vitro diagnostics (IVDs) for early disease detection. The company's metabolomic kits are used in areas of nephrology, central nervous system disorders, gynecology, sports, nutrition, diabetics, pharmaceutical research and endocrinology. Its product portfolio includes Research Products comprising AbsoluteIDQ Kits and Diagnostic Products including MetaDisIDQKit and SteroIDQ Kit. The company offers partners with pharmaceutical, biotechnology and nutrition companies, namely, Chenomox, Hamilton, Pfize, Gene Go and V&amp;F among others. The company markets its products through distributors in Denmark, Spain, Sweden, Finland, Norway and Iceland. Biocrates is headquartered Innsbruck, Austria.

This report is a source for data, analysis and actionable intelligence on the Biocrates Life Sciences AG portfolio of pipeline products. The report provides detailed analysis on e <br><br>Original Post <a href=http://www.researchmoz.com/biocrates-life-sciences-ag-product-pipeline-analysis-2013-update-report.html>Biocrates Life Sciences AG - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/biocrates-life-sciences-ag-product-pipeline-analysis-2013-update-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Adocia (ADOC) - Product Pipeline Analysis, 2013 Update</title><link>http://www.researchmoz.com/adocia-adoc-product-pipeline-analysis-2013-update-report.html</link><comments>http://www.researchmoz.com/adocia-adoc-product-pipeline-analysis-2013-update-report.html#comments</comments><pubDate>Thu, 09 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/adocia-adoc-product-pipeline-analysis-2013-update-report.html</guid><description><![CDATA[

Summary

Adocia, formerly Proteins &amp; Peptides Management S.A.S. is a biotechnology company. It specializes in insulin therapy and the treatment of the diabetic foot ulcer. The company controls the activity of therapeutic proteins through its BioChaperone state-of-the-art technological platform. Its pipeline products include BioChaperone PDGF for chronic wound healing, BioChaperone insulins for insulinotherapy and BioChaperone for monoclonal antibodies. The company has completed two phases I and II studies on the formulation of a fast-acting human insulin and has received adequate phase I/II results on a diabetic foot ulcer-healing product. Adocia is headquartered in Lyon, France.

With the positive results of the phase II clinical trial in India, the company, he company has filed a dossier for a phase III clinical trial which is under review of (Drugs Controller General of India. It announced its phase III development program of its product, BioChaperone PDGF-BB for the tre <br><br>Original Post <a href=http://www.researchmoz.com/adocia-adoc-product-pipeline-analysis-2013-update-report.html>Adocia (ADOC) - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Summary

Adocia, formerly Proteins &amp; Peptides Management S.A.S. is a biotechnology company. It specializes in insulin therapy and the treatment of the diabetic foot ulcer. The company controls the activity of therapeutic proteins through its BioChaperone state-of-the-art technological platform. Its pipeline products include BioChaperone PDGF for chronic wound healing, BioChaperone insulins for insulinotherapy and BioChaperone for monoclonal antibodies. The company has completed two phases I and II studies on the formulation of a fast-acting human insulin and has received adequate phase I/II results on a diabetic foot ulcer-healing product. Adocia is headquartered in Lyon, France.

With the positive results of the phase II clinical trial in India, the company, he company has filed a dossier for a phase III clinical trial which is under review of (Drugs Controller General of India. It announced its phase III development program of its product, BioChaperone PDGF-BB for the tre <br><br>Original Post <a href=http://www.researchmoz.com/adocia-adoc-product-pipeline-analysis-2013-update-report.html>Adocia (ADOC) - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/adocia-adoc-product-pipeline-analysis-2013-update-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Alfa Wassermann, Inc. - Product Pipeline Analysis, 2013 Update</title><link>http://www.researchmoz.com/alfa-wassermann-inc-product-pipeline-analysis-2013-update-report.html</link><comments>http://www.researchmoz.com/alfa-wassermann-inc-product-pipeline-analysis-2013-update-report.html#comments</comments><pubDate>Thu, 09 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/alfa-wassermann-inc-product-pipeline-analysis-2013-update-report.html</guid><description><![CDATA[

Summary

Alfa Wassermann, Inc. (Alfa Wassermann) is a clinical device manufacturer. It designs and manufactures devices and equipment for clinical laboratories and diagnostic centers. The companys products include medical diagnostic instruments and reagents such as Alera clinical chemistry systems, ACE, a random access centrifugal clinical chemistry system, VetACE chemistry systems, and Starlyte III ISE analyzers. Alfa Wassermann also manufactures continuous flow ultracentrifuges that include Promatix 1000, a bio-separation system that is designed to develop protocols for the separation, fractionation, and concentration of viral vectors and virus, such as particles, viruses, viral, among others. It also provides in-field service, telephone support, factory repair and maintenance training, among other services. It is ISO 9001:2000 certified company. Alfa Wassermann is headquartered in Caldwell, New Jersey, the US.

This report is a source for data, analysis and actionable intell <br><br>Original Post <a href=http://www.researchmoz.com/alfa-wassermann-inc-product-pipeline-analysis-2013-update-report.html>Alfa Wassermann, Inc. - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Summary

Alfa Wassermann, Inc. (Alfa Wassermann) is a clinical device manufacturer. It designs and manufactures devices and equipment for clinical laboratories and diagnostic centers. The companys products include medical diagnostic instruments and reagents such as Alera clinical chemistry systems, ACE, a random access centrifugal clinical chemistry system, VetACE chemistry systems, and Starlyte III ISE analyzers. Alfa Wassermann also manufactures continuous flow ultracentrifuges that include Promatix 1000, a bio-separation system that is designed to develop protocols for the separation, fractionation, and concentration of viral vectors and virus, such as particles, viruses, viral, among others. It also provides in-field service, telephone support, factory repair and maintenance training, among other services. It is ISO 9001:2000 certified company. Alfa Wassermann is headquartered in Caldwell, New Jersey, the US.

This report is a source for data, analysis and actionable intell <br><br>Original Post <a href=http://www.researchmoz.com/alfa-wassermann-inc-product-pipeline-analysis-2013-update-report.html>Alfa Wassermann, Inc. - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/alfa-wassermann-inc-product-pipeline-analysis-2013-update-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Helena Laboratories Corp. - Product Pipeline Analysis, 2013 Update</title><link>http://www.researchmoz.com/helena-laboratories-corp-product-pipeline-analysis-2013-update-report.html</link><comments>http://www.researchmoz.com/helena-laboratories-corp-product-pipeline-analysis-2013-update-report.html#comments</comments><pubDate>Thu, 09 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/helena-laboratories-corp-product-pipeline-analysis-2013-update-report.html</guid><description><![CDATA[

Summary

Helena Laboratories Corp. (Helena) is a medical device company. The company manufactures and supplies clinical laboratory instruments and reagents. Its products include electrophoresis analyzers, densitometers, electrophoresis supplies, hemostasis reagents and instruments, immunology and protein diagnostic products, column chromatography supplies, disposable laboratory plasticware and test kits for fecal occult blood. Helena develops diagnostic tests. The company supplies products through its distribution network in Algeria, Argentina, Austria, Bahrain, Bangladesh, Belgium, Brazil, China, Colombia, Costa Rica and others. Its clients include medical centers, hospitals, reference laboratories and private doctor's laboratories. The company has ISO 13485:2003 certification. Helena is headquartered in Beaumont, Texas, the US.

This report is a source for data, analysis and actionable intelligence on the Helena Laboratories Corp. portfolio of pipeline products. The report pr <br><br>Original Post <a href=http://www.researchmoz.com/helena-laboratories-corp-product-pipeline-analysis-2013-update-report.html>Helena Laboratories Corp. - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Summary

Helena Laboratories Corp. (Helena) is a medical device company. The company manufactures and supplies clinical laboratory instruments and reagents. Its products include electrophoresis analyzers, densitometers, electrophoresis supplies, hemostasis reagents and instruments, immunology and protein diagnostic products, column chromatography supplies, disposable laboratory plasticware and test kits for fecal occult blood. Helena develops diagnostic tests. The company supplies products through its distribution network in Algeria, Argentina, Austria, Bahrain, Bangladesh, Belgium, Brazil, China, Colombia, Costa Rica and others. Its clients include medical centers, hospitals, reference laboratories and private doctor's laboratories. The company has ISO 13485:2003 certification. Helena is headquartered in Beaumont, Texas, the US.

This report is a source for data, analysis and actionable intelligence on the Helena Laboratories Corp. portfolio of pipeline products. The report pr <br><br>Original Post <a href=http://www.researchmoz.com/helena-laboratories-corp-product-pipeline-analysis-2013-update-report.html>Helena Laboratories Corp. - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/helena-laboratories-corp-product-pipeline-analysis-2013-update-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>AdvanDx, Inc. - Product Pipeline Analysis, 2013 Update</title><link>http://www.researchmoz.com/advandx-inc-product-pipeline-analysis-2013-update-report.html</link><comments>http://www.researchmoz.com/advandx-inc-product-pipeline-analysis-2013-update-report.html#comments</comments><pubDate>Thu, 09 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/advandx-inc-product-pipeline-analysis-2013-update-report.html</guid><description><![CDATA[

Summary

AdvanDx (AdvanDx) is a pharmaceutical and healthcare company. The company develops and markets molecular-based in vitro diagnostic tests for the diagnosis and prevention of infectious diseases. The companys products includes development of peptide nucleic acid fluorescence in situ hybridization, whole cell analysis, fluorescence microscopy, and EVIGENE tests that provide rapid identification results for bacteria and yeast to support antibiotic therapy and improve overall patient care. AdvanDx also provides technical and customer services. The company provides its services through its research and development centers in Denmark and the US. It operates through its sales and marketing offices in the US and Europe. AdvanDx is headquartered in Woburn, Massachusetts, the US.

This report is a source for data, analysis and actionable intelligence on the AdvanDx, Inc. portfolio of pipeline products. The report provides detailed analysis on each pipeline product with informatio <br><br>Original Post <a href=http://www.researchmoz.com/advandx-inc-product-pipeline-analysis-2013-update-report.html>AdvanDx, Inc. - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Summary

AdvanDx (AdvanDx) is a pharmaceutical and healthcare company. The company develops and markets molecular-based in vitro diagnostic tests for the diagnosis and prevention of infectious diseases. The companys products includes development of peptide nucleic acid fluorescence in situ hybridization, whole cell analysis, fluorescence microscopy, and EVIGENE tests that provide rapid identification results for bacteria and yeast to support antibiotic therapy and improve overall patient care. AdvanDx also provides technical and customer services. The company provides its services through its research and development centers in Denmark and the US. It operates through its sales and marketing offices in the US and Europe. AdvanDx is headquartered in Woburn, Massachusetts, the US.

This report is a source for data, analysis and actionable intelligence on the AdvanDx, Inc. portfolio of pipeline products. The report provides detailed analysis on each pipeline product with informatio <br><br>Original Post <a href=http://www.researchmoz.com/advandx-inc-product-pipeline-analysis-2013-update-report.html>AdvanDx, Inc. - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/advandx-inc-product-pipeline-analysis-2013-update-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>EKF Diagnostics Holdings plc (EKF) - Product Pipeline Analysis, 2013 Update</title><link>http://www.researchmoz.com/ekf-diagnostics-holdings-plc-ekf-product-pipeline-analysis-2013-update-report.html</link><comments>http://www.researchmoz.com/ekf-diagnostics-holdings-plc-ekf-product-pipeline-analysis-2013-update-report.html#comments</comments><pubDate>Thu, 09 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/ekf-diagnostics-holdings-plc-ekf-product-pipeline-analysis-2013-update-report.html</guid><description><![CDATA[

Summary

EKF Diagnostics Holdings plc (EKF Diagnostics), formerly International Brand Licensing plc, is a medical device company. It undertakes the design, development, manufacture and marketing of point of care blood analyzing equipments and reagents for the detection and management of anemia, diabetes, lactate, and renal diseases among others. The company's product portfolio includes hemoglobin analyzers, glycated hemoglobin analyzers, glucose analyzers, lactate analyzers, liquid stable reagents and pregnancy test strips. EKF Diagnostics markets these products to GP surgeries, pharmacies, blood banks, sports clinics, hospitals, and laboratories through a network of distributors in over 70 countries. Geographically, the company has its research and manufacturing facilities spread across Germany, Ireland, the US and the UK. EKF Diagnostics is headquartered in London, England, the UK.

In March 2013, the company acquired 360 Genomics Limited, from Oxitec Limited, Dr Guoliang Fu, <br><br>Original Post <a href=http://www.researchmoz.com/ekf-diagnostics-holdings-plc-ekf-product-pipeline-analysis-2013-update-report.html>EKF Diagnostics Holdings plc (EKF) - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Summary

EKF Diagnostics Holdings plc (EKF Diagnostics), formerly International Brand Licensing plc, is a medical device company. It undertakes the design, development, manufacture and marketing of point of care blood analyzing equipments and reagents for the detection and management of anemia, diabetes, lactate, and renal diseases among others. The company's product portfolio includes hemoglobin analyzers, glycated hemoglobin analyzers, glucose analyzers, lactate analyzers, liquid stable reagents and pregnancy test strips. EKF Diagnostics markets these products to GP surgeries, pharmacies, blood banks, sports clinics, hospitals, and laboratories through a network of distributors in over 70 countries. Geographically, the company has its research and manufacturing facilities spread across Germany, Ireland, the US and the UK. EKF Diagnostics is headquartered in London, England, the UK.

In March 2013, the company acquired 360 Genomics Limited, from Oxitec Limited, Dr Guoliang Fu, <br><br>Original Post <a href=http://www.researchmoz.com/ekf-diagnostics-holdings-plc-ekf-product-pipeline-analysis-2013-update-report.html>EKF Diagnostics Holdings plc (EKF) - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/ekf-diagnostics-holdings-plc-ekf-product-pipeline-analysis-2013-update-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Mitomics Inc. - Product Pipeline Analysis, 2013 Update</title><link>http://www.researchmoz.com/mitomics-inc-product-pipeline-analysis-2013-update-report.html</link><comments>http://www.researchmoz.com/mitomics-inc-product-pipeline-analysis-2013-update-report.html#comments</comments><pubDate>Thu, 09 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/mitomics-inc-product-pipeline-analysis-2013-update-report.html</guid><description><![CDATA[

Summary

Mitomics Inc. (Mitomics) is a medical diagnostic device manufacturing company. The company researches and develops mitochondrial genome-based products to improve clinical insight and therapeutic decisions. It develops mitochondria DNA based biomarkers for the screening, diagnosis and management of cancer and gynecology disease states, including prostate, breast, lung, colorectal, ovarian, endometrial, cervical, bladder, testicular and skin cancers, as well as endometriosis. The company also offers prostate core mitomic test to identify men at high risk of having a prostate tumor missed by the prostate biopsy procedure, without the need for further invasive biopsy procedures. Mitomics is headquartered in Thunder Bay, Ontario, Canada.

This report is a source for data, analysis and actionable intelligence on the Mitomics Inc. portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the development  <br><br>Original Post <a href=http://www.researchmoz.com/mitomics-inc-product-pipeline-analysis-2013-update-report.html>Mitomics Inc. - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Summary

Mitomics Inc. (Mitomics) is a medical diagnostic device manufacturing company. The company researches and develops mitochondrial genome-based products to improve clinical insight and therapeutic decisions. It develops mitochondria DNA based biomarkers for the screening, diagnosis and management of cancer and gynecology disease states, including prostate, breast, lung, colorectal, ovarian, endometrial, cervical, bladder, testicular and skin cancers, as well as endometriosis. The company also offers prostate core mitomic test to identify men at high risk of having a prostate tumor missed by the prostate biopsy procedure, without the need for further invasive biopsy procedures. Mitomics is headquartered in Thunder Bay, Ontario, Canada.

This report is a source for data, analysis and actionable intelligence on the Mitomics Inc. portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the development  <br><br>Original Post <a href=http://www.researchmoz.com/mitomics-inc-product-pipeline-analysis-2013-update-report.html>Mitomics Inc. - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/mitomics-inc-product-pipeline-analysis-2013-update-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>IQuum, Inc. - Product Pipeline Analysis, 2013 Update</title><link>http://www.researchmoz.com/iquum-inc-product-pipeline-analysis-2013-update-report.html</link><comments>http://www.researchmoz.com/iquum-inc-product-pipeline-analysis-2013-update-report.html#comments</comments><pubDate>Thu, 09 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/iquum-inc-product-pipeline-analysis-2013-update-report.html</guid><description><![CDATA[

Summary

IQuum, Inc. (IQuum) is a biotechnology company. The company conducts biological sample testing through its unique platform and performs multiple biological assays in an "insert-and-test" format. The companys product categories include Clinical IVD Products, RUO Products and Product Pipeline. Its Clinical IVD Products comprise Liat Analyzer, which enables sensitive molecular diagnostic tests to be performed by healthcare workers, providing accurate results immediately and Liat Influenza A/B Assay is a lab-based nucleic acid test. The company's Product Pipeline category conducts two diagnostic processes, namely, LiatWorkstation and assay pipeline. IQuums Liat Assay Pipeline is responsible for genetic diseases, pharmacogenomics and microbiology diagnosis. Its research and development is supported by Small Business Innovation Research (SBIR)-National Institutes of Health (NIH) grants. IQuum is headquartered in Marlborough, Massachusetts, the US.

This report is a source fo <br><br>Original Post <a href=http://www.researchmoz.com/iquum-inc-product-pipeline-analysis-2013-update-report.html>IQuum, Inc. - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Summary

IQuum, Inc. (IQuum) is a biotechnology company. The company conducts biological sample testing through its unique platform and performs multiple biological assays in an "insert-and-test" format. The companys product categories include Clinical IVD Products, RUO Products and Product Pipeline. Its Clinical IVD Products comprise Liat Analyzer, which enables sensitive molecular diagnostic tests to be performed by healthcare workers, providing accurate results immediately and Liat Influenza A/B Assay is a lab-based nucleic acid test. The company's Product Pipeline category conducts two diagnostic processes, namely, LiatWorkstation and assay pipeline. IQuums Liat Assay Pipeline is responsible for genetic diseases, pharmacogenomics and microbiology diagnosis. Its research and development is supported by Small Business Innovation Research (SBIR)-National Institutes of Health (NIH) grants. IQuum is headquartered in Marlborough, Massachusetts, the US.

This report is a source fo <br><br>Original Post <a href=http://www.researchmoz.com/iquum-inc-product-pipeline-analysis-2013-update-report.html>IQuum, Inc. - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/iquum-inc-product-pipeline-analysis-2013-update-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>ARTANN Laboratories, Inc. - Product Pipeline Analysis, 2013 Update</title><link>http://www.researchmoz.com/artann-laboratories-inc-product-pipeline-analysis-2013-update-report.html</link><comments>http://www.researchmoz.com/artann-laboratories-inc-product-pipeline-analysis-2013-update-report.html#comments</comments><pubDate>Thu, 09 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/artann-laboratories-inc-product-pipeline-analysis-2013-update-report.html</guid><description><![CDATA[

Summary

ARTANN Laboratories, Inc. (Artann) is a research development company. It develops ultrasonic devices for diagnostic imaging markets. The companys products include breast models, tissue elastometer, TRA electronic systems, and temperature controller. Its technologies include bone ultrasonometry, colonoscopy force monitor, mechanical imaging, breast mechanical imaging, prostate mechanical imaging, vaginal tactile imager, shear wave elasticity imaging, temperature profile spectroscopy and others. Artanns TRA electronic systems are used in medical and industrial applications which receives, digitizes, stores, time reverses and transmit acoustic signals. The company partners with ProUroCare Medical Inc., Pressure Profile Systems Inc., Medical Tactile Inc., and IBET Inc. It has presence in Trenton and Lambertville. Artann is headquartered in West Trenton, New Jersey, the US.

This report is a source for data, analysis and actionable intelligence on the ARTANN Laboratories, I <br><br>Original Post <a href=http://www.researchmoz.com/artann-laboratories-inc-product-pipeline-analysis-2013-update-report.html>ARTANN Laboratories, Inc. - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Summary

ARTANN Laboratories, Inc. (Artann) is a research development company. It develops ultrasonic devices for diagnostic imaging markets. The companys products include breast models, tissue elastometer, TRA electronic systems, and temperature controller. Its technologies include bone ultrasonometry, colonoscopy force monitor, mechanical imaging, breast mechanical imaging, prostate mechanical imaging, vaginal tactile imager, shear wave elasticity imaging, temperature profile spectroscopy and others. Artanns TRA electronic systems are used in medical and industrial applications which receives, digitizes, stores, time reverses and transmit acoustic signals. The company partners with ProUroCare Medical Inc., Pressure Profile Systems Inc., Medical Tactile Inc., and IBET Inc. It has presence in Trenton and Lambertville. Artann is headquartered in West Trenton, New Jersey, the US.

This report is a source for data, analysis and actionable intelligence on the ARTANN Laboratories, I <br><br>Original Post <a href=http://www.researchmoz.com/artann-laboratories-inc-product-pipeline-analysis-2013-update-report.html>ARTANN Laboratories, Inc. - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/artann-laboratories-inc-product-pipeline-analysis-2013-update-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>TiGenix NV (TIG) - Product Pipeline Analysis, 2013 Update</title><link>http://www.researchmoz.com/tigenix-nv-tig-product-pipeline-analysis-2013-update-report.html</link><comments>http://www.researchmoz.com/tigenix-nv-tig-product-pipeline-analysis-2013-update-report.html#comments</comments><pubDate>Thu, 09 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/tigenix-nv-tig-product-pipeline-analysis-2013-update-report.html</guid><description><![CDATA[

Summary

TiGenix NV (TiGenix) is a biomedical cell therapy company. The company specializes in the development of innovative local treatments for damaged and diseased tissues. It mainly focuses on the therapeutic area of orthopedic, such as damaged cartilage and osteoarthritis joints. The flagship product of the company include ChondroCelect, which is used for the cartilage repair in the knee. It also offers a strong product pipeline with clinical stage adult stem cell programs used for the treatment of inflammatory and autoimmune diseases. The company is developing a proprietary stem cell platform that can be used in cartilage, meniscus, bone, tendon and muscle tissue repair. Geographically, through its subsidiaries, the company has operations in Madrid, Spain and Sittard-Geleen, the Netherlands. TiGenix is headquartered in Leuven, Belgium.

The key business strategies of the company include enhanced focus on providing cell therapy treatments for damaged and diseased tissues.  <br><br>Original Post <a href=http://www.researchmoz.com/tigenix-nv-tig-product-pipeline-analysis-2013-update-report.html>TiGenix NV (TIG) - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Summary

TiGenix NV (TiGenix) is a biomedical cell therapy company. The company specializes in the development of innovative local treatments for damaged and diseased tissues. It mainly focuses on the therapeutic area of orthopedic, such as damaged cartilage and osteoarthritis joints. The flagship product of the company include ChondroCelect, which is used for the cartilage repair in the knee. It also offers a strong product pipeline with clinical stage adult stem cell programs used for the treatment of inflammatory and autoimmune diseases. The company is developing a proprietary stem cell platform that can be used in cartilage, meniscus, bone, tendon and muscle tissue repair. Geographically, through its subsidiaries, the company has operations in Madrid, Spain and Sittard-Geleen, the Netherlands. TiGenix is headquartered in Leuven, Belgium.

The key business strategies of the company include enhanced focus on providing cell therapy treatments for damaged and diseased tissues.  <br><br>Original Post <a href=http://www.researchmoz.com/tigenix-nv-tig-product-pipeline-analysis-2013-update-report.html>TiGenix NV (TIG) - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/tigenix-nv-tig-product-pipeline-analysis-2013-update-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Saladax Biomedical, Inc. - Product Pipeline Analysis, 2013 Update</title><link>http://www.researchmoz.com/saladax-biomedical-inc-product-pipeline-analysis-2013-update-report.html</link><comments>http://www.researchmoz.com/saladax-biomedical-inc-product-pipeline-analysis-2013-update-report.html#comments</comments><pubDate>Thu, 09 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/saladax-biomedical-inc-product-pipeline-analysis-2013-update-report.html</guid><description><![CDATA[

Summary

Saladax Biomedical, Inc. (Saladax) is a healthcare diagnostics company. The company develops and commercializes diagnostic assays for the practical delivery of personalized medicine. Its products include 5-Fluorouacil, dotacexel, paclitaxel, cyclophosphamide, irinotecan, busulfan, lenalidomide, doxorubicin, thalidomide, imatinib myselate, tyrosine kinase inhib, gemicitabine, risperidone, vincristine and clozapine. The company focuses on oncology drug dose optimization, with a portfolio of thirteen proprietary cancer drug assays and two in anti-psychotics in various stages of development. Saladax is ISO 13485:2003 certified. It partners with AB Analitica, FALCO Biosystems, Genoxa, Kaan Med, Myriad and others. Saladax is headquartered in Bethlehem, Pennsylvania, the US.

This report is a source for data, analysis and actionable intelligence on the Saladax Biomedical, Inc. portfolio of pipeline products. The report provides detailed analysis on each pipeline product with  <br><br>Original Post <a href=http://www.researchmoz.com/saladax-biomedical-inc-product-pipeline-analysis-2013-update-report.html>Saladax Biomedical, Inc. - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Summary

Saladax Biomedical, Inc. (Saladax) is a healthcare diagnostics company. The company develops and commercializes diagnostic assays for the practical delivery of personalized medicine. Its products include 5-Fluorouacil, dotacexel, paclitaxel, cyclophosphamide, irinotecan, busulfan, lenalidomide, doxorubicin, thalidomide, imatinib myselate, tyrosine kinase inhib, gemicitabine, risperidone, vincristine and clozapine. The company focuses on oncology drug dose optimization, with a portfolio of thirteen proprietary cancer drug assays and two in anti-psychotics in various stages of development. Saladax is ISO 13485:2003 certified. It partners with AB Analitica, FALCO Biosystems, Genoxa, Kaan Med, Myriad and others. Saladax is headquartered in Bethlehem, Pennsylvania, the US.

This report is a source for data, analysis and actionable intelligence on the Saladax Biomedical, Inc. portfolio of pipeline products. The report provides detailed analysis on each pipeline product with  <br><br>Original Post <a href=http://www.researchmoz.com/saladax-biomedical-inc-product-pipeline-analysis-2013-update-report.html>Saladax Biomedical, Inc. - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/saladax-biomedical-inc-product-pipeline-analysis-2013-update-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Savyon Diagnostics Ltd. - Product Pipeline Analysis, 2013 Update</title><link>http://www.researchmoz.com/savyon-diagnostics-ltd-product-pipeline-analysis-2013-update-report.html</link><comments>http://www.researchmoz.com/savyon-diagnostics-ltd-product-pipeline-analysis-2013-update-report.html#comments</comments><pubDate>Thu, 09 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/savyon-diagnostics-ltd-product-pipeline-analysis-2013-update-report.html</guid><description><![CDATA[

Summary

Savyon Diagnostics Ltd. (Savyon) is a biotechnology company. The company develops, manufactures and markets diagnostic kits and systems for the detection of infectious diseases and genetic screening. Its products include ELISA kits, DNA/RNA micro arrays, rapid tests and automation instrument. Savyon offers ELISA-based tests for detection of common gastrointestinal protozoan parasites that include CoproELISA Blastocystis, CoproELISA Cryptosporidium, CoproELISA Giardia, SeroELISA, SeroCP RT, SeroPertussis and many more. The company also offers contract manufacturing service. Its products are used in the areas of Sexually Transmitted Diseases, Respiratory Tract Infections, genetic carriers screening, urinary tract infections and womens health. The company distributes its products in Europe, Asia Pacific, North and South America, Africa, and the Middle East. Savyon is headquartered in Ashdod, Israel.

This report is a source for data, analysis and actionable intelligence o <br><br>Original Post <a href=http://www.researchmoz.com/savyon-diagnostics-ltd-product-pipeline-analysis-2013-update-report.html>Savyon Diagnostics Ltd. - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Summary

Savyon Diagnostics Ltd. (Savyon) is a biotechnology company. The company develops, manufactures and markets diagnostic kits and systems for the detection of infectious diseases and genetic screening. Its products include ELISA kits, DNA/RNA micro arrays, rapid tests and automation instrument. Savyon offers ELISA-based tests for detection of common gastrointestinal protozoan parasites that include CoproELISA Blastocystis, CoproELISA Cryptosporidium, CoproELISA Giardia, SeroELISA, SeroCP RT, SeroPertussis and many more. The company also offers contract manufacturing service. Its products are used in the areas of Sexually Transmitted Diseases, Respiratory Tract Infections, genetic carriers screening, urinary tract infections and womens health. The company distributes its products in Europe, Asia Pacific, North and South America, Africa, and the Middle East. Savyon is headquartered in Ashdod, Israel.

This report is a source for data, analysis and actionable intelligence o <br><br>Original Post <a href=http://www.researchmoz.com/savyon-diagnostics-ltd-product-pipeline-analysis-2013-update-report.html>Savyon Diagnostics Ltd. - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/savyon-diagnostics-ltd-product-pipeline-analysis-2013-update-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>CytoCore, Inc. (CYOE) - Product Pipeline Analysis, 2013 Update</title><link>http://www.researchmoz.com/cytocore-inc-cyoe-product-pipeline-analysis-2013-update-report.html</link><comments>http://www.researchmoz.com/cytocore-inc-cyoe-product-pipeline-analysis-2013-update-report.html#comments</comments><pubDate>Thu, 09 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/cytocore-inc-cyoe-product-pipeline-analysis-2013-update-report.html</guid><description><![CDATA[

Summary

CytoCore, Inc. (CCI), formerly Molecular Diagnostics, Inc., is a biotechnology company that undertakes the design, development and commercialization of cost-effective screening systems for the early detection of cancer. The major product developed by the company is CytoCore Solutions System, a simple and cost-effective method to screen women for endometrial cancer. It consists of four distinct components, namely, the SoftPAP cervical cell collector, the AIPS microscope platform, drug delivery system for treating cervical lesions, and a protein-based biochemical cocktails and slide-based tests. CCI is also licensed by Cell Solutions LLC to sell the PadKit, a sample collection device for cytological applications. The company is headquartered in Illinois, the US.

This report is a source for data, analysis and actionable intelligence on the CytoCore, Inc. portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the <br><br>Original Post <a href=http://www.researchmoz.com/cytocore-inc-cyoe-product-pipeline-analysis-2013-update-report.html>CytoCore, Inc. (CYOE) - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Summary

CytoCore, Inc. (CCI), formerly Molecular Diagnostics, Inc., is a biotechnology company that undertakes the design, development and commercialization of cost-effective screening systems for the early detection of cancer. The major product developed by the company is CytoCore Solutions System, a simple and cost-effective method to screen women for endometrial cancer. It consists of four distinct components, namely, the SoftPAP cervical cell collector, the AIPS microscope platform, drug delivery system for treating cervical lesions, and a protein-based biochemical cocktails and slide-based tests. CCI is also licensed by Cell Solutions LLC to sell the PadKit, a sample collection device for cytological applications. The company is headquartered in Illinois, the US.

This report is a source for data, analysis and actionable intelligence on the CytoCore, Inc. portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the <br><br>Original Post <a href=http://www.researchmoz.com/cytocore-inc-cyoe-product-pipeline-analysis-2013-update-report.html>CytoCore, Inc. (CYOE) - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/cytocore-inc-cyoe-product-pipeline-analysis-2013-update-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Hycor Biomedical Inc. - Product Pipeline Analysis, 2013 Update</title><link>http://www.researchmoz.com/hycor-biomedical-inc-product-pipeline-analysis-2013-update-report.html</link><comments>http://www.researchmoz.com/hycor-biomedical-inc-product-pipeline-analysis-2013-update-report.html#comments</comments><pubDate>Thu, 09 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/hycor-biomedical-inc-product-pipeline-analysis-2013-update-report.html</guid><description><![CDATA[

Summary

Hycor Biomedical Inc. (Hycor) is a medical diagnostic company. The company manufactures and markets diagnostic products used in clinical laboratories. It offers urinalysis, allergy testing and autoimmune testing. Its product portfolio includes ultra-sensitive EIA system, 288 plus system, reagents, allergy products, ELISA microplate assay kits, urinalysis products, and serology reagents. The company provides sensitive, specific serology assays for detection of antibodies to target organisms. It offers reagents for IgE testing. The company provides organ-specific, systemic, ENA-6 tests, DNA, anti-nuclear cytoplasmic, phospholipid, rheumatoid factor, celiac disease autoantibodies, and bulk reagents and components for autoimmune applications. Hycor markets its products through the brand name Hycor. It is an ISO 9001:2000 and ISO 13485:2003 certified company. Hycor is headquartered in Garden Grove, California, the US.

This report is a source for data, analysis and actionab <br><br>Original Post <a href=http://www.researchmoz.com/hycor-biomedical-inc-product-pipeline-analysis-2013-update-report.html>Hycor Biomedical Inc. - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Summary

Hycor Biomedical Inc. (Hycor) is a medical diagnostic company. The company manufactures and markets diagnostic products used in clinical laboratories. It offers urinalysis, allergy testing and autoimmune testing. Its product portfolio includes ultra-sensitive EIA system, 288 plus system, reagents, allergy products, ELISA microplate assay kits, urinalysis products, and serology reagents. The company provides sensitive, specific serology assays for detection of antibodies to target organisms. It offers reagents for IgE testing. The company provides organ-specific, systemic, ENA-6 tests, DNA, anti-nuclear cytoplasmic, phospholipid, rheumatoid factor, celiac disease autoantibodies, and bulk reagents and components for autoimmune applications. Hycor markets its products through the brand name Hycor. It is an ISO 9001:2000 and ISO 13485:2003 certified company. Hycor is headquartered in Garden Grove, California, the US.

This report is a source for data, analysis and actionab <br><br>Original Post <a href=http://www.researchmoz.com/hycor-biomedical-inc-product-pipeline-analysis-2013-update-report.html>Hycor Biomedical Inc. - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/hycor-biomedical-inc-product-pipeline-analysis-2013-update-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Biomagnetics Diagnostics Corporation (BMGP) - Product Pipeline Analysis, 2013 Update</title><link>http://www.researchmoz.com/biomagnetics-diagnostics-corporation-bmgp-product-pipeline-analysis-2013-update-report.html</link><comments>http://www.researchmoz.com/biomagnetics-diagnostics-corporation-bmgp-product-pipeline-analysis-2013-update-report.html#comments</comments><pubDate>Thu, 09 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/biomagnetics-diagnostics-corporation-bmgp-product-pipeline-analysis-2013-update-report.html</guid><description><![CDATA[

Summary

Biomagnetics Diagnostics Corporation (Biomagnetics Diagnostics) is a medical devices and biotechnology company. The company designs, patents and markets diagnostic equipment and immunoassays, and other biotechnologies. Its products include high throughput screening magnetic testing platform and integrity optical biosensor. Biomagnetics Diagnostics develops drugs, vaccines and determines the health care treatments. The company&rsquo;s diagnostic equipment is designed to detect the virus by measuring and defining a single paramagnetic microsphere attached to virus molecule of immunoassays. It offers treatment for diseases such as HIV, Hepatitis B, Tuberculosis and others. The company has a licensing and collaborative research and development agreement with Las Alamos National Security LLC. Biomagnetics Diagnostics is headquartered in Orangevale, California, the US.

This report is a source for data, analysis and actionable intelligence on the Biomagnetics Diagnostics Cor <br><br>Original Post <a href=http://www.researchmoz.com/biomagnetics-diagnostics-corporation-bmgp-product-pipeline-analysis-2013-update-report.html>Biomagnetics Diagnostics Corporation (BMGP) - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Summary

Biomagnetics Diagnostics Corporation (Biomagnetics Diagnostics) is a medical devices and biotechnology company. The company designs, patents and markets diagnostic equipment and immunoassays, and other biotechnologies. Its products include high throughput screening magnetic testing platform and integrity optical biosensor. Biomagnetics Diagnostics develops drugs, vaccines and determines the health care treatments. The company&rsquo;s diagnostic equipment is designed to detect the virus by measuring and defining a single paramagnetic microsphere attached to virus molecule of immunoassays. It offers treatment for diseases such as HIV, Hepatitis B, Tuberculosis and others. The company has a licensing and collaborative research and development agreement with Las Alamos National Security LLC. Biomagnetics Diagnostics is headquartered in Orangevale, California, the US.

This report is a source for data, analysis and actionable intelligence on the Biomagnetics Diagnostics Cor <br><br>Original Post <a href=http://www.researchmoz.com/biomagnetics-diagnostics-corporation-bmgp-product-pipeline-analysis-2013-update-report.html>Biomagnetics Diagnostics Corporation (BMGP) - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/biomagnetics-diagnostics-corporation-bmgp-product-pipeline-analysis-2013-update-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>AbSorber AB - Product Pipeline Analysis, 2013 Update</title><link>http://www.researchmoz.com/absorber-ab-product-pipeline-analysis-2013-update-report.html</link><comments>http://www.researchmoz.com/absorber-ab-product-pipeline-analysis-2013-update-report.html#comments</comments><pubDate>Thu, 09 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/absorber-ab-product-pipeline-analysis-2013-update-report.html</guid><description><![CDATA[

Summary

AbSorber AB (AbSorber) is a biotechnology company. The company develops products for allogeneic transplantation. Its product XM-ONE detects antibodies specific for endothelial specific antigens and antibodies specific to transplantation antigens. AbSorber operates through xenotransplantation, and develops techniques for removing antibodies against alpha-Gal and for reducing the immunogenicity of neural stem cells. Its products are used in the treatment of neurological disorders. The company conducts researches on developing ABO Columns, ABO diagnostics, artificial vessel grafts. It operates as a subsidiary of Allenex AB. AbSorber is headquartered in Stockholm, Sweden.

This report is a source for data, analysis and actionable intelligence on the AbSorber AB portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the development stage, trial phase, product milestones, pipeline territory, estimate <br><br>Original Post <a href=http://www.researchmoz.com/absorber-ab-product-pipeline-analysis-2013-update-report.html>AbSorber AB - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Summary

AbSorber AB (AbSorber) is a biotechnology company. The company develops products for allogeneic transplantation. Its product XM-ONE detects antibodies specific for endothelial specific antigens and antibodies specific to transplantation antigens. AbSorber operates through xenotransplantation, and develops techniques for removing antibodies against alpha-Gal and for reducing the immunogenicity of neural stem cells. Its products are used in the treatment of neurological disorders. The company conducts researches on developing ABO Columns, ABO diagnostics, artificial vessel grafts. It operates as a subsidiary of Allenex AB. AbSorber is headquartered in Stockholm, Sweden.

This report is a source for data, analysis and actionable intelligence on the AbSorber AB portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the development stage, trial phase, product milestones, pipeline territory, estimate <br><br>Original Post <a href=http://www.researchmoz.com/absorber-ab-product-pipeline-analysis-2013-update-report.html>AbSorber AB - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/absorber-ab-product-pipeline-analysis-2013-update-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>AcelRx Pharmaceuticals, Inc. (ACRX) - Product Pipeline Analysis, 2013 Update</title><link>http://www.researchmoz.com/acelrx-pharmaceuticals-inc-acrx-product-pipeline-analysis-2013-update-report.html</link><comments>http://www.researchmoz.com/acelrx-pharmaceuticals-inc-acrx-product-pipeline-analysis-2013-update-report.html#comments</comments><pubDate>Thu, 09 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/acelrx-pharmaceuticals-inc-acrx-product-pipeline-analysis-2013-update-report.html</guid><description><![CDATA[

Summary

AcelRx Pharmaceuticals, Inc. (AcelRx) is a specialty pharmaceutical company. It focuses on the development and marketing of novel therapies for the diagnosis of pain and other related disorders. The company's pipeline product portfolio includes ARX-01, ARX-02, ARX-03, and ARX-04. Its lead product candidate ARX-01 is for addressing IV PCA problems that comes post-sugery such as the invasive IV route of delivery, the side effects of morphine, and the underlying potential for programming and delivery errors related to the complexity of infusion pumps. The other product candidates ARX-02 is for treating cancer breakthrough pain; ARX-03 is to provide anxiety reduction, mild sedation and pain relief for the patients undergoing painful procedures in a doctor's office; and ARX-04 is for the treatment of acute pain. AcelRx is headquartered in Redwood City, California, the US.

This report is a source for data, analysis and actionable intelligence on the AcelRx Pharmaceuticals,  <br><br>Original Post <a href=http://www.researchmoz.com/acelrx-pharmaceuticals-inc-acrx-product-pipeline-analysis-2013-update-report.html>AcelRx Pharmaceuticals, Inc. (ACRX) - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Summary

AcelRx Pharmaceuticals, Inc. (AcelRx) is a specialty pharmaceutical company. It focuses on the development and marketing of novel therapies for the diagnosis of pain and other related disorders. The company's pipeline product portfolio includes ARX-01, ARX-02, ARX-03, and ARX-04. Its lead product candidate ARX-01 is for addressing IV PCA problems that comes post-sugery such as the invasive IV route of delivery, the side effects of morphine, and the underlying potential for programming and delivery errors related to the complexity of infusion pumps. The other product candidates ARX-02 is for treating cancer breakthrough pain; ARX-03 is to provide anxiety reduction, mild sedation and pain relief for the patients undergoing painful procedures in a doctor's office; and ARX-04 is for the treatment of acute pain. AcelRx is headquartered in Redwood City, California, the US.

This report is a source for data, analysis and actionable intelligence on the AcelRx Pharmaceuticals,  <br><br>Original Post <a href=http://www.researchmoz.com/acelrx-pharmaceuticals-inc-acrx-product-pipeline-analysis-2013-update-report.html>AcelRx Pharmaceuticals, Inc. (ACRX) - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/acelrx-pharmaceuticals-inc-acrx-product-pipeline-analysis-2013-update-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>XDx, Inc. - Product Pipeline Analysis, 2013 Update</title><link>http://www.researchmoz.com/xdx-inc-product-pipeline-analysis-2013-update-report.html</link><comments>http://www.researchmoz.com/xdx-inc-product-pipeline-analysis-2013-update-report.html#comments</comments><pubDate>Thu, 09 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/xdx-inc-product-pipeline-analysis-2013-update-report.html</guid><description><![CDATA[

Summary

XDx, Inc. (XDx) is a biotechnology company. The company develops molecular diagnostic assays that translate a patient's immune status into clinically actionable information. It discovers gene expression testing for the monitoring of transplant rejection and autoimmune diseases. Gene expression patterns reflect the activity of genes in the various blood cells types. XDx provides modern genomics and bioinformatics technology to develop molecular diagnostic assays. The company pipeline product focused on repeat testing for life-long immune-mediated conditions. It also includes Post Transplant Management under that kidney transplant, heart transplant and lung transplant. XDx is headquartered in Brisbane, California, the US.

This report is a source for data, analysis and actionable intelligence on the XDx, Inc. portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the development stage, trial phas <br><br>Original Post <a href=http://www.researchmoz.com/xdx-inc-product-pipeline-analysis-2013-update-report.html>XDx, Inc. - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Summary

XDx, Inc. (XDx) is a biotechnology company. The company develops molecular diagnostic assays that translate a patient's immune status into clinically actionable information. It discovers gene expression testing for the monitoring of transplant rejection and autoimmune diseases. Gene expression patterns reflect the activity of genes in the various blood cells types. XDx provides modern genomics and bioinformatics technology to develop molecular diagnostic assays. The company pipeline product focused on repeat testing for life-long immune-mediated conditions. It also includes Post Transplant Management under that kidney transplant, heart transplant and lung transplant. XDx is headquartered in Brisbane, California, the US.

This report is a source for data, analysis and actionable intelligence on the XDx, Inc. portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the development stage, trial phas <br><br>Original Post <a href=http://www.researchmoz.com/xdx-inc-product-pipeline-analysis-2013-update-report.html>XDx, Inc. - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/xdx-inc-product-pipeline-analysis-2013-update-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Sequenom, Inc. (SQNM) - Product Pipeline Analysis, 2013 Update</title><link>http://www.researchmoz.com/sequenom-inc-sqnm-product-pipeline-analysis-2013-update-report.html</link><comments>http://www.researchmoz.com/sequenom-inc-sqnm-product-pipeline-analysis-2013-update-report.html#comments</comments><pubDate>Thu, 09 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/sequenom-inc-sqnm-product-pipeline-analysis-2013-update-report.html</guid><description><![CDATA[

Summary

Sequenom, Inc. (Sequenom) is a molecular diagnostic testing and genetics analysis company. It carries out the development and manufacture of DNA analysis systems and related consumables and reagent kits for fine mapping genotyping applications, biomedical research, agricultural applications, molecular medicine and non-invasive prenatal diagnostics research. The companys major product is MassARRAY system, a proprietary nucleic acid analysis platform. The company operates across the Americas, Asia and Europe. Sequenom is headquartered in California, the US.&nbsp;

The company focuses on expanding its product portfolio, as recently, its subsidiary, Sequenom Center for Molecular Medicine launched an advanced new cystic fibrosis carrier screen test under the Heredi-T brand.

This report is a source for data, analysis and actionable intelligence on the Sequenom, Inc. portfolio of pipeline products. The report provides detailed analysis on each pipeline product with informa <br><br>Original Post <a href=http://www.researchmoz.com/sequenom-inc-sqnm-product-pipeline-analysis-2013-update-report.html>Sequenom, Inc. (SQNM) - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Summary

Sequenom, Inc. (Sequenom) is a molecular diagnostic testing and genetics analysis company. It carries out the development and manufacture of DNA analysis systems and related consumables and reagent kits for fine mapping genotyping applications, biomedical research, agricultural applications, molecular medicine and non-invasive prenatal diagnostics research. The companys major product is MassARRAY system, a proprietary nucleic acid analysis platform. The company operates across the Americas, Asia and Europe. Sequenom is headquartered in California, the US.&nbsp;

The company focuses on expanding its product portfolio, as recently, its subsidiary, Sequenom Center for Molecular Medicine launched an advanced new cystic fibrosis carrier screen test under the Heredi-T brand.

This report is a source for data, analysis and actionable intelligence on the Sequenom, Inc. portfolio of pipeline products. The report provides detailed analysis on each pipeline product with informa <br><br>Original Post <a href=http://www.researchmoz.com/sequenom-inc-sqnm-product-pipeline-analysis-2013-update-report.html>Sequenom, Inc. (SQNM) - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/sequenom-inc-sqnm-product-pipeline-analysis-2013-update-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>CryoLife, Inc. (CRY) - Product Pipeline Analysis, 2013 Update</title><link>http://www.researchmoz.com/cryolife-inc-cry-product-pipeline-analysis-2013-update-report.html</link><comments>http://www.researchmoz.com/cryolife-inc-cry-product-pipeline-analysis-2013-update-report.html#comments</comments><pubDate>Thu, 09 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/cryolife-inc-cry-product-pipeline-analysis-2013-update-report.html</guid><description><![CDATA[

Summary

CryoLife, Inc. (CryoLife) is a biological medical device company that develops and commercializes biomaterials, implantable medical devices and surgical adhesives, and also preserves and distributes human tissues for cardiovascular and vascular transplant applications. The companys product portfolio includes CryoValve SG pulmonary heart valve, CryoPatch SG pulmonary cardiac patch tissue and surgical sealants and hemostats including BioGlue surgical adhesive, BioFoam surgical Matrix, and PerClot absorbable powdered hemostat. The company through its subsidiary Cardiogenesis Corporation specializes in the treatment of coronary artery disease using a laser console system and single use, fiber-optic handpieces to treat patients with severe angina. Additionally, CryoLife and its subsidiary, Hemosphere, Inc. markets the Hemodialysis Reliable Outflow Graft (HeRO Graft). The company distributes its preserved human cardiac and vascular tissues to implanting institutions across the <br><br>Original Post <a href=http://www.researchmoz.com/cryolife-inc-cry-product-pipeline-analysis-2013-update-report.html>CryoLife, Inc. (CRY) - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Summary

CryoLife, Inc. (CryoLife) is a biological medical device company that develops and commercializes biomaterials, implantable medical devices and surgical adhesives, and also preserves and distributes human tissues for cardiovascular and vascular transplant applications. The companys product portfolio includes CryoValve SG pulmonary heart valve, CryoPatch SG pulmonary cardiac patch tissue and surgical sealants and hemostats including BioGlue surgical adhesive, BioFoam surgical Matrix, and PerClot absorbable powdered hemostat. The company through its subsidiary Cardiogenesis Corporation specializes in the treatment of coronary artery disease using a laser console system and single use, fiber-optic handpieces to treat patients with severe angina. Additionally, CryoLife and its subsidiary, Hemosphere, Inc. markets the Hemodialysis Reliable Outflow Graft (HeRO Graft). The company distributes its preserved human cardiac and vascular tissues to implanting institutions across the <br><br>Original Post <a href=http://www.researchmoz.com/cryolife-inc-cry-product-pipeline-analysis-2013-update-report.html>CryoLife, Inc. (CRY) - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/cryolife-inc-cry-product-pipeline-analysis-2013-update-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Bayer HealthCare AG - Product Pipeline Analysis, 2013 Update</title><link>http://www.researchmoz.com/bayer-healthcare-ag-product-pipeline-analysis-2013-update-report.html</link><comments>http://www.researchmoz.com/bayer-healthcare-ag-product-pipeline-analysis-2013-update-report.html#comments</comments><pubDate>Thu, 09 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/bayer-healthcare-ag-product-pipeline-analysis-2013-update-report.html</guid><description><![CDATA[

Summary

Bayer HealthCare AG (Bayer Healthcare), a division of the Bayer Group is a healthcare company. It undertakes the design, research, development, manufacture and sale of medical products for the healthcare industry. The company develops innovative products such as animal healthcare products, consumer care products, blood glucose monitoring systems, diagnostic imaging products, oncology products and primary care products. It operates through four business divisions, namely, Animal Health, Consumer Care, Medical Care and Pharmaceuticals. Bayer Healthcares products are marketed across the world through regional and national distribution companies. It operates in more than 100 countries and has about 60 manufacturing facilities across five continents. The company is headquartered in Leverkusen, Germany.

Bayer Healthcare focuses on enhancing its market share through strategic alliances and acquisitions. In line with this strategy, the company recently collaborated with Covan <br><br>Original Post <a href=http://www.researchmoz.com/bayer-healthcare-ag-product-pipeline-analysis-2013-update-report.html>Bayer HealthCare AG - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Summary

Bayer HealthCare AG (Bayer Healthcare), a division of the Bayer Group is a healthcare company. It undertakes the design, research, development, manufacture and sale of medical products for the healthcare industry. The company develops innovative products such as animal healthcare products, consumer care products, blood glucose monitoring systems, diagnostic imaging products, oncology products and primary care products. It operates through four business divisions, namely, Animal Health, Consumer Care, Medical Care and Pharmaceuticals. Bayer Healthcares products are marketed across the world through regional and national distribution companies. It operates in more than 100 countries and has about 60 manufacturing facilities across five continents. The company is headquartered in Leverkusen, Germany.

Bayer Healthcare focuses on enhancing its market share through strategic alliances and acquisitions. In line with this strategy, the company recently collaborated with Covan <br><br>Original Post <a href=http://www.researchmoz.com/bayer-healthcare-ag-product-pipeline-analysis-2013-update-report.html>Bayer HealthCare AG - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/bayer-healthcare-ag-product-pipeline-analysis-2013-update-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Advanced Circulatory Systems, Inc. - Product Pipeline Analysis, 2013 Update</title><link>http://www.researchmoz.com/advanced-circulatory-systems-inc-product-pipeline-analysis-2013-update-report.html</link><comments>http://www.researchmoz.com/advanced-circulatory-systems-inc-product-pipeline-analysis-2013-update-report.html#comments</comments><pubDate>Thu, 09 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/advanced-circulatory-systems-inc-product-pipeline-analysis-2013-update-report.html</guid><description><![CDATA[

Summary

Advanced Circulatory Systems, Inc. (Advanced Circulatory) is a medical device manufacturer. It manufactures and distributes circulatory technology and blood circulatory products. The companys products include ResQPOD, an impedance threshold device that provides perfusion on demand by regulating pressures in the thorax, CardioPump that allows the standard method of external chest compressions to be enhanced with active expansion of the chest. Advanced Circulatory also provides ResQCPR demo kit, an interactive tool to train rescuers and healthcare providers on how conventional manual cardiopulmonary resuscitation (CPR) circulates blood. The company was formerly known as ResQSystems. Advanced Circulatory is headquartered in Roseville, Minnesota, the US.

This report is a source for data, analysis and actionable intelligence on the Advanced Circulatory Systems, Inc. portfolio of pipeline products. The report provides detailed analysis on each pipeline product with informat <br><br>Original Post <a href=http://www.researchmoz.com/advanced-circulatory-systems-inc-product-pipeline-analysis-2013-update-report.html>Advanced Circulatory Systems, Inc. - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Summary

Advanced Circulatory Systems, Inc. (Advanced Circulatory) is a medical device manufacturer. It manufactures and distributes circulatory technology and blood circulatory products. The companys products include ResQPOD, an impedance threshold device that provides perfusion on demand by regulating pressures in the thorax, CardioPump that allows the standard method of external chest compressions to be enhanced with active expansion of the chest. Advanced Circulatory also provides ResQCPR demo kit, an interactive tool to train rescuers and healthcare providers on how conventional manual cardiopulmonary resuscitation (CPR) circulates blood. The company was formerly known as ResQSystems. Advanced Circulatory is headquartered in Roseville, Minnesota, the US.

This report is a source for data, analysis and actionable intelligence on the Advanced Circulatory Systems, Inc. portfolio of pipeline products. The report provides detailed analysis on each pipeline product with informat <br><br>Original Post <a href=http://www.researchmoz.com/advanced-circulatory-systems-inc-product-pipeline-analysis-2013-update-report.html>Advanced Circulatory Systems, Inc. - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/advanced-circulatory-systems-inc-product-pipeline-analysis-2013-update-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>AbaStar MDx, Inc. - Product Pipeline Analysis, 2013 Update</title><link>http://www.researchmoz.com/abastar-mdx-inc-product-pipeline-analysis-2013-update-report.html</link><comments>http://www.researchmoz.com/abastar-mdx-inc-product-pipeline-analysis-2013-update-report.html#comments</comments><pubDate>Thu, 09 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/abastar-mdx-inc-product-pipeline-analysis-2013-update-report.html</guid><description><![CDATA[

Summary

AbaStar MDx, Inc. (AbaStar) is a physiological diagnostics provider. It develops blood-based gene expression and molecular diagnostic tests for the diagnosis of mental disorders and neurodegenerative diseases. The company provides physiological diagnostics from the molecular signature of the disease in circulating blood. It offers products for schizophrenia, bipolar disorder, depression, autism, bipolar disorder, Down's syndrome, epilepsy, Huntington's disease, Klinefelter's syndrome, multiple sclerosis, nicotine dependence, panic disorder, post-traumatic stress disorder, Tourette's Syndrome and Schizophrenia, Alzheimer's disease and Parkinson's disease. Its products are used in hospitals and clinical reference labs. The company served over 10 million people with neurodegenerative diseases. AbaStar is headquartered in San Diego, California, the US.

This report is a source for data, analysis and actionable intelligence on the AbaStar MDx, Inc. portfolio of pipeline pro <br><br>Original Post <a href=http://www.researchmoz.com/abastar-mdx-inc-product-pipeline-analysis-2013-update-report.html>AbaStar MDx, Inc. - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Summary

AbaStar MDx, Inc. (AbaStar) is a physiological diagnostics provider. It develops blood-based gene expression and molecular diagnostic tests for the diagnosis of mental disorders and neurodegenerative diseases. The company provides physiological diagnostics from the molecular signature of the disease in circulating blood. It offers products for schizophrenia, bipolar disorder, depression, autism, bipolar disorder, Down's syndrome, epilepsy, Huntington's disease, Klinefelter's syndrome, multiple sclerosis, nicotine dependence, panic disorder, post-traumatic stress disorder, Tourette's Syndrome and Schizophrenia, Alzheimer's disease and Parkinson's disease. Its products are used in hospitals and clinical reference labs. The company served over 10 million people with neurodegenerative diseases. AbaStar is headquartered in San Diego, California, the US.

This report is a source for data, analysis and actionable intelligence on the AbaStar MDx, Inc. portfolio of pipeline pro <br><br>Original Post <a href=http://www.researchmoz.com/abastar-mdx-inc-product-pipeline-analysis-2013-update-report.html>AbaStar MDx, Inc. - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/abastar-mdx-inc-product-pipeline-analysis-2013-update-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Debiotech S.A. - Product Pipeline Analysis, 2013 Update</title><link>http://www.researchmoz.com/debiotech-sa-product-pipeline-analysis-2013-update-report.html</link><comments>http://www.researchmoz.com/debiotech-sa-product-pipeline-analysis-2013-update-report.html#comments</comments><pubDate>Thu, 09 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/debiotech-sa-product-pipeline-analysis-2013-update-report.html</guid><description><![CDATA[

Summary

Debiotech S.A. (Debiotech) is a medical device company. The company develops therapeutic devices and diagnostic products. It operates through its product categories such as Electronic Infusion Systems, Drug Delivery Devices, Microsystems and Diagnostics. Debiotechs drug delivery devices include debiostar, debiostent, debioject, debioclip and debiopass. The company offers micro systems such as nanopumpm, jewel pump, MIP implatable and chronoflow. It also develops novel technologies for the delivery of vaccines, diagnostic and imaging devices. The company develops products in the field of implantable and external drug delivery systems using micromechanics, nanotechnologies and microelectromechanical systems. Debiotech is headquartered in Lausanne, Switzerland.

This report is a source for data, analysis and actionable intelligence on the Debiotech S.A. portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the i <br><br>Original Post <a href=http://www.researchmoz.com/debiotech-sa-product-pipeline-analysis-2013-update-report.html>Debiotech S.A. - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Summary

Debiotech S.A. (Debiotech) is a medical device company. The company develops therapeutic devices and diagnostic products. It operates through its product categories such as Electronic Infusion Systems, Drug Delivery Devices, Microsystems and Diagnostics. Debiotechs drug delivery devices include debiostar, debiostent, debioject, debioclip and debiopass. The company offers micro systems such as nanopumpm, jewel pump, MIP implatable and chronoflow. It also develops novel technologies for the delivery of vaccines, diagnostic and imaging devices. The company develops products in the field of implantable and external drug delivery systems using micromechanics, nanotechnologies and microelectromechanical systems. Debiotech is headquartered in Lausanne, Switzerland.

This report is a source for data, analysis and actionable intelligence on the Debiotech S.A. portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the i <br><br>Original Post <a href=http://www.researchmoz.com/debiotech-sa-product-pipeline-analysis-2013-update-report.html>Debiotech S.A. - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/debiotech-sa-product-pipeline-analysis-2013-update-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Hadasit Medical Research Services &amp; Development Ltd - Product Pipeline Analysis, 2013 Update</title><link>http://www.researchmoz.com/hadasit-medical-research-services-and-development-ltd-product-pipeline-analysis-2013-update-report.html</link><comments>http://www.researchmoz.com/hadasit-medical-research-services-and-development-ltd-product-pipeline-analysis-2013-update-report.html#comments</comments><pubDate>Thu, 09 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/hadasit-medical-research-services-and-development-ltd-product-pipeline-analysis-2013-update-report.html</guid><description><![CDATA[

Summary

Hadasit Medical Research Services &amp; Development Ltd (Hadasit Ltd) is a biomedical technology company. It provides, promotes and commercializeS pre-clinical and clinical research and development capabilities through product licensing, establishing start-up companies and collaboration with academy and industry. The company provides services in various categories such as research services which include clinical and pre-clinical services, consulting services which cover dentistry, cardiology, internal medicine, neurology, oncology, ophthalmology, and orthopedics. Hadasit Ltd also provides pharmaceutical technologies, medical device technologies, medical diagnostics and imaging technologies, and others. The company owns the Hadassah Clinical Research Center (HCRC), which is a GCP-compliant and is also into development of many technologies in various fields of healthcare sector. It operates as a subsidiary of Hadassah Medical Organization (HMO). Hadasit Ltd is headquartere <br><br>Original Post <a href=http://www.researchmoz.com/hadasit-medical-research-services-and-development-ltd-product-pipeline-analysis-2013-update-report.html>Hadasit Medical Research Services &amp; Development Ltd - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Summary

Hadasit Medical Research Services &amp; Development Ltd (Hadasit Ltd) is a biomedical technology company. It provides, promotes and commercializeS pre-clinical and clinical research and development capabilities through product licensing, establishing start-up companies and collaboration with academy and industry. The company provides services in various categories such as research services which include clinical and pre-clinical services, consulting services which cover dentistry, cardiology, internal medicine, neurology, oncology, ophthalmology, and orthopedics. Hadasit Ltd also provides pharmaceutical technologies, medical device technologies, medical diagnostics and imaging technologies, and others. The company owns the Hadassah Clinical Research Center (HCRC), which is a GCP-compliant and is also into development of many technologies in various fields of healthcare sector. It operates as a subsidiary of Hadassah Medical Organization (HMO). Hadasit Ltd is headquartere <br><br>Original Post <a href=http://www.researchmoz.com/hadasit-medical-research-services-and-development-ltd-product-pipeline-analysis-2013-update-report.html>Hadasit Medical Research Services &amp; Development Ltd - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/hadasit-medical-research-services-and-development-ltd-product-pipeline-analysis-2013-update-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Autoimmune Technologies, LLC - Product Pipeline Analysis, 2013 Update</title><link>http://www.researchmoz.com/autoimmune-technologies-llc-product-pipeline-analysis-2013-update-report.html</link><comments>http://www.researchmoz.com/autoimmune-technologies-llc-product-pipeline-analysis-2013-update-report.html#comments</comments><pubDate>Thu, 09 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/autoimmune-technologies-llc-product-pipeline-analysis-2013-update-report.html</guid><description><![CDATA[

Summary

Autoimmune Technologies, LLC (Autoimmune) is a biomedical company. The company develops medical diagnostic tests, explores disease mechanisms and investigates therapies for autoimmune diseases and disorders. It develops anti-viral drugs that are designed to prevent viral particles from fusing with target cells. Autoimmune also develops Flufirvitide, influenza drug a blood test to aid in diagnosis of Lassa fever, fibromyalgia, systemic lupus erythematosus, Sjogren's syndrome, juvenile rheumatoid arthritis and Grave's disease. The companys laboratory tests include fibromyalgia, lassa fever, gulf war syndrome, lupus, sjogren's, juvenile rheumatoid arthritis, grave's disease, breast cancer, and non-HIV AIDS. Autoimmune is headquartered in New Orleans, Louisiana, the US.

This report is a source for data, analysis and actionable intelligence on the Autoimmune Technologies, LLC portfolio of pipeline products. The report provides detailed analysis on each pipeline product wit <br><br>Original Post <a href=http://www.researchmoz.com/autoimmune-technologies-llc-product-pipeline-analysis-2013-update-report.html>Autoimmune Technologies, LLC - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Summary

Autoimmune Technologies, LLC (Autoimmune) is a biomedical company. The company develops medical diagnostic tests, explores disease mechanisms and investigates therapies for autoimmune diseases and disorders. It develops anti-viral drugs that are designed to prevent viral particles from fusing with target cells. Autoimmune also develops Flufirvitide, influenza drug a blood test to aid in diagnosis of Lassa fever, fibromyalgia, systemic lupus erythematosus, Sjogren's syndrome, juvenile rheumatoid arthritis and Grave's disease. The companys laboratory tests include fibromyalgia, lassa fever, gulf war syndrome, lupus, sjogren's, juvenile rheumatoid arthritis, grave's disease, breast cancer, and non-HIV AIDS. Autoimmune is headquartered in New Orleans, Louisiana, the US.

This report is a source for data, analysis and actionable intelligence on the Autoimmune Technologies, LLC portfolio of pipeline products. The report provides detailed analysis on each pipeline product wit <br><br>Original Post <a href=http://www.researchmoz.com/autoimmune-technologies-llc-product-pipeline-analysis-2013-update-report.html>Autoimmune Technologies, LLC - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/autoimmune-technologies-llc-product-pipeline-analysis-2013-update-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>SpinalMotion, Inc. - Product Pipeline Analysis, 2013 Update</title><link>http://www.researchmoz.com/spinalmotion-inc-product-pipeline-analysis-2013-update-report.html</link><comments>http://www.researchmoz.com/spinalmotion-inc-product-pipeline-analysis-2013-update-report.html#comments</comments><pubDate>Thu, 09 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/spinalmotion-inc-product-pipeline-analysis-2013-update-report.html</guid><description><![CDATA[

Summary

SpinalMotion, Inc. (SpinalMotion) is a medical device company. The company designs and develops innovative artificial discs and instrumentation. It offers products such as kineflex cervical disc, and kineflex lumbar disc designed to potentially mimic the motion of a normal spinal disc. SpinalMotions products are incorporating a mobile bearing design, allowing translational movement within limits defined by a specially-designed retention ring. The company also focuses on providing surgical treatment for degenerative disc disease. It operates through its offices in Fairfax and Mountain View. SpinalMotion is headquartered in Mountain View, California, the US.

This report is a source for data, analysis and actionable intelligence on the SpinalMotion, Inc. portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the development stage, trial phase, product milestones, pipeline territory, estimated app <br><br>Original Post <a href=http://www.researchmoz.com/spinalmotion-inc-product-pipeline-analysis-2013-update-report.html>SpinalMotion, Inc. - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Summary

SpinalMotion, Inc. (SpinalMotion) is a medical device company. The company designs and develops innovative artificial discs and instrumentation. It offers products such as kineflex cervical disc, and kineflex lumbar disc designed to potentially mimic the motion of a normal spinal disc. SpinalMotions products are incorporating a mobile bearing design, allowing translational movement within limits defined by a specially-designed retention ring. The company also focuses on providing surgical treatment for degenerative disc disease. It operates through its offices in Fairfax and Mountain View. SpinalMotion is headquartered in Mountain View, California, the US.

This report is a source for data, analysis and actionable intelligence on the SpinalMotion, Inc. portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the development stage, trial phase, product milestones, pipeline territory, estimated app <br><br>Original Post <a href=http://www.researchmoz.com/spinalmotion-inc-product-pipeline-analysis-2013-update-report.html>SpinalMotion, Inc. - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/spinalmotion-inc-product-pipeline-analysis-2013-update-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Acrostak (Schweiz) AG - Product Pipeline Analysis, 2013 Update</title><link>http://www.researchmoz.com/acrostak-schweiz-ag-product-pipeline-analysis-2013-update-report.html</link><comments>http://www.researchmoz.com/acrostak-schweiz-ag-product-pipeline-analysis-2013-update-report.html#comments</comments><pubDate>Thu, 09 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/acrostak-schweiz-ag-product-pipeline-analysis-2013-update-report.html</guid><description><![CDATA[

Summary

Acrostak (Schweiz) AG (Acrostak Schweiz) is a medical device company. The company develops, manufactures and distributes single use medical devices. Its products include grip, across CTO, across HP and genie. Acrostak Schweiz offers quality management, clinical, regulatory affairs services and clinical support. The company provides treatment in the field of interventional cardiology, radiology and oncology. It develops solutions to improve the treatment of peripheral arterial diseases. The company also develops products to research and development projects. It markets products through the brands such as GRIP, ACROSS CTO, ACROSS HP and GENIE. The company sells products through a network of retailers worldwide. Acrostak Schweiz is headquartered in Winterthur, Zurich, Switzerland.

This report is a source for data, analysis and actionable intelligence on the Acrostak (Schweiz) AG portfolio of pipeline products. The report provides detailed analysis on each pipeline produc <br><br>Original Post <a href=http://www.researchmoz.com/acrostak-schweiz-ag-product-pipeline-analysis-2013-update-report.html>Acrostak (Schweiz) AG - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Summary

Acrostak (Schweiz) AG (Acrostak Schweiz) is a medical device company. The company develops, manufactures and distributes single use medical devices. Its products include grip, across CTO, across HP and genie. Acrostak Schweiz offers quality management, clinical, regulatory affairs services and clinical support. The company provides treatment in the field of interventional cardiology, radiology and oncology. It develops solutions to improve the treatment of peripheral arterial diseases. The company also develops products to research and development projects. It markets products through the brands such as GRIP, ACROSS CTO, ACROSS HP and GENIE. The company sells products through a network of retailers worldwide. Acrostak Schweiz is headquartered in Winterthur, Zurich, Switzerland.

This report is a source for data, analysis and actionable intelligence on the Acrostak (Schweiz) AG portfolio of pipeline products. The report provides detailed analysis on each pipeline produc <br><br>Original Post <a href=http://www.researchmoz.com/acrostak-schweiz-ag-product-pipeline-analysis-2013-update-report.html>Acrostak (Schweiz) AG - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/acrostak-schweiz-ag-product-pipeline-analysis-2013-update-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>BrainScope Company, Inc. - Product Pipeline Analysis, 2013 Update</title><link>http://www.researchmoz.com/brainscope-company-inc-product-pipeline-analysis-2013-update-report.html</link><comments>http://www.researchmoz.com/brainscope-company-inc-product-pipeline-analysis-2013-update-report.html#comments</comments><pubDate>Thu, 09 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/brainscope-company-inc-product-pipeline-analysis-2013-update-report.html</guid><description><![CDATA[

Summary

BrainScope Company, Inc. (Brain Scope) is a medical neurotechnology company. The company develops and distributes non-invasive instruments for the treatment of traumatic brain injuries, moderate traumatic brain injury and mild traumatic brain injury. The company offers non-invasive instruments to aid medical professionals to aid in the assessment of brain function at the initial point of care. BrainScopes brain scope system contains substantial information regarding a patients brain function and neurological condition for assessment of abnormality of brain function. The company manufactures products for military and civilians treatment. Its products offers services such as adjunctive brain electrical data to aid in assessment of brain injury, rapid and clinically meaningful, adjunctive front-line assessment of brain function to aid in timely triage decision-making and additional brain function information when both the neurologic exam and the imaging tests show a negativ <br><br>Original Post <a href=http://www.researchmoz.com/brainscope-company-inc-product-pipeline-analysis-2013-update-report.html>BrainScope Company, Inc. - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Summary

BrainScope Company, Inc. (Brain Scope) is a medical neurotechnology company. The company develops and distributes non-invasive instruments for the treatment of traumatic brain injuries, moderate traumatic brain injury and mild traumatic brain injury. The company offers non-invasive instruments to aid medical professionals to aid in the assessment of brain function at the initial point of care. BrainScopes brain scope system contains substantial information regarding a patients brain function and neurological condition for assessment of abnormality of brain function. The company manufactures products for military and civilians treatment. Its products offers services such as adjunctive brain electrical data to aid in assessment of brain injury, rapid and clinically meaningful, adjunctive front-line assessment of brain function to aid in timely triage decision-making and additional brain function information when both the neurologic exam and the imaging tests show a negativ <br><br>Original Post <a href=http://www.researchmoz.com/brainscope-company-inc-product-pipeline-analysis-2013-update-report.html>BrainScope Company, Inc. - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/brainscope-company-inc-product-pipeline-analysis-2013-update-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Olympus Medical Systems Corp. - Product Pipeline Analysis, 2013 Update</title><link>http://www.researchmoz.com/olympus-medical-systems-corp-product-pipeline-analysis-2013-update-report.html</link><comments>http://www.researchmoz.com/olympus-medical-systems-corp-product-pipeline-analysis-2013-update-report.html#comments</comments><pubDate>Thu, 09 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/olympus-medical-systems-corp-product-pipeline-analysis-2013-update-report.html</guid><description><![CDATA[

Summary

Olympus Medical Systems Corp. (OMSC) is a medical device company. The company manufactures and sells endosurgery and endotherapy products. It offers therapeutic endoscopes and endotherapy accessories, service and repair solutions and web-based endoscopy information products. OMSC also markets medical treatment peripherals, ancillary products, veterinary endoscopes, endosurgery systems and endoscopy products for gastroenterological surgery. The company broadly classifies its products into three categories, namely, medical endoscopes, surgical endoscopes and endo-therapy devices. It operates across Americas, Asia-Pacific, Europe and Africa. The company was found in the year 1920. It is a business division of Olympus Corporation. OMSC is headquartered in Tokyo, Japan.

This report is a source for data, analysis and actionable intelligence on the Olympus Medical Systems Corp. portfolio of pipeline products. The report provides detailed analysis on each pipeline product wit <br><br>Original Post <a href=http://www.researchmoz.com/olympus-medical-systems-corp-product-pipeline-analysis-2013-update-report.html>Olympus Medical Systems Corp. - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Summary

Olympus Medical Systems Corp. (OMSC) is a medical device company. The company manufactures and sells endosurgery and endotherapy products. It offers therapeutic endoscopes and endotherapy accessories, service and repair solutions and web-based endoscopy information products. OMSC also markets medical treatment peripherals, ancillary products, veterinary endoscopes, endosurgery systems and endoscopy products for gastroenterological surgery. The company broadly classifies its products into three categories, namely, medical endoscopes, surgical endoscopes and endo-therapy devices. It operates across Americas, Asia-Pacific, Europe and Africa. The company was found in the year 1920. It is a business division of Olympus Corporation. OMSC is headquartered in Tokyo, Japan.

This report is a source for data, analysis and actionable intelligence on the Olympus Medical Systems Corp. portfolio of pipeline products. The report provides detailed analysis on each pipeline product wit <br><br>Original Post <a href=http://www.researchmoz.com/olympus-medical-systems-corp-product-pipeline-analysis-2013-update-report.html>Olympus Medical Systems Corp. - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/olympus-medical-systems-corp-product-pipeline-analysis-2013-update-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Acoustic MedSystems, Inc. - Product Pipeline Analysis, 2013 Update</title><link>http://www.researchmoz.com/acoustic-medsystems-inc-product-pipeline-analysis-2013-update-report.html</link><comments>http://www.researchmoz.com/acoustic-medsystems-inc-product-pipeline-analysis-2013-update-report.html#comments</comments><pubDate>Thu, 09 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/acoustic-medsystems-inc-product-pipeline-analysis-2013-update-report.html</guid><description><![CDATA[

Summary

Acoustic MedSystems, Inc. (AMS) is a medical device company. The company designs ultrasound and radiation therapy systems and instrumentation. Its products include ablation, radiation treatment planning, delivery guidance software and systems, intensity needle-based and catheter-based interventional devices for thermal ablative therapy. AMS develops interventional devices and systems for the treatment of localized disease. The companys products find applications such as treatment planning and image-guided interventions using ablative therapy technologies and radiation therapy. It also develops applications for Windows 7 and Windows XP using Microsoft Visual Studio Visual C++ and C#, including .NET and MFC applications. The company partners with research teams in the US and Canada. AMS is headquartered in Savoy, Illinois, the US.

This report is a source for data, analysis and actionable intelligence on the Acoustic MedSystems, Inc. portfolio of pipeline products. The r <br><br>Original Post <a href=http://www.researchmoz.com/acoustic-medsystems-inc-product-pipeline-analysis-2013-update-report.html>Acoustic MedSystems, Inc. - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Summary

Acoustic MedSystems, Inc. (AMS) is a medical device company. The company designs ultrasound and radiation therapy systems and instrumentation. Its products include ablation, radiation treatment planning, delivery guidance software and systems, intensity needle-based and catheter-based interventional devices for thermal ablative therapy. AMS develops interventional devices and systems for the treatment of localized disease. The companys products find applications such as treatment planning and image-guided interventions using ablative therapy technologies and radiation therapy. It also develops applications for Windows 7 and Windows XP using Microsoft Visual Studio Visual C++ and C#, including .NET and MFC applications. The company partners with research teams in the US and Canada. AMS is headquartered in Savoy, Illinois, the US.

This report is a source for data, analysis and actionable intelligence on the Acoustic MedSystems, Inc. portfolio of pipeline products. The r <br><br>Original Post <a href=http://www.researchmoz.com/acoustic-medsystems-inc-product-pipeline-analysis-2013-update-report.html>Acoustic MedSystems, Inc. - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/acoustic-medsystems-inc-product-pipeline-analysis-2013-update-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Nanospectra Biosciences, Inc. - Product Pipeline Analysis, 2013 Update</title><link>http://www.researchmoz.com/nanospectra-biosciences-inc-product-pipeline-analysis-2013-update-report.html</link><comments>http://www.researchmoz.com/nanospectra-biosciences-inc-product-pipeline-analysis-2013-update-report.html#comments</comments><pubDate>Thu, 09 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/nanospectra-biosciences-inc-product-pipeline-analysis-2013-update-report.html</guid><description><![CDATA[

Summary

Nanospectra Biosciences, Inc. (Nanospectra) is a life science company. The company develops and commercializes particle based therapies for the selective and precise thermal destruction of solid tumors. It offers AuroLase therapy that combines the unique physical and optical properties of AuroShell particles with an infrared laser source to thermally destroy cancer tissue without significant damage to surrounding healthy tissue. Nanospectra has license from Rice University to eleven issued US patents related to nanoshells and related commercial uses of these and other nanoparticles. It also offers research use only nanoparticles with specific optical characteristics. The company has an open investigational device exemption with the U.S. FDA to evaluate the safety and efficacy of AuroLase therapy for the treatment of refractory or recurrent head and neck cancers. Nanospectra is headquartered in Houston, Texas, the US.

This report is a source for data, analysis and acti <br><br>Original Post <a href=http://www.researchmoz.com/nanospectra-biosciences-inc-product-pipeline-analysis-2013-update-report.html>Nanospectra Biosciences, Inc. - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Summary

Nanospectra Biosciences, Inc. (Nanospectra) is a life science company. The company develops and commercializes particle based therapies for the selective and precise thermal destruction of solid tumors. It offers AuroLase therapy that combines the unique physical and optical properties of AuroShell particles with an infrared laser source to thermally destroy cancer tissue without significant damage to surrounding healthy tissue. Nanospectra has license from Rice University to eleven issued US patents related to nanoshells and related commercial uses of these and other nanoparticles. It also offers research use only nanoparticles with specific optical characteristics. The company has an open investigational device exemption with the U.S. FDA to evaluate the safety and efficacy of AuroLase therapy for the treatment of refractory or recurrent head and neck cancers. Nanospectra is headquartered in Houston, Texas, the US.

This report is a source for data, analysis and acti <br><br>Original Post <a href=http://www.researchmoz.com/nanospectra-biosciences-inc-product-pipeline-analysis-2013-update-report.html>Nanospectra Biosciences, Inc. - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/nanospectra-biosciences-inc-product-pipeline-analysis-2013-update-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Bolton Medical, Inc. - Product Pipeline Analysis, 2013 Update</title><link>http://www.researchmoz.com/bolton-medical-inc-product-pipeline-analysis-2013-update-report.html</link><comments>http://www.researchmoz.com/bolton-medical-inc-product-pipeline-analysis-2013-update-report.html#comments</comments><pubDate>Thu, 09 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/bolton-medical-inc-product-pipeline-analysis-2013-update-report.html</guid><description><![CDATA[

Summary

Bolton Medical, Inc. (Bolton Medical) is a medical device company. The company designs, develops, manufactures and distributes endovascular devices. Its products include thoracic stent grafts and abdominal stent-graft. The company offers products for the treatment of thoracic aortic pathologies such as aneurysms, penetrating ulcers, pseudoaneurysms, and intramural hematomas. It has implanted more than 7,000 Relay and Relay NBS Stent-Grafts worldwide. The company has received United States FDA approval of the Relay Stent-Graft. Bolton Medical is present in more than 40 counties around the world. It is a wholly-owned subsidiary of the Werfen Life Group. Bolton Medical is headquartered in Florida, the US.

This report is a source for data, analysis and actionable intelligence on the Bolton Medical, Inc. portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the development stage, trial phase, prod <br><br>Original Post <a href=http://www.researchmoz.com/bolton-medical-inc-product-pipeline-analysis-2013-update-report.html>Bolton Medical, Inc. - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Summary

Bolton Medical, Inc. (Bolton Medical) is a medical device company. The company designs, develops, manufactures and distributes endovascular devices. Its products include thoracic stent grafts and abdominal stent-graft. The company offers products for the treatment of thoracic aortic pathologies such as aneurysms, penetrating ulcers, pseudoaneurysms, and intramural hematomas. It has implanted more than 7,000 Relay and Relay NBS Stent-Grafts worldwide. The company has received United States FDA approval of the Relay Stent-Graft. Bolton Medical is present in more than 40 counties around the world. It is a wholly-owned subsidiary of the Werfen Life Group. Bolton Medical is headquartered in Florida, the US.

This report is a source for data, analysis and actionable intelligence on the Bolton Medical, Inc. portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the development stage, trial phase, prod <br><br>Original Post <a href=http://www.researchmoz.com/bolton-medical-inc-product-pipeline-analysis-2013-update-report.html>Bolton Medical, Inc. - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/bolton-medical-inc-product-pipeline-analysis-2013-update-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Antares Pharma, Inc. (ATRS) - Product Pipeline Analysis, 2013 Update</title><link>http://www.researchmoz.com/antares-pharma-inc-atrs-product-pipeline-analysis-2013-update-report.html</link><comments>http://www.researchmoz.com/antares-pharma-inc-atrs-product-pipeline-analysis-2013-update-report.html#comments</comments><pubDate>Thu, 09 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/antares-pharma-inc-atrs-product-pipeline-analysis-2013-update-report.html</guid><description><![CDATA[

Summary

Antares Pharma, Inc. (Antares Pharma) is a specialty pharmaceutical company, which focuses on the self-injection pharmaceutical drugs and technologies and topical gel-based products. The company is focused on topical gel-based products and self-injection pharmaceutical products and technologies. The company has developed three proprietary platforms. Its subcutaneous and intramuscular injection technology platform consists of Vibex disposable pressure-assisted auto injectors, Vision reusable needle-free injectors, and disposable multi-use pen injectors while its gel-based platform consists of Anturol, for the treatment of OAB (over active bladder) and Elestrin (estradiol gel) used to treat vasomotor symptoms associated with menopause. Antares Pharma applies its drug delivery systems in alliance with pharmaceutical partners to enhance its partners' drug compounds. It has multiple development partnerships with leading pharmaceutical companies. The company's parenteral produ <br><br>Original Post <a href=http://www.researchmoz.com/antares-pharma-inc-atrs-product-pipeline-analysis-2013-update-report.html>Antares Pharma, Inc. (ATRS) - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Summary

Antares Pharma, Inc. (Antares Pharma) is a specialty pharmaceutical company, which focuses on the self-injection pharmaceutical drugs and technologies and topical gel-based products. The company is focused on topical gel-based products and self-injection pharmaceutical products and technologies. The company has developed three proprietary platforms. Its subcutaneous and intramuscular injection technology platform consists of Vibex disposable pressure-assisted auto injectors, Vision reusable needle-free injectors, and disposable multi-use pen injectors while its gel-based platform consists of Anturol, for the treatment of OAB (over active bladder) and Elestrin (estradiol gel) used to treat vasomotor symptoms associated with menopause. Antares Pharma applies its drug delivery systems in alliance with pharmaceutical partners to enhance its partners' drug compounds. It has multiple development partnerships with leading pharmaceutical companies. The company's parenteral produ <br><br>Original Post <a href=http://www.researchmoz.com/antares-pharma-inc-atrs-product-pipeline-analysis-2013-update-report.html>Antares Pharma, Inc. (ATRS) - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/antares-pharma-inc-atrs-product-pipeline-analysis-2013-update-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>MicroPhage Inc. - Product Pipeline Analysis, 2013 Update</title><link>http://www.researchmoz.com/microphage-inc-product-pipeline-analysis-2013-update-report.html</link><comments>http://www.researchmoz.com/microphage-inc-product-pipeline-analysis-2013-update-report.html#comments</comments><pubDate>Thu, 09 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/microphage-inc-product-pipeline-analysis-2013-update-report.html</guid><description><![CDATA[

Summary

MicroPhage Inc. (MicroPhage) is a medical device development company. The company focuses on patented and proprietary Bacteriophage Amplification Technology (BAT) on the clinical diagnostic market. MicroPhage IVD products enhance the clinician's ability to effectively treat patients, thereby reducing mortality, improving patient condition, reducing hospital length of stay and enhancing antibiotic stewardship. The company's products are bacterial identification and antibiotic susceptibility testing (ID/AST), KeyPath MRSA/MSSA Blood Culture Test BT and Multiple Pathogen / Multiple Antibiotic Test Panels. The products help physicians to facilitate optimization of antibiotic therapy earlier in the course of disease and save the lives of people. The ID/AST diagnostic test can identify the disease and support antibiotic selection for patients with infections. KeyPath MRSA/MSSA Blood Culture Test BT identifies Staphylococcus aureus directly from blood cultures for determining m <br><br>Original Post <a href=http://www.researchmoz.com/microphage-inc-product-pipeline-analysis-2013-update-report.html>MicroPhage Inc. - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Summary

MicroPhage Inc. (MicroPhage) is a medical device development company. The company focuses on patented and proprietary Bacteriophage Amplification Technology (BAT) on the clinical diagnostic market. MicroPhage IVD products enhance the clinician's ability to effectively treat patients, thereby reducing mortality, improving patient condition, reducing hospital length of stay and enhancing antibiotic stewardship. The company's products are bacterial identification and antibiotic susceptibility testing (ID/AST), KeyPath MRSA/MSSA Blood Culture Test BT and Multiple Pathogen / Multiple Antibiotic Test Panels. The products help physicians to facilitate optimization of antibiotic therapy earlier in the course of disease and save the lives of people. The ID/AST diagnostic test can identify the disease and support antibiotic selection for patients with infections. KeyPath MRSA/MSSA Blood Culture Test BT identifies Staphylococcus aureus directly from blood cultures for determining m <br><br>Original Post <a href=http://www.researchmoz.com/microphage-inc-product-pipeline-analysis-2013-update-report.html>MicroPhage Inc. - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/microphage-inc-product-pipeline-analysis-2013-update-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Beckman Coulter, Inc. - Product Pipeline Analysis, 2013 Update</title><link>http://www.researchmoz.com/beckman-coulter-inc-product-pipeline-analysis-2013-update-report.html</link><comments>http://www.researchmoz.com/beckman-coulter-inc-product-pipeline-analysis-2013-update-report.html#comments</comments><pubDate>Thu, 09 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/beckman-coulter-inc-product-pipeline-analysis-2013-update-report.html</guid><description><![CDATA[

Summary

Beckman Coulter, Inc. (Beckman) is a medical device company. It undertakes the manufacture and marketing of biomedical laboratory instruments, software and supplies that simplify, automate and innovate complex biomedical tests. Its products are used in a wide range of applications such as medical research, clinical trials and drug discovery, and diagnostic laboratories in hospitals. The company has three divisions, namely, Research and Discovery, Diagnostics and Industrial. It operates across the US, Canada, Europe and Asia. Its products are sold in over 160 countries worldwide. The company has an installed base of over 275,000 clinical and research systems operating in laboratories around the world. Beckman is a subsidiary of Danaher Corporation, and is headquartered in California, the US.&nbsp;

The company seeks to offer its customers the world's most efficient laboratories that would contribute in improving patient health and at the same time reduce the cost of car <br><br>Original Post <a href=http://www.researchmoz.com/beckman-coulter-inc-product-pipeline-analysis-2013-update-report.html>Beckman Coulter, Inc. - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Summary

Beckman Coulter, Inc. (Beckman) is a medical device company. It undertakes the manufacture and marketing of biomedical laboratory instruments, software and supplies that simplify, automate and innovate complex biomedical tests. Its products are used in a wide range of applications such as medical research, clinical trials and drug discovery, and diagnostic laboratories in hospitals. The company has three divisions, namely, Research and Discovery, Diagnostics and Industrial. It operates across the US, Canada, Europe and Asia. Its products are sold in over 160 countries worldwide. The company has an installed base of over 275,000 clinical and research systems operating in laboratories around the world. Beckman is a subsidiary of Danaher Corporation, and is headquartered in California, the US.&nbsp;

The company seeks to offer its customers the world's most efficient laboratories that would contribute in improving patient health and at the same time reduce the cost of car <br><br>Original Post <a href=http://www.researchmoz.com/beckman-coulter-inc-product-pipeline-analysis-2013-update-report.html>Beckman Coulter, Inc. - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/beckman-coulter-inc-product-pipeline-analysis-2013-update-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Anaxsys Technology Ltd - Product Pipeline Analysis, 2013 Update</title><link>http://www.researchmoz.com/anaxsys-technology-ltd-product-pipeline-analysis-2013-update-report.html</link><comments>http://www.researchmoz.com/anaxsys-technology-ltd-product-pipeline-analysis-2013-update-report.html#comments</comments><pubDate>Thu, 09 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/anaxsys-technology-ltd-product-pipeline-analysis-2013-update-report.html</guid><description><![CDATA[

Summary

Anaxsys Technology Ltd (Anaxsys) is a medical device company. The company develops and markets respiratory devices. Its product respiR8, is a respiratory rate counter that helps in an early indication of patient deterioration and enhances patient safety. Anaxsys has developed and patented core sensor technology. The company offers services such as patient monitoring, screening, and diagnostics in the areas of vital signs, asthma and COPD diagnosis, sleep apnoea, asthma management and lung cancer screening. Its technology provides easy to use products that offer the advantage to the patient and healthcare professionals. The company markets products through the brand respiR8. Anaxsys is headquartered in Surrey, England, the UK.

This report is a source for data, analysis and actionable intelligence on the Anaxsys Technology Ltd portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the developmen <br><br>Original Post <a href=http://www.researchmoz.com/anaxsys-technology-ltd-product-pipeline-analysis-2013-update-report.html>Anaxsys Technology Ltd - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Summary

Anaxsys Technology Ltd (Anaxsys) is a medical device company. The company develops and markets respiratory devices. Its product respiR8, is a respiratory rate counter that helps in an early indication of patient deterioration and enhances patient safety. Anaxsys has developed and patented core sensor technology. The company offers services such as patient monitoring, screening, and diagnostics in the areas of vital signs, asthma and COPD diagnosis, sleep apnoea, asthma management and lung cancer screening. Its technology provides easy to use products that offer the advantage to the patient and healthcare professionals. The company markets products through the brand respiR8. Anaxsys is headquartered in Surrey, England, the UK.

This report is a source for data, analysis and actionable intelligence on the Anaxsys Technology Ltd portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the developmen <br><br>Original Post <a href=http://www.researchmoz.com/anaxsys-technology-ltd-product-pipeline-analysis-2013-update-report.html>Anaxsys Technology Ltd - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/anaxsys-technology-ltd-product-pipeline-analysis-2013-update-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Singulex, Inc. - Product Pipeline Analysis, 2013 Update</title><link>http://www.researchmoz.com/singulex-inc-product-pipeline-analysis-2013-update-report.html</link><comments>http://www.researchmoz.com/singulex-inc-product-pipeline-analysis-2013-update-report.html#comments</comments><pubDate>Thu, 09 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/singulex-inc-product-pipeline-analysis-2013-update-report.html</guid><description><![CDATA[

Summary

Singulex, Inc., (Singulex) is a medical device company. The company discovers, develops and markets life science products to healthcare markets. It has single-molecule counting technology, which can quantitatively measure single molecules such as proteins and metabolites directly in complex biological samples without protein stripping techniques. Singulex provides instrumentation and immunoassay with the requisite sensitivity and specificity to enable biomarker discovery and validation for drug safety and efficacy. Its technology and instrumentation products are marketed through its brand Erenna Technology, Erenna Immunoassay System and Sgx link Software. The companys ultra-sensitive immunoassay systems are used for the treatment of inflammation, cardiovascular, neurology, oncology, metabolism and toxicity. Singulex is headquartered in Alameda, California, the US.

This report is a source for data, analysis and actionable intelligence on the Singulex, Inc. portfolio of <br><br>Original Post <a href=http://www.researchmoz.com/singulex-inc-product-pipeline-analysis-2013-update-report.html>Singulex, Inc. - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Summary

Singulex, Inc., (Singulex) is a medical device company. The company discovers, develops and markets life science products to healthcare markets. It has single-molecule counting technology, which can quantitatively measure single molecules such as proteins and metabolites directly in complex biological samples without protein stripping techniques. Singulex provides instrumentation and immunoassay with the requisite sensitivity and specificity to enable biomarker discovery and validation for drug safety and efficacy. Its technology and instrumentation products are marketed through its brand Erenna Technology, Erenna Immunoassay System and Sgx link Software. The companys ultra-sensitive immunoassay systems are used for the treatment of inflammation, cardiovascular, neurology, oncology, metabolism and toxicity. Singulex is headquartered in Alameda, California, the US.

This report is a source for data, analysis and actionable intelligence on the Singulex, Inc. portfolio of <br><br>Original Post <a href=http://www.researchmoz.com/singulex-inc-product-pipeline-analysis-2013-update-report.html>Singulex, Inc. - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/singulex-inc-product-pipeline-analysis-2013-update-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Great Basin Corporation - Product Pipeline Analysis, 2013 Update</title><link>http://www.researchmoz.com/great-basin-corporation-product-pipeline-analysis-2013-update-report.html</link><comments>http://www.researchmoz.com/great-basin-corporation-product-pipeline-analysis-2013-update-report.html#comments</comments><pubDate>Thu, 09 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/great-basin-corporation-product-pipeline-analysis-2013-update-report.html</guid><description><![CDATA[

Summary

Great Basin Corporation (Great Basin) is a life science company. The company develops and distributes point-of-care technology and products which improve automation, throughput, scalability, reliability and ease-of-use in rapid diagnostic testing. It develops tests in the areas of staph, clostridium difficile, nasal MRSA, and fungal pathogens. The company offers its products and services to the molecular, rapid diagnostic testing market. It serves healthcare providers and patients in the US and internationally. Great Basin markets its products through its distributors. It has partnership with Great Basin Corporation. Great Basin is headquartered in Salt Lake, Utah, the US.

This report is a source for data, analysis and actionable intelligence on the Great Basin Corporation portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the development stage, trial phase, product milestones, pipeline te <br><br>Original Post <a href=http://www.researchmoz.com/great-basin-corporation-product-pipeline-analysis-2013-update-report.html>Great Basin Corporation - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Summary

Great Basin Corporation (Great Basin) is a life science company. The company develops and distributes point-of-care technology and products which improve automation, throughput, scalability, reliability and ease-of-use in rapid diagnostic testing. It develops tests in the areas of staph, clostridium difficile, nasal MRSA, and fungal pathogens. The company offers its products and services to the molecular, rapid diagnostic testing market. It serves healthcare providers and patients in the US and internationally. Great Basin markets its products through its distributors. It has partnership with Great Basin Corporation. Great Basin is headquartered in Salt Lake, Utah, the US.

This report is a source for data, analysis and actionable intelligence on the Great Basin Corporation portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the development stage, trial phase, product milestones, pipeline te <br><br>Original Post <a href=http://www.researchmoz.com/great-basin-corporation-product-pipeline-analysis-2013-update-report.html>Great Basin Corporation - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/great-basin-corporation-product-pipeline-analysis-2013-update-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Protagen AG - Product Pipeline Analysis, 2013 Update</title><link>http://www.researchmoz.com/protagen-ag-product-pipeline-analysis-2013-update-report.html</link><comments>http://www.researchmoz.com/protagen-ag-product-pipeline-analysis-2013-update-report.html#comments</comments><pubDate>Thu, 09 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/protagen-ag-product-pipeline-analysis-2013-update-report.html</guid><description><![CDATA[

Summary

Protagen AG (Protagen) is a healthcare company. The company develops diagnosis of severe chronic diseases and the associated treatment. It operates through two business segments such as Diagnostics and Protein Services. Protagen&rsquo;s Diagnostics segment provides UNIchip and UNIarray. UNIchip is a family of protein microarrays to assess the binding potential of antibodies. UNIarray, which interacts with auto-antibodies from patients with auto-antigens. The company&rsquo;s Protein Services segment offers protein quantification, glycosylation, protein modification, bioassays, release testing, GMP protein analysis, antibodies, mass spectrometry, liquid chromatography, among others. It partners with Serva Electrophoresis GmbH, Zelle Biotechnology, Bionamics GmbH, University of Innsbruck, Technical University Munich and University Hospital Hamburg, among others. Protagen is headquartered in Dortmund, Germany.

This report is a source for data, analysis and actionable inte <br><br>Original Post <a href=http://www.researchmoz.com/protagen-ag-product-pipeline-analysis-2013-update-report.html>Protagen AG - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Summary

Protagen AG (Protagen) is a healthcare company. The company develops diagnosis of severe chronic diseases and the associated treatment. It operates through two business segments such as Diagnostics and Protein Services. Protagen&rsquo;s Diagnostics segment provides UNIchip and UNIarray. UNIchip is a family of protein microarrays to assess the binding potential of antibodies. UNIarray, which interacts with auto-antibodies from patients with auto-antigens. The company&rsquo;s Protein Services segment offers protein quantification, glycosylation, protein modification, bioassays, release testing, GMP protein analysis, antibodies, mass spectrometry, liquid chromatography, among others. It partners with Serva Electrophoresis GmbH, Zelle Biotechnology, Bionamics GmbH, University of Innsbruck, Technical University Munich and University Hospital Hamburg, among others. Protagen is headquartered in Dortmund, Germany.

This report is a source for data, analysis and actionable inte <br><br>Original Post <a href=http://www.researchmoz.com/protagen-ag-product-pipeline-analysis-2013-update-report.html>Protagen AG - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/protagen-ag-product-pipeline-analysis-2013-update-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>TEI Biosciences, Inc. - Product Pipeline Analysis, 2013 Update</title><link>http://www.researchmoz.com/tei-biosciences-inc-product-pipeline-analysis-2013-update-report.html</link><comments>http://www.researchmoz.com/tei-biosciences-inc-product-pipeline-analysis-2013-update-report.html#comments</comments><pubDate>Thu, 09 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/tei-biosciences-inc-product-pipeline-analysis-2013-update-report.html</guid><description><![CDATA[

Summary

TEI Biosciences, Inc. (TEI) is a biomedical company. The company develops and commercializes novel biological products for soft tissue repair, reconstruction and reinforcement applications. Its products include SurgiMend, SurgiMend PRS, PriMatrix, PriMatrix Ag, Durepair, TissueMend and Xenform Matrix. TEIs products are used in the areas of general surgery, hernia repair, plastic and reconstructive surgery, trauma, wound care and burns, neurosurgery, orthopedics and urogynecology. The company partners with Boston Scientific Womens Health Division, Medtronic Neurosurgery and Stryker Orthopaedics (Reconstructive, Joint Preservation, &amp; Orthobiologics). It is FDA certified company.. TEI is headquartered in Boston, Massachusetts, the US.

This report is a source for data, analysis and actionable intelligence on the TEI Biosciences, Inc. portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the d <br><br>Original Post <a href=http://www.researchmoz.com/tei-biosciences-inc-product-pipeline-analysis-2013-update-report.html>TEI Biosciences, Inc. - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Summary

TEI Biosciences, Inc. (TEI) is a biomedical company. The company develops and commercializes novel biological products for soft tissue repair, reconstruction and reinforcement applications. Its products include SurgiMend, SurgiMend PRS, PriMatrix, PriMatrix Ag, Durepair, TissueMend and Xenform Matrix. TEIs products are used in the areas of general surgery, hernia repair, plastic and reconstructive surgery, trauma, wound care and burns, neurosurgery, orthopedics and urogynecology. The company partners with Boston Scientific Womens Health Division, Medtronic Neurosurgery and Stryker Orthopaedics (Reconstructive, Joint Preservation, &amp; Orthobiologics). It is FDA certified company.. TEI is headquartered in Boston, Massachusetts, the US.

This report is a source for data, analysis and actionable intelligence on the TEI Biosciences, Inc. portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the d <br><br>Original Post <a href=http://www.researchmoz.com/tei-biosciences-inc-product-pipeline-analysis-2013-update-report.html>TEI Biosciences, Inc. - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/tei-biosciences-inc-product-pipeline-analysis-2013-update-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Technolas Perfect Vision GmbH - Product Pipeline Analysis, 2013 Update</title><link>http://www.researchmoz.com/technolas-perfect-vision-gmbh-product-pipeline-analysis-2013-update-report.html</link><comments>http://www.researchmoz.com/technolas-perfect-vision-gmbh-product-pipeline-analysis-2013-update-report.html#comments</comments><pubDate>Thu, 09 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/technolas-perfect-vision-gmbh-product-pipeline-analysis-2013-update-report.html</guid><description><![CDATA[

Summary

Technolas Perfect Vision GmbH (Technolas) is a medical device company. The company develops, manufactures and markets therapeutic technologies that are used in ophthalmology. Its products include excimer workstation, femtosecond workstation, diagnostics and microkeratome. Technolas offers various procedures such as Femto-Cataract, Supracor, Intracor, Customflap, Zyoptix Lasik and Customshape. The companys products deliver refractive surgery solutions to ophthalmology market. The companys femto-cataract procedure with the victus femtosecond laser platform is a femtosecond laser procedure for key steps in the cataract surgery procedure. It has its presence in the US and Singapore. Technolas is headquartered in Munich, Germany.

This report is a source for data, analysis and actionable intelligence on the Technolas Perfect Vision GmbH portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the deve <br><br>Original Post <a href=http://www.researchmoz.com/technolas-perfect-vision-gmbh-product-pipeline-analysis-2013-update-report.html>Technolas Perfect Vision GmbH - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Summary

Technolas Perfect Vision GmbH (Technolas) is a medical device company. The company develops, manufactures and markets therapeutic technologies that are used in ophthalmology. Its products include excimer workstation, femtosecond workstation, diagnostics and microkeratome. Technolas offers various procedures such as Femto-Cataract, Supracor, Intracor, Customflap, Zyoptix Lasik and Customshape. The companys products deliver refractive surgery solutions to ophthalmology market. The companys femto-cataract procedure with the victus femtosecond laser platform is a femtosecond laser procedure for key steps in the cataract surgery procedure. It has its presence in the US and Singapore. Technolas is headquartered in Munich, Germany.

This report is a source for data, analysis and actionable intelligence on the Technolas Perfect Vision GmbH portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the deve <br><br>Original Post <a href=http://www.researchmoz.com/technolas-perfect-vision-gmbh-product-pipeline-analysis-2013-update-report.html>Technolas Perfect Vision GmbH - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/technolas-perfect-vision-gmbh-product-pipeline-analysis-2013-update-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>TransMedics, Inc. - Product Pipeline Analysis, 2013 Update</title><link>http://www.researchmoz.com/transmedics-inc-product-pipeline-analysis-2013-update-report.html</link><comments>http://www.researchmoz.com/transmedics-inc-product-pipeline-analysis-2013-update-report.html#comments</comments><pubDate>Thu, 09 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/transmedics-inc-product-pipeline-analysis-2013-update-report.html</guid><description><![CDATA[

Summary

TransMedics, Inc. (TransMedics) is a medical device company. The company develops organ transplant systems. Its product organ care system used by surgeons in heart transplants is a warm blood perfusion system which maintains organs in a warm functioning state outside of the body during transport from organ donor to recipient. The system can also be used for lung, liver and kidney transplants. Its organ care system functions are blood oxygenation, pulsative flow, physiological monitoring and warming. TransMedics enable surgeons to transplant more organs from the available donor pool. TransMedics is headquartered in Andover, Massachusetts, the US.

This report is a source for data, analysis and actionable intelligence on the TransMedics, Inc. portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the development stage, trial phase, product milestones, pipeline territory, estimated approval date,  <br><br>Original Post <a href=http://www.researchmoz.com/transmedics-inc-product-pipeline-analysis-2013-update-report.html>TransMedics, Inc. - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Summary

TransMedics, Inc. (TransMedics) is a medical device company. The company develops organ transplant systems. Its product organ care system used by surgeons in heart transplants is a warm blood perfusion system which maintains organs in a warm functioning state outside of the body during transport from organ donor to recipient. The system can also be used for lung, liver and kidney transplants. Its organ care system functions are blood oxygenation, pulsative flow, physiological monitoring and warming. TransMedics enable surgeons to transplant more organs from the available donor pool. TransMedics is headquartered in Andover, Massachusetts, the US.

This report is a source for data, analysis and actionable intelligence on the TransMedics, Inc. portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the development stage, trial phase, product milestones, pipeline territory, estimated approval date,  <br><br>Original Post <a href=http://www.researchmoz.com/transmedics-inc-product-pipeline-analysis-2013-update-report.html>TransMedics, Inc. - Product Pipeline Analysis, 2013 Update</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/transmedics-inc-product-pipeline-analysis-2013-update-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item></channel></rss>